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Also in the water of flower vases there was movement...: 
tapered, agile, crooked like old slippers, they flashed by at 
such speed that in order to follow them the magnification had 
to be reduced: they navigated in the ocean of a drop of water, 
rotating on their axis, smashing into obstacles, and then 
immediately turned around and were off again like crazed 
speedboats. They seemed to be hunting for light and air, 
solitary and bustling: 
but I saw two of them put on the brakes as (f one had 
noticed the other, as if they had taken a liking to each 
other; I saw them get close, adhere tightly, and continue the 
voyage together at a slower pace, as if by these blind 
nuptials they had exchanged something and from it drew a 
mysterious, infinitesimal pleasure. 
Primo Levi, Other people's trades: "The invisible world". 
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Chapter 1 
General introduction 
Parts of this chapter are published in Cancer Surveys 24, 43-65, 1995 
General introduction 
The process of tumor progression involves a series of sequential steps leading to 
metastasis. For several of these steps, tumor cells must be equipped with the 
appropriate adhesive phenotype. The molecules that mediate cell adhesion can be 
grouped in several distinct families; selectins, members of the immunoglobulin 
superfamily, Cadherins, integrins, and CD44 molecules. In this chapter, the general 
properties of each of these families are introduced and their involvement in cancer, 
specifically in melanoma, is discussed. Since direct evidence for a role for adhesion 
molecules in melanoma growth and metastasis in vivo is limited to the integrins and 
CD44, these families are discussed in more detail. 
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CELL ADHESION AND TUMOR PROGRESSION 
In the establishment of a primary tumor, genetic changes occur, including activation 
of proto-oncogenes and inactivation of tumor suppressor genes, that lead to cellular 
transformation [14]. During these initial steps in oncogenesis, cells become less 
differentiated and their growth is no longer contact inhibited and often growth factor 
independent. Further tumor progression involves a series of sequential steps eventually 
resulting in the outgrowth of distant metastases [46]. It is this ability to metastasize that 
contributes most to the lethality of the disease. 
This thesis focusses on melanoma, a cancer originating from melanocytes, the 
pigment producing cells in the skin (cutaneous melanoma) or in the eye (uveal 
melanoma). Cutaneous melanoma is an ideal model to study tumor progression because 
lesions of the different stages that are defined clinically, histopathologically, and 
immunologically are attainable [29,64], and because many well characterized human 
melanoma cell lines are available. 
Figure 1: Adhesive events in melanocytic tumor progression. Tumor cells penetrate the epidermal 
basement membrane (bm) (1) and invade into the dermis β). They detach from the primary tumor, 
migrate through the dermis (3) and penetrate the basement membrane and endothelial cell layer 
(ec) of a blood vessel (intravasation) (4). In the blood stream, tumor cells may adhere to platelets 
(5). Finally, they extravasate at a distant site (6), followed by invasion (7) and proliferation (8) in 
the target organ. 
In order to be able to move through the steps of tumor progression and metastasize, 
tumor cells must acquire a number of molecular properties, many of which effect their 
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adhesive behavior (Fig 1) [207]. Tumor cells have been demonstrated to produce 
qualitatively or quantitatively altered extracellular matrix (ECM) deposits [134], to have 
reduced contacts with neighboring cells [191], and to synthesize elevated levels of 
proteases [118]. These features are likely to be important for the detachment from the 
primary tumor mass and for invasion into the surrounding ECM. Stimulation of 
angiogenesis [206] and expression of cellular adhesion molecules recognizing basement 
membrane components [194], may enable tumor cells to enter the blood stream. 
Downmodulation of expression of major histocompatibility antigens [119] and binding to 
platelets [84], can help tumor cells to circumvent the immune surveillance. The ability to 
adhere to endothelial cells [142] may be important for extravasation, and finally, 
mimicking the adhesive phenotype of activated lymphocytes may permit them to retain 
and proliferate in lymph nodes [65]. 
Thus, invasive and metastatic behavior requires various adhesive interactions of tumor 
cells with other cells and with ECM components. To date, several cell adhesion receptor 
families have been defined, including selectins, members of the immunoglobulin (Ig) 
superfamily, Cadherins, integrins, and CD44 molecules (Fig 2) [74,102]. 
selectins Ig- Cadherins integrins CD44 
superfamily 
Figure 2. Cell adhesion receptor families. For selectins. Ig superfamily members, and Cadherins, 
the arrangement of known repeats is shown. For integrins and CD44, a schematic arrangement of 
the polypeptide chains is drawn. The filled horizontal bar indicates the cell membrane. Ligand 
binding domains are represented by dotted areas. The octagon depicts the lectin domain, the 
double hatched bar depicts the EGF-like repeat, ovals represent complement-binding protein 
related repeats, hatched bars represent fibronectin type III repeats, and circles represent Ig 
repeats. Ca2*-dependent domains and metal (m) binding sites are indicated. For CD44, dotted 
lines are chondroitin sulphate chains and the triangle points the position where variant exons can 
be inserted. For references see text. 
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FAMILIES OF CELL ADHESION RECEPTORS 
Selectins 
Three members of the selectin family have been identified, termed E-, P-, and L-
selectin, and they are also referred to as LECAMs [11,96,193]. Each is a transmembrane 
molecule and has a Ca2+-dependent C-type lectin domain, an EGF-like repeat, and 
various repeats with similarity to complement-binding proteins. They heterophilically 
(contact between different molecules) bind specific carbohydrate moieties via their lectin 
domains [146]. P- and L-selectin ligands are mucin-like molecules such as CD34, Gly-
CAM, and the mucosal addressin MAdCAM, all expressed on endothelial cells [193]. 
The ligand for E-selectin (ESL-1) was recently cloned and shown to be 94% identical to 
the fibroblast growth factor receptor [179]. 
Selectins are expressed on leukocytes and endothelial cells and mediate adhesion 
between these cell types. This interaction slows the leukocytes down (rolling), probably 
allowing factors in the local environment to activate them. Subsequently, firm adhesion is 
induced (involving integrins and members of the Ig superfamily), followed by lymphocyte 
homing into lymph nodes and leukocyte extravasation at sites of inflammation [170,175]. 
Studies with P-, L-, or E-selectin-deficient mice, combined with antibody inhibition 
studies, clearly demonstrate the crucial role for selectins in these processes [see 193]. 
Ig superfamily members 
The Ig superfamily comprises a large number of adhesion molecules, all typified by 
several Ig-related domains and, usually, by several fibronectin type III repeats [209]. 
Most members are transmembrane molecules but phosphatidylinositol anchorage has also 
been found. N-CAM was the first member to be identified [30] and it belongs to a group 
that mediates homophilic (contact between identical molecules) cell adhesion. The 
members of a second group, i.e. ICAM-1, -2, and -3, VCAM-1, and MAdCAM-1 bind 
to members of the integrin family [10,16,36,41,147,178]. 
The ICAMs play a pivotal role in leukocyte interactions in various steps of an 
immune response and in the multistep cascade of leukocyte extravasation [173]. 
Furthermore, recent findings show that ICAM-1 [148] and ICAM-3 [80] can act as 
mediators of signal transduction as well as cell adhesion. 
Cadherins 
Members of the Cadherin family are transmembrane molecules that mediate adhesion 
between cells in a homophilic, Ca2+-dependent manner [55,74,188-191]. In addition, E-
cadherin on keratinocytes can heterophilically bind integrin ae/37 on lymphocytes [23]. 
Extracellularly, Cadherins consist of four homologous repeats, and the ligand binding 
region is located in the most distal repeat [129,166]. Intracellular^, they are linked to the 
cytoskeleton via a complex of intermediate proteins (catenins for E-cadherin), and these 
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associated molecules are essential for the adhesive function [86,123,133]. A large number 
of different Cadherins are known, that all have their own specific pattern of spatial and 
temporal regulation during embryonic development, and their own pattern of tissue 
distribution [55,90,183,188-190]. 
Selective cadherin-mediated adhesion of cells to cells of their own type, is thought to 
be fundamental in the control of development and maintenance of tissues [128,188-190]. 
In adult normal tissue, specific Cadherins are usually clustered in specialized regions of 
contact between the plasma membranes of opposing cells. For example, E-cadherin 
molecules are concentrated in adherens junctions of epithelial cells, whereas in 
desmosomal junctions of several different cell types, desmogleins and desmocollins are 
clustered [15,48,98,161,198]. 
Integrins 
Structural aspects: Integrins form a family of heterodimeric transmembrane receptors 
[73]. Their a- and /3-subunits are derived from separate genes and form glycoproteins 
with a generally conserved structure, made up of a large extracellular domain (ca. 1000 
aminoacids for a-subunits and 750 aminoacids for /3-subunits), a transmembrane segment, 
and a very short cytoplasmic tail (with the exception of the 04-subunit, see below). 
Complete sequence information has been obtained for most a- and /3-chains [see 
databanks and references in 37,73,107,155]. The high conservation of /31 cytoplasmic 
domains across vertebrates, invertebrates, and even fungi, indicates the early origin of the 
integrins in evolution [111]. The subunits non-covalently associate in the cytoplasm and 
are subsequently transported to the cell surface [27]. Divalent cations are required for 
dimerization [53] and involvement of the chaperone calnexin has been reported [99]. 
Diversity within the family of integrins is generated by a large number of a-subunits 
which form heterodimers with at least nine different /3-subunits (Table 1). The fact that 
one a-subunit can associate with more than one /3-subunit, and the existence of alternative 
splicing for a- and /8-chains further enhances the complexity of the family. 
Ligand binding: Extracellularly, integrins can bind ECM components or counter receptors 
on other cells in a divalent cation-dependent way (Ca2+, Mg2+, or Mn2+). Redundancy is 
a common feature in the integrin family as several integrins bind the same ligand and one 
integrin may bind several ligands (Table 1). Chemical cross-linking studies and mutational 
analyses have narrowed down the ligand binding site to a small region in the N-terminal 
domains of both subunits [see 73,107]. A highly conserved sequence in this region in the 
l8-subunits, has homology to the calcium-binding loop of EF-hand proteins, and several 
lines of evidence suggest that the ligand interacts with divalent cations bound to this site 
[39,107]. A number of integrin recognition sites have been molecularly defined in various 
ligands and the best studied of those is the RGD sequence. It is present within several 
ECM proteins, and it is recognized by a large number of integrins (Table 1) [153]. 
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Table 1. The inte grin family. 
submits 
01* 
02 
03* 
04 
05 
06 
07 
αϊ 
α2 
α3* 
α4 
α5 
об* 
α7* 
α8 
αν 
α9 
αϊ 
am 
αχ 
allb 
αν 
α6* 
αν 
αν 
α4 
ae 
ligands 
Ln.Co 
Ln,Co,Tn,a301 
Ln,Co,Fn,Ep,En,a201 ,a301 
Fn.VCAMl 
Fn 
Ln 
Ln 
Tn 
Fn.Vn 
Ln.Co.Tn 
ICAM1,ICAM2,ICAM3 
iC3B,Fb,FX,ICAMl 
iC3B,Fb 
Fb,Fn,VWF,Vn,Ts 
Vn,Fb,Fn,VWF,Ts,Os,Co,Tn 
Ln 
Vn 
Fn 
Fn,VCAMl,MAdCAM 
E-cadherin 
recognition sites 
DGEA 
EILDV.IDAPS.REDV 
RGD(+PHSRN) 
RGD 
KELLLPGNNRKV 
KQAGDV 
GPRP 
RGD(+PHSRN),KQAGDV 
RGD(not PHSRN) 
RGD 
RGD 
EILDV 
08 αν Vn RGD 
09 a? ? 
*Alternative splicing reported. Abbreviations used: Ln=laminin, Co=collagen, Tn=tenascin, 
Fn=fibronectin, Ep=epiligrin, En=entactin, VCAM=vascular cell adhesion molecule, Vn= 
vitronectin, ICAM=intercellular adhesion molecule, іСЗЬ-inactivated complement component C3, 
Fb=fibrinogen, Fx=factor X, VWF=von willebrand factor, Ts=thrombospondin, 0s= 
osteopontin, MAdCAM=mucosal addressin cell adhesion molecule. For references see text. 
Integrins of the 01,2,3 subfamilies have been most extensively studied. The /31- and 
03-integrins are mainly involved in cell-ECM interactions whereas 02-integrins mediate 
cell-cell adhesion. However, 01-integrins can also be involved in cell-cell adhesion. E.g., 
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α4/31 is the receptor for vascular cell adhesion molecule (VCAM)-I [41]; a3/31 can be 
localized at cell-cell contact sites [85]; a2 and a3 subunits accumulate in areas of cell-cell 
contacts in cultured keratinocytes [95]; binding of affinity purified a2j81 to a3/31 has been 
demonstrated [186]; and finally, homophylic аЗДІ interactions have been reported [181]. 
The finding that the binding specificities of a certain integrin may vary depending on 
the cell type involved, further enhances the complexity. For instance, a2/31 is a collagen 
receptor on platelets and a collagen/laminin receptor on endothelial cells [87]. 
Functional aspects: One function of integrin-mediated adhesion, is the anchorage of cells 
to basement membranes and to each other. This may be of critical importance in tissue 
morphogenesis. Integrins also play an important role in cell migration (Fig 3) [72]. For 
example, a4/31 and a5/31 mediate migration on fibronectin [210] and a201 mediates 
migration on collagen [25]. Importantly, murine embryonic stem cells in which the /31 
integrin gene was knocked out, show decreased cell migration [43]. 
Apart from their role in cell adhesion and migration, /31-integrins are also involved in 
the assembly of the ECM. Antibodies against the cytoplasmic domain of the /31 -subunit 
have been demonstrated to inhibit fibronectin fibril formation in vivo during development 
[35]; fibronectin matrix assembly is inhibited in vitro by RGD synthetic peptides [112] 
and by anti-a5 or anti-/31 antibodies [1]; and fibroblasts and melanoma cells can use a2/31 
to reorganize and contract hydrated collagen matrices [88]. 
Finally, yet another, though pathological role for integrins, may be in viral infections. 
This is illustrated by the reports that a2/31 binds echovirus [9] and that αν/33 and αν/35 
bind adenovirus [208]. 
Cytoplasmic interactions: The fact that cells can use various integrins for binding to one 
ligand (Table 1) has important functional consequences. For example, while both αν/33 
and αν/35 bind to vitronectin, only αν/33 promotes subsequent migration [97]. Using 
chimeric integrins, made up of the a2 extracellular and membrane spanning domain and 
various integrin cytoplasmic domains, it was shown that the cytoplasmic domain plays an 
important role in such post ligand binding events [24]. 
The integrin cytoplasmic domains are linked to the cytoskeleton. Following adhesion 
and spreading of cells, integrins concentrate in focal adhesions (adhesion plaques/adherens 
junctions) where actin filament bundles are linked to the ECM via integrins (Fig 3). This 
occurs through indirect linkage, involving talin, vinculin, a-actinin and others 
[20,50,69,103,131,200]. By using chimeric molecules made up of the cytoplasmic domain 
of the ßl subunit and the IL2r extracellular domain, it has been shown that the /31 
integrin cytoplasmic part is sufficient for localization in adhesion plaques [94]. 
Focal adhesions are not the only possible structures for integrin interactions with the 
cytoskeleton. Integrin a6/34 is part of a distinct epithelial adhesive structure, the 
hemidesmosome complex [140]. In this complex the extremely long cytoplasmic part of 
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the /34-chain reaches to the intermediate filaments. 
A В 
spreading migration 
Figure 3. Integrins in adhesion, migration and signaling events. A: During cell spreading, 
specialized structures called focal adhesions are formed where clustered integrins link actin 
filament bundles to the ECM. B: By means of the inward centripetal cytoskeletal stresses (small 
arrows), these structures provide the traction required for cell migration given that a front-to-rear 
asymmetry in adhesive contacts exists (e.g. selective downregulation of integrin-cytoskeletal 
binding strength at the cell rear). C: Clustered integrins infocai adhesions function as a signal 
transduction unit where cytoskeletal and signaling molecules (e.g. FAK, tensin, and paxilin) are 
concentrated and phosphorylated (pTyr), ultimately influencing gene expression. D: Unidentified 
cytoplasmic factors induce conformational changes that control the affinity state of the integrin 
(inside-out signaling). For references see text. 
Signaling: Concentration of integrins and linkage with the actin filament bundles in focal 
adhesions are important features in cell migration [72]. In addition, several molecules that 
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are involved in signal transduction, also assemble in these structures [see 28,73,81,155, 
159,167]. Recently, integrin-mediated clustering of more than 30 cytoskeletal and 
signaling molecules was studied [116,117]. It was found that integrin aggregation alone, 
induces clustering of two molecules, tensin and FAK (focal adhesion kinase). Co-
clustering of other cytoskeletal and signaling molecules, as well as activation of the MAP 
kinase pathway, required additional integrin ligand occupation, tyrosine phosphorylation, 
and/or actin cytoskeleton integrity. 
These initial steps of integrin signaling, are probably at the basis of ECM regulated 
gene expression (Fig 3) [see 28,73,81]. In this way, proliferation and differentiation of 
cells is not only controlled by soluble growth factors, but also by integrin-mediated 
adhesion events [122,171,182]. Cyclin A is a key element in adhesion-dependent control 
of cell proliferation [56], but there is no evidence yet for a link between integrin signaling 
and cyclin A gene expression. Signal transduction through integrins, neuropeptides, 
growth factors, and oncogenes may converge in FAK [149,168]. This cytosolic tyrosine 
kinase can be activated by integrin signaling [57], G-coupled receptor signaling [211], 
growthfactor receptor signaling [141], and oncogenic pp60'rc [158]. 
Finally, integrin-mediated adhesion may also induce signaling events in an alternative 
fashion. CD47 is a 50 kDa transmembrane molecule with characteristics of a calcium 
channel that can be expressed in an integrin-bound fashion, hence the name integrin 
associated protein (IAP). IAP has been shown to be required for RGD stimulation of 
phagocytosis by PMNs and for integrin-regulated calcium influx in endothelial cells, and 
it acts in concert with the leukocyte-response-integrin as a signal transduction unit to 
activate the respiratory burst in phagocytes [19,104,105,160,212]. 
Regulated activity: In addition to the regulation of adhesion at the level of expression or 
clustering of integrins, the affinity of individual integrins can be modulated as well. 
Divalent cations [106], protein kinase С activation [203], lipid factors [66], and even the 
ligand itself [21], can modulate the activity of integrins. The highly conserved membrane-
proximal GFFKR sequence in the a-subunit cytoplasmic tail, has been shown to maintain 
the default low affinity state of integrins [132]. It is suggested that cytoplasmic signals are 
required to change the structure of this region, finally resulting in an active conformation 
of the extracellular part of the integrin. Such a process has been termed inside-out 
signaling (Fig 3) [73]. 
Integrins may thus cycle through multiple conformations on the cell surface and 
antibodies have been generated recognizing or stabilizing active conformations [see 37]. A 
number of antibodies have been generated that enhance ligand binding activity of /31-
[92,127,201], /32- [143], and /33-integrins [47]. For the /Sl-subunit, a small region has 
been identified that is recognized by both activating and inhibiting antibodies [187]. The 
authors postulate that binding of activating antibodies to this flexible region leads to an 
active conformation whereas binding of inhibiting antibodies induces an inactive 
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conformation. 
CD44 
Several cell surface molecules that were independently identified over the past decade, 
later proved to be identical to a human immune cell marker, CD44 [5,62,115]. CD44 is 
homologous to the cartilage link proteins [54,176]. The 37 kDa transmembrane protein 
predicted by the cDNA, is post-translationally modified by N- and O-linked glycosilations 
to an 80-90 kDa glycoprotein [54,176]. In addition, several larger isoforms of CD44 have 
been described that are generated by alternative splicing of 10 exons (Fig 4) 
[18,38,58,162,17η. The current view is that CD44 is a family of cell surface 
glycoproteins, all encoded by a single gene [102]. The 80-90 kDa CD44 species (CD44H) 
is abundantly expressed on most cell types whereas the larger CD44 isoforms are 
expressed principally on epithelia and activated leukocytes [4,91,109,169]. 
This heterogeneity in the CD44 family is probably responsible for the multifunctional 
character of CD44 on different cell types. CD44H is the receptor for the ECM component 
hyaluronate (HA) [5,115], whereas data on HA binding by the larger isoform CD44E 
(CD44v8-10) are conflicting [63,177]. CD44H also binds purified MAdCAM whereas 
CD44E does not [135]. Conversely, a 180-200 kDa isoform was found to bind 
fibronectin, whereas CD44H did not [77]. Glycosaminoglycans have been implicated in 
growthfactor presentation at sites of inflammation [192] and CD44 species containing the 
v3 exon product are proteoglycans [8,76], which indeed provides these isoforms with the 
capacity to bind growth factors [8]. Thus, alternative splicing regulates CD44 binding to 
the ECM-components HA and fibronectin, to the cellular adhesion molecule MAdCAM, 
and to growth factors. In addition, CD44 has been reported to bind collagen [22]. 
Intracellularly, CD44H binds ankyrin and this interaction is essential for HA binding 
[108]. Members of the ERM family (ezrin, radixin, and moesin) have been reported to 
function as molecular linkers between CD44 and the actin cytoskeleton [199]. These 
molecules linked a 140 kDa isoform tightly to the cytoskeleton, whereas binding of the 
80-90 kDa CD44H molecules was much weaker, despite the fact that both isoforms share 
the same cytoplasmic domain. It was suggested that this may be related to the tendency of 
the 140 kDa isoform to cluster. 
As adhesion receptors for several ECM components and ligands on endothelial cells, 
CD44 molecules are involved in cell migration [196], cell aggregation [180], lymphocyte 
homing [78], and hemopoiesis [114]. Furthermore, CD44 molecules have been implicated 
in Τ cell activation [70,172]. In order for a cell adhesion mechanism, involving such 
broadly distributed molecules as HA and CD44, to be selective, CD44 molecules would 
not be expected to be constitutively active. Indeed, the HA binding activity of CD44 can 
be enhanced on Τ cells during an in vivo immune response [101], and antibodies have 
been described that activate murine CD44, though the exact mechanism is still unknown 
[100]. 
19 
vi v2 v3 v4 v5 v6 v7 v8 v9 ν 10 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
11111HHWWHW 
tm 
Figure 4. Alternative splicing of CD44 The CD44 gene includes 10 exons that are alternatively 
spliced (vl-10), resulting either in CD44H that lacks variant exon products, or in isoforms that 
contain one or several of them, e g CD44E which has vS-10 tm=transmembrane domain 
CELL ADHESION RECEPTORS IN MELANOMA AND OTHER CANCERS 
In the concept of evolution through random mutations and natural selection during 
tumor progression, the idea that the adhesive character is among the important acquired 
properties of the few cells which eventually metastasize, is not new [45,138] The 
discovery and characterization of the cell adhesion receptors over the past decade, has 
initiated a search for the aberrant expression or function of these molecules in cancer 
cells. Immunohistochemical studies have demonstrated changes in the expression of 
Cadherins, întegnns, or CD44 isoforms to be related to tumor progression in various 
human cancers [see 2,12,13,52,59,67,82,136,137]. 
For melanoma, most studies in this field have focussed on integnns [see 31,32,121, 
152]. Consistent findings are decrease of a6/31, increase of a3/31 and a4/31, and 
acquirement of a5/31 and αν/33 with melanocyte tumor progression (Table 2) In 
addition, the level of expression of certain integnns has been shown to be related to the 
metastatic potential of melanoma cell lines [see 31]. Of the Ig superfamily, ICAM-1 
expression has also been reported to correlate with melanocyte tumor progression in situ 
[79] In contrast, for CD44, data from a few studies show that it is strongly expressed in 
all stages of melanocyte tumor progression in situ and in most melanoma cell lines, 
irrespective of their metastatic potential [40,110,120]. 
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Table 2. Integriti expression in melanocytic tumor progression. 
t 
I 
t 
t 
t 
t 
t 
IT 
It 
t 
1Í 
1 
I 
a 
αϊ/31 α2/31 α301 α4/31 α5/31 α6/31 α7/31 αν/33 o6/S4 αν/35 reference 
І [17,89] 
li [ИЗ] 
t IT t f [3] 
Л [125] 
li [93] 
[124] 
li t [120] 
[156] 
IT i [33] 
[202] 
lì I [34] 
1Г [157] 
It or Л indicates that up- or downregulation of those integrins was a major finding, and 
t or i indicates minor changes. The aIIb/33/av/S3 antibody used in [113], is assumed 
to stain αν/ЗЗ as neither we nor others find allb03 in human melanoma. 
Importantly, for Cadherins, integrins, and CD44, direct in vitro and in vivo 
experimental evidence exists for their role in tumor growth, invasion, and metastasis. For 
melanoma, this is limited to integrins and CD44 molecules. 
Cadherins: Incubation with antibodies to E-cadherin, can induce invasiveness of otherwise 
non-invasive epithelial cells [7]. Conversely, E-cadherin cDNA transfection into highly 
invasive, E-cadherin negative carcinoma cells, greatly reduces their invasive capacity 
[204]. Finally, transfection experiments have shown that expression of E-cadherin in 
carcinoma cells can reduce their tumorigenicity [126]. 
Integrins: Overexpression of integrin a5/31 in malignant Chinese hamster ovary (CHO) 
cells, has been reported to reduce tumorigenicity in nude mice [51]. A role for al/32 in 
lymphoma metastasis has been shown by generating mutants of the highly metastatic 
TAM2D2 T-cell hybridoma that lacked this integrin. Following intravenous (i.v.) 
injection, liver colonization was reduced for the mutants [145]. Furthermore, revertants 
that were obtained by in vivo transplantation, had high al/32 expression and were highly 
metastatic again [144]. A role for the /31 integrins in lung colonization of i.v. injected 
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carcinoma cells has been demonstrated by an antibody inhibition study [42]. Transfection 
of non-metastatic rhabdomyosarcoma cells with a2-cDNA, resulting in a2/31 -expression 
and increased adhesion to collagen and laminin, has been observed to induce lung 
colonization both after i.v. and subcutaneous (s.c.) injection [25]. 
For human melanoma, a5/31 binding to fibronectin has been shown to induce a 
mitogenic signal in vitro [122], and av-cDNA transfection resulting in αν/33-expression, 
has been shown to enhance proliferation in vivo [44]. Furthermore, triggering of a5/31 or 
αν/33 has been reported to induce enhanced metalloprotease expression and invasiveness 
of human melanoma cells [163,164]. Experimental metastasis of murine melanoma cells 
after i.v. injection can be inhibited with RGD-containing synthetic peptides, non-peptide 
mimetics, or disintegrins (RGD-containing peptides isolated from snake venom) 
[61,71,154,174]. It is not known which RGD-binding integrin is blocked in these 
experiments but in contrast to human melanoma cells, the B16 murine melanoma cells 
that were used can express aIIb/33 that may be affected [26,68]. In one study, a /31-
integrin-binding disintegrin was found to inhibit lung colonization of human melanoma 
cells [197]. The inhibitory effect observed in all these studies may be due to interference 
with integrin-mediated adhesion during melanoma cell extravasation or subsequent 
invasion. However, an alternative mode of action might involve inhibition of platelet 
aggregation or stimulation of natural killer cell activity. 
Two reports strongly suggest that the c*4/31-VCAM-l interaction is involved in late 
stages of melanoma metastasis. First, B16 cells show enhanced lung colonization upon 
i.v. injection in TNFa-treated mice, and this effect is inhibited by previous injection of 
antibodies to VCAM-1 [130], and second, the interleukin 1-augmented metastasis of i.v. 
injected human melanoma cells can be blocked by pretreatment of the melanoma cells 
with antibodies to <*4 [49]. In contrast, by <*4-cDNA viral infection, it has been 
demonstrated that expression of a4/31 inhibits metastasis of s.c. but not i.v. injected B16 
cells [139]. Thus, it seems that a4/31 plays a dual role in melanoma progression, 
inhibiting early stages but facilitating later events of the metastatic cascade. 
Antibodies that block attachment to laminin in vitro [205] and peptides from the 
YIGSR sequence in the laminin Bl chain [75] have been shown to inhibit melanoma cell 
lung colonization. Furthermore, exposure of cultured cells to laminin before intravenous 
injection [195] and co-injection of a peptide from the sequence of the laminin A-chain 
[83] promoted experimental metastasis of melanoma cells. It is not known which laminin 
receptors are involved (integrins or non-integrins) but αββ\ may be a candidate integrin 
since an antibody to a6 has been shown to inhibit experimental metastasis of B16 
melanoma cells [151]. It may be expected that the antibody would inhibit аб/31 binding to 
laminin present in the endothelial basement membrane. However, since the same antibody 
did not inhibit in vitro adhesion to laminin, another function of аб/31 must be affected. 
CD44: CD44-Ig fusion proteins have been shown to inhibit tumorigenicity of human 
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lymphoma cells [185] and cDNA transfection of CD44H but not the larger isoform 
CD44E, can enhance lymphoma tumorigenicity and lung colonization [184]. Thus, the 
standard 80-90 kDa CD44 isoform seems to be involved in lymphoma growth and 
metastasis. A causal role in metastasis of rat prostate carcinoma cells has been 
demonstrated for CD44 isoforms containing the variant exon v6 product by transfection 
[58] and antibody inhibition studies [165]. Two v6-containing isoforms, pMetal 
(containing v4,5,6,7) and pMeta2 (containing v6,7) were each found to be sufficient to 
establish metastatic properties in a non-metastatic cell line [150]. As the HA binding 
capacity of these isoforms is not different from CD44H which was expressed on the cell 
line, and as both isoforms lack v3 that is implicated in growth factor binding (see above), 
the mechanism by which they confer metastatic behavior remains to be determined. 
For human melanoma, CD44 antibodies that block HA binding have been reported to 
inhibit tumorigenicity of a human melanoma cell line and inhibit metastasis from a s.c. 
tumor of that cell line [60]. Furthermore, using a CD44 negative human melanoma cell 
line (which is very rare), it has been demonstrated by cDNA transfection of wild type and 
mutant CD44, and by administration of CD44-Ig fusion proteins, that HA binding by 
CD44 is involved in melanoma tumorigenicity [6]. 
Thus, for melanoma, the relation of integrin expression with melanocyte tumor 
progression in situ and with the metastatic potential of cell lines, is extended by findings 
that integrins can be directly involved in several steps of the metastatic cascade. Even 
though CD44 molecules are strongly expressed in all stages of melanocyte tumor 
progression and on most cell lines independent of their metastatic capacity, there is 
evidence that CD44 may be involved in melanoma growth and metastasis. 
SCOPE OF THIS THESIS 
For a study on cell adhesion receptors in melanoma, knowledge of the adhesive 
phenotype of normal melanocytes is important. Therefore, chapter 2 deals with expression 
and function of the cell adhesion receptors in cultured melanocytes, maintained either in a 
highly proliferative state or in a differentiated non-proliferative state. Besides various 
integrins, melanocytes are shown to express E-cadherin, a cell-cell adhesion molecule that 
is lost with tumor progression in many epithelial cancers. In order to investigate if E-
cadherin is also lost with melanocytic tumor progression, chapter 3 deals with the 
expression of this molecule in lesions of the various stages of melanocytic tumor 
progression in situ, and in melanoma cell lines with different metastatic capacities. 
In chapter 4, a panel of antibodies is used to determine the pattern of integrin 
expression in cutaneous melanocytic lesions. The fact that expression of several integrins 
is found to change dramatically with tumor progression, suggests that integrins may be 
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involved in melanoma metastasis. As the clinical behavior of uveal melanoma differs from 
that of cutaneous melanoma, in chapter 5 the hypothesis that uveal melanoma may 
express a different pattern of integrins is investigated. 
Metastatic melanoma cells penetrate the epidermal and endothelial basement 
membranes, and integrins that recognize basement membrane components may be 
important. Therefore, in chapter 6, expression and function of аб/îl and a2ßl integrins 
that bind the basement membrane components laminin and collagen, is investigated in 
relation to the metastatic potential of melanoma cell lines. 
RGD-peptides can inhibit melanoma metastasis, though the integrin(s) involved have 
not been identified. In chapter 7, it is shown that even though αν/33 emerges in late 
stages of tumor progression in situ, two highly metastatic cell lines lack expression of this 
RGD-binding integrin, suggesting that avjS3 is not critical for melanoma metastasis. In 
contrast, a5ßl, another RGD-recognizing integrin that is acquired in late stages of tumor 
progression (chapter 4), is strongly expressed on the highly metastatic cell lines. In 
chapter 8, the mechanism of binding of a5/31 to the RGD-region in fibronectin is 
investigated. The finding that a5/31 in its high affinity state binds RGD as strong as 
αν/33, suggests that a5ßl may be a possible target for the inhibition of metastasis with 
RGD peptides. Therefore, in chapter 9, various reagents interfering with a5/81 are used 
in experimental metastasis assays, to investigate the hypothesis that a5/31 may be critical 
for metastasis of an avj93-negative cell line. The results suggest that this is not the case 
but a disintegrin that does not bind aS/31, blocks lung colonization and its mode of action 
is investigated in in vitro assays. In addition, the effect of expression of αν/33 on 
metastasis of this αν/33-negative cell line is investigated. 
Although CD44 is expressed in all stages of melanocyte tumor progression and in 
most melanoma cell lines, it has been demonstrated to play a role in growth and 
metastasis of melanoma cells. It may be that its HA-binding capacity or the availability of 
HA is critical for metastasis. Therefore, in chapter 10, production of HA and other 
glycosaminoglycans and CD44-mediated adhesion to HA is investigated for human 
melanoma cell lines in relation to their metastatic potential. As the pattern of CD44 
alternative splicing has been related to tumor progression in several malignancies, in 
chapters 11 and 12, expression of CD44 isoforms is investigated in cutaneous and uveal 
melanoma, both in patients lesions and in cell lines. 
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We studied the adhesive characteristics of melanocytes, cultured either in the 
presence of the mitogen PMA that keeps them in a proliferative state, or in the 
absence of PMA allowing them to differentiate. On proliferating melanocytes, several 
integrins, ICAM-1, E-cadherin, and CD44 were expressed. In the absence of PMA, 
proliferation was arrested, melanin synthesis increased, and the morphology of the 
melanocytes became more spreaded. Under these conditions, expression of integrins 
0(3/31 and aSßl decreased whereas expression of α2)31, a4ß\, and a6ßl increased. No 
changes were observed for any of the other adhesion molecules. Immuno-
precipitations from metabolically labeled cells confirmed the shift in integrin 
expression at the level of biosynthesis. The increased surface expression of alßl and 
об/31 in the absence of PMA was accompanied by an induction of adhesion to 
basement membrane components collagen and laminin through these integrins. 
Integrin a5/Jl/av/J3-mediated adhesion to fibronectin, CD44-mediated adhesion to 
hyaluronate, and E-cadherin/01-integrin-mediated adhesion to keratinocytes were not 
affected by PMA. These findings indicate that by selective modulation of the 
expression of adhesion molecules, adhesion to components of the basement membrane 
is reduced in proliferating melanocytes whereas adhesion to keratinocytes is 
maintained. Similar events may be involved in melanocyte proliferation and 
migration during wound healing and initial steps of melanocytic tumor progression. 
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INTRODUCnON 
Melanocytes are neural crest-derived cells that are mainly situated in the basal cell 
layer of the epidermis where they make contact with the basement membrane and with 
adjacent keratinocytes. A single melanocyte distributes pigment to 25 to 35 keratinocytes 
through its dendrites, and such a cluster has been termed an "epidermal melanin unit" 
[12]. By production and transfer of melanin to keratinocytes, melanocytes protect 
keratinocytes from damage by UV radiation. In vitro, the morphology of melanocytes is 
controlled by contact with extracellular matrix (ECM) components [13], and keratinocytes 
control differentiation and proliferation of melanocytes [11,38]. In vivo, normal 
melanocytes do not proliferate unless stimulated by environmental factors such as UV 
radiation or during processes such as wound healing [38]. Adhesive contacts with 
surrounding keratinocytes and the underlaying basement membrane may help to conserve 
the non-proliferative state and characteristic morphology of melanocytes. 
Molecules that mediate cell adhesion can be grouped in distinct families based on 
structural homologies between the members [17]. Integrins are α/î-heterodimeric cell 
surface glycoproteins that make heterophilic contacts with ECM proteins or with 
counterreceptors on other cells. Their cytoplasmic domains contact the cytoskeleton and 
they act as signaling receptors. Binding of integrins to their ligands can influence gene 
expression and control proliferation of cells [16]. Members of the immunoglobulin (Ig) 
superfamify are cell surface glycoproteins made up of Ig repeats. They bind in a 
heterophilic manner to counterreceptors on other cells and these counterreceptors are 
usually of the /32-integrin type [43]. Cadherins homophilically bind to Cadherins on other 
cells [35]. Their short cytoplasmic tail contacts the cytoskeleton via a group of proteins 
called catenins, and this feature is critically involved in Cadherin function. The selectins 
are heavily glycosilated cell surface proteins that bind to counterreceptors on other cells 
but the exact nature of such counterstructures is still largely unknown [4]. Finally, a 
member of the cartilage-link proteins, CD44, is a cell adhesion molecule involved in 
adhesion to hyaluronate (HA) and it is thought to act as a homing receptor on 
lymphocytes [22]. 
Integrin-mediated adhesion to ECM components and E-cadherin mediated binding to 
keratinocytes has been reported for melanocytes in vitro [36,44]. In the present study we 
investigated the adhesive characteristics of melanocytes cultured in the presence or 
absence of the mitogen phorbol 12-myristate 13-acetate (PMA). 
MATERIALS AND METHODS 
Materials and antibodies 
Laminin (Ln) and collagen type IV (CoIV), both isolated from Englebreth-Holm-
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Swarm mouse sarcoma cells, were purchased from Life Technologies (Grand Island, 
NY). Collagen type I (Col) was isolated from rat tail. Fibronectin (Fn), isolated from 
human plasma, and hyaluronate (HA), isolated from human umbilical cord, were 
purchased from Sigma (St Louis, MO). The antibodies used are listed in Table 1. 
Table 1. Monoclonal antibodies. 
antibody 
NKI-beteb 
TS2/7 
5E8 
P1B5 
HP2/1 
NKI-SAM1 
GoH3 
13C2 
10E5 
4B4 
CLB-LFA1/1 
23C6 
3E1 
P1F6 
SN1 
NKI-P2 
CL203 
CBRIC2/2 
CBRIC3/2 
El/6 
H18/7 
HECD-1 
WT31 
antigen 
gplOO 
αϊ 
α2 
α3 
α4 
«5 
«6 
αν 
allb 
/31 
/32 
αν/33 
/34 
αν/35 
08 
CD44 
ICAM-1 
ICAM-2 
ICAM-3 
VCAM-1 
E-selectin 
E-cadherin 
CD3 
source and reference 
Dr. Figdor, Nijmegen, The Netherlands [2] 
T-Cell Science, Cambridge MA [14] 
Dr. Bankert, Buffalo, NY [45] 
Life Technologies, Gaithersburg, MD [41] 
Dr. Sanchez-Madrid, Madrid, Spain [30] 
Dr. Figdor, Nijmegen, The Netherlands [39] 
Dr. Sonnenberg, Amsterdam, The Netherlands [34] 
Dr. Horton, London, UK [8] 
Dr. Coller, Stoneybrook, NY [5] 
Coulter, Hialeah, FL [26] 
Dr. Figdor, Nijmegen, The Netherlands [19] 
Dr. Horton, London, UK [8] 
Telios, San Diego, CA [15] 
Life Technologies, Gaithersburg, MD [42] 
Dr. Nishimura, San Francisco, CA [27] 
Dr. Figdor, Nijmegen, The Netherlands [28] 
Dr. Ferrane, Valhalla, NY [24] 
Dr. Springer, Boston, MA [9] 
Dr. Springer, Boston, MA [10] 
Dr. Bevilacqua, La Jolla, CA [29] 
Dr. Bevilacqua, La Jolla, CA [29] 
Takara Biomedicals, Otsu, Japan [33] 
Dr. Tax, Nijmegen, The Netherlands [37] 
Isolation and culturing of melanocytes and keratinocytes 
Melanocytes were isolated from human foreskin epidermal cell suspensions by 
selective adherence and growth in HAM's FIO medium (Flow, Irvine, UK) supplemented 
40 
with 2% Ultroser-G synthetic serum (Life Technologies), glutamate, penicillin and 
streptomycin, 100 μΜ IBMX (Sigma) and 16 nM PMA (Sigma) and were cultured for a 
maximum of 6 passages. For some experiments, melanocytes were allowed to 
differentiate by removal of PMA from the medium. Freshly isolated human keratinocytes 
were a kind gift from Mieke Latijnhouwers (Dept. of Dermatology, University Hospital, 
Nijmegen, The Netherlands). Keratinocytes were cultured for a maximum of 3 passages 
in serum free keratinocyte growth medium containing 0.09 mM calcium and 
supplemented with 50 /ig/ml bovine pituitary extract and 5 ng/ml recombinant epidermal 
growth factor (Life Technologies). Under these conditions keratinocytes proliferate and 
express a basal phenotype without stratification [36]. 
Flow cytometry 
Cultured cells were harvested by short trypsinization of subconfluent monolayers and 
suspended in complete HAM's FIO medium. After washing with PBS containing 0.5% 
BSA and 0.02% azide, they were incubated with mAbs (Table 1) in PBS/BSA/azide for 
30 min at 4°C. After washing with PBS/BSA/azide, the cells were incubated with 
fluorescein-isothiocyanate (FITC)-conjugated F(ab')2 fragments of rabbit anti-mouse Ig 
antibodies (Dako, Glostrup, Denmark) or, in the case of GoH3 mAbs, with FITC-
conjugated rabbit anti-rat Ig antibodies (Dako). Analyses were performed on an Epics 
Elite Flowcytometer (Coulter, Mijdrecht, The Netherlands). 
Immunoprecipitation 
Subconfluent monolayer cell cultures (75 cm2) were labeled overnight at 37°C with 
0.5 mCi [35S]-methionine (Amersham, Houten, The Netherlands) in methionine-free 
medium (Flow) containing 10% dialyzed FCS. The cells were washed 2 times with PBS 
and incubated with NP40 lysis buffer (0.5% NP40, 0.015 M NaCl, 0.01 M Tris pH 7.5, 
1.0 mM phenyl-methyl-sulphonyl-fluoride and 4 /tg/ml Aprotinin) at 4°C for 10 min. 
Subsequently the cells were scraped off the culture flask, repeatedly aspired into syringes 
and forced through needles with decreasing diameter. Glycoproteins were isolated from 
NP40 solubilized cell extracts by adsorption to concanavalin A (Con A)-Sepharose 
(Pharmacia Inc., Uppsala, Sweden). Immunoprecipitations were performed as described 
before [20]. To compare the amount of glycoproteins in the various cell lines, equal 
numbers of counts of the Con Α-bound fractions were used for immunoprecipitation. 
Cell adhesion assay 
Adhesion assays were performed as described before [7]. For adhesion to ECM 
components, polystyrene microtiter plates (96 flatbottomed wells; Greiner, Alphen a/d 
Rijn, The Netherlands) were coated overnight with 20 /*g/ml of the appropriate ECM 
component, washed and blocked with PBS/BSA. Coupling of HA to the wells was done 
as described before [40]. For adhesion assays to keratinocytes, these were allowed to 
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adhere and spread in wells for 3 h in keratinocyte growth medium and unattached cells 
were washed away. Subsequently, 51Cr-labeled melanocytes in DMEM (Flow) containing 
0.25% BSA were seeded into the wells (10,000 cells/well) and allowed to attach for 30 
min at 37°C. After washing, the adherent cells were lysed in Triton-X-100 and 
radioactivity was measured in a gamma-counter. For adhesion inhibition assays, 
melanocytes were incubated with m Abs for 30 min at 4°C before being added to the 
wells, and keratinocytes were incubated with m Abs for 30 min at 37'С prior to addition 
of labeled melanocytes. 
RESULTS 
Surface expression of adhesion molecules on cultured melanocytes 
Of the integrin family, proliferating melanocytes in the presence of PMA expressed 
predominantly integrins a3/31 and αν/33 (Table 2). Moderate levels of a5/31 and αν/35 
were expressed. Low expression was observed of α2/31, α6/31 and αν/38, whereas αϊ/31, 
«401, aIIb/33 and /32- and /34-integrins were absent. Of the Ig superfamily only ICAM-1 
was expressed whereas ICAM-2, ICAM-3 and VCAM-1 were absent. No expression of 
E-selectin was detected whereas high expression of E-cadherin was observed and CD44 
was very strongly expressed. 
Table 2. Surface expression of adhesion molecules on melanocytes 
cultured in the presence of PMA. 
control1 
5/62 
ICAM-3 
6/6 
a5 
24/27 
αν/33 
48/32 
E-cadherin 
85/98 
CD44 
860/801 
об 
13/14 
/94 
5/5 
VCAM-1 
7/8 
αϊ 
6/9 
allb 
7/5 
αν/35 
20/22 
E-selectin 
4/6 
a2 
12/17 
av 
50/37 
/38 
12/12 
ICAM-1 
41/30 
a3 
80/101 
181 
96/127 
ICAM-2 
5/9 
a4 
5/5 
/32 
6/8 
'WT31 anti-CD3 mAbs 
2Mean fluorescence given for 2 patients. 
Removal of PMA from the medium induced a shift in morphology from a dendritic 
bipolar morphology to a more spreaded appearance (Fig 1), it strongly increased melanin 
synthesis (not shown) and it arrested proliferation. In the absence of PMA, surface 
expression of a3/31 and a5/31 decreased (Fig 2). In contrast, faint expression of «401 
42 
became detectable and expression of a6/31 was enhanced. Similarly, for melanocytes of 1 
individual, enhanced expression of a2/31 was observed in the absence of PMA (Fig 2), 
but this was not found for melanocytes from 2 other individuals (not shown). No 
differences in expression were observed between cells cultured with or without PMA for 
any of the other adhesion molecules studied (not shown). 
Figure 1. Effect of PMA on the 
morphology of cultured melanocytes. 
^ Ч ^ ? Ч Melanocytes were cultured in the 
ίΤ/ presence (A) or absence (B) of PMA for 
two weeks. 
These data show that arrest of proliferation and acquirement of a differentiated 
phenotype of melanocytes in the absence of PMA is accompanied by selective up- and 
down modulation of integrin expression levels. 
Figure 2. Effect of PMA on the 
expression of integrins. Melanocytes 
were cultured in the presence (line) or 
absence (dotted line) of PMA for two 
weeks and incubated with anti-integrin 
mAbs followed by FITC-labeled second 
antibodies. Results are shown for one 
out of three individuals. 
- «3 
1
 /м 
Ί °™ "~ 1 
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Synthesis of integrins in cultured melanocytes 
We next investigated if the shift in the level of surface expression of аЗ/31 and аб/îl, 
upon transition from a proliferative to a diferentiated state, was reflected by changes in 
the level of biosynthesis of these integrins. Therefore, we immunoprecipitated the аЗ and 
аб chain from metabolically labeled melanocytes cultured in the presence or absence of 
PMA. In line with the surface expression data, synthesis of аЗ decreased whereas 
synthesis of аб increased in the absence of PMA (Fig 3). In melanocytes obtained from 
one individual we also observed induction of oil synthesis in the absence of PMA but in 
melanocytes of another individual this was not the case (Fig 3). 
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These results indicate that changes in surface expression of integrins upon removal of 
PMA from the culture medium are accompanied by changes in the level of biosynthesis of 
these molecules. 
+PMA -PMA MW +PHA -РИА 
o2 аЗ аб а2 аЭ аб (kD) л2 аЗ аб а2 аЗ аб 
а З — 
а б — 
patient 1 patient 2 
fïjjiire 3. Effect of PMA on the biosynthesis of integrins. Melanocytes of two patients were 
cultured in the presence or absence of PMA for two weeks as indicated. Subconfluent monolayers 
were metabolically labeled overnight, lysed, and glycoproteins were isolated by adsorption to Con 
A-Sepharose. Equal amounts of counts from the Con Α-bound fraction were used for 
immunoprecipitation with mAbs to ой, OLÌ, or аб. 
Effect of PMA on adhesion of melanocytes to ECM-components 
As removal of PMA from the culture medium affected the expression pattern of 
adhesion molecules, we performed adhesion assays with melanocytes cultured in the 
presence or absence of PMA. Melanocytes cultured with PMA adhered to Fn and HA but 
they adhered very poorly to Ln and not to Col or CoIV (Fig 4A). However, after 
culturing in the absence of PMA for one week, melanocytes gained the ability to adhere 
strongly to Ln and Co whereas adhesion to Fn and HA was unaffected. Adhesion to Fn 
was inhibited by mAbs to integrins a5/31 and αν/33 in the presence (Fig 4B) or absence 
(not shown) of PMA. We have previously demonstrated that adhesion of melanocytes to 
HA is mediated by CD44 [40]. The enhanced adhesion to Ln of melanocytes grown in the 
absence of PMA could be blocked with anti-integrin /31 and anti-аб mAbs but not with 
anti-a2 or anti-аЗ mAbs (Fig 4C). The induced adhesion to Co was blocked with anti-
integrin /31 and anti-a2 mAbs and not with anti-аЗ or anti-аб mAbs. 
These results indicate that, in line with loss of expression of аб/31 and a2ß\, 
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OSA 
Fn 
Ln 
Col 
ColV 
HA 
К 
^ ^ _ J - i 
% a d h e r e n t o e i l · 
adhesion to Ln and Co through these integrins as observed for non-proliferative 
melanocytes, is absent from proliferating melanocytes in the presence of PMA. 
Figure 4. Effect of PMA on adhesion to 
ECM components. A: Melanocytes were 
cultured in the presence (dotted bar) or 
absence (filled bar) of PMA for two 
weeks before being tested in adhesion 
assays. Shown is the percentage of 
adherent cells to wells coated with 
different ECM components as indicated. 
B: Melanocytes cultured in the presence 
of PMA were allowed to adhere to Fn 
in the absence or presence of mAbs to 
integrins as indicated. C: Melanocytes 
cultured in the absence of PMA were 
allowed to adhere to wells coated with 
Ln, Col or ColV in the absence or 
presence of mAbs to integrins as 
indicated. For A and В one experiment 
of three, and for С one experiment of 
two is shown. Means ± s.d. from 
triplicate wells are shown. 
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Effect of PMA on adhesion of melanocytes to keratinocytes 
As melanocytes expressed several receptors that have been implicated in cell-cell 
interactions in the epidermis (E-cadherin and integrins a2/31 and a3/?l), we investigated 
adhesion to keratinocytes of melanocytes cultured in the presence or absence of PMA. 
Melanocytes adhered to keratinocytes under both conditions (Fig 5A). Removal of 
keratinocytes with EDTA and washing the wells 3 times with DMEM/BSA shortly before 
addition of the labeled melanocytes completely abrogated adhesion, indicating that ECM 
proteins produced by the keratinocytes and attached to the wells were not involved, and 
that indeed cell-cell interactions were studied. We used mAbs to integrin subunits a2, a3, 
and 01, and to E-cadherin to inhibit adhesion. MAbs to integrin ßl and to E-cadherin 
moderately inhibited adhesion to keratinocytes and the combination of these mAbs 
inhibited adhesion for approximately 60% (Fig 5B). No effect was observed of the mAbs 
to integrin a2 or a3 subunits. 
These findings indicate that E-cadherin//31-integrin-mediated contacts of melanocytes 
with proliferating non stratifying keratinocytes are not influenced by PMA. 
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Figure S. Effect of PMA on adhesion to 
keratinocytes. A: Melanocytes from two 
individuals were grown in the absence 
or presence of PMA for two weeks 
before being allowed to adhere to wells 
coated with increasing amounts of 
keratinocytes as indicated. In a parallel 
experiment, keratinocytes were removed 
by EDTA and wells were washed prior 
to addition of the labeled melanocytes 
(dashed lines). B: Melanocytes of two 
individuals were cultured in the 
presence of PMA and allowed to adhere 
to wells coated with l.5xl(f keratino­
cytes. Melanocytes and keratinocytes 
were incubated with 10 ßg/ml of rnAbs 
to ы2 (5E8), a3 (P1B5), ßl (4B4), E-
cadherin (HECD-1) or combinations as 
indicated. For A one experiment of 
three, and for В one experiment of two 
is shown. Means ± s.d. from triplicate 
wells are shown. 
DISCUSSION 
In the present study, we have investigated the adhesive characteristics of cultured 
normal human melanocytes maintained either in a differentiated non-proliferative state 
(characterized by cell spreading, high level of melanin synthesis, and lack of cell division) 
or in a highly proliferative state induced by the phorbol ester PMA. Expression of 
adhesion molecules of the integrin-, Ig-, Cadherin-, selectin-, and CD44 families was 
determined and the role of these receptors in adhesion to ECM components and to 
keratinocytes was explored. 
The finding that melanocytes express predominantly α301 of the integrins and that 
they have E-cadherin expression is in line with earlier reports [36,44]. We also detect 
expression of integrins a5/?l and αν/33 and of ICAM-1, three adhesion molecules that 
have been implicated in melanocytic tumor progression [3,6,18]. This is not due to any 
effect of the tumor promotor PMA since these molecules can also be detected in the 
absence of PMA. Expression may be induced by other culture conditions since these 
molecules are absent from melanocytes in situ. The capacity of melanocytes to express 
such melanocytic tumor progression-associated adhesion molecules may be important 
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features during embryonic development and wound healing. 
We find that proliferating melanocytes adhere strongly to Fn but not or hardly to Ln 
and Co. This is probably due to the very low expression of a2/31 Ln/Co- and аб/Jl Ln 
receptors in the presence of PMA and to the absence of a 1/31 Ln/Co binding integrin. 
Even though a301 is a receptor for Ln, Co, and Fn, its high level of expression does not 
provide melanocytes with the capacity to adhere to Ln and Co, and аЗ/31 is not involved 
in the adhesion to Fn. It has been shown that аЗ/31 can be involved in migration of 
melanocytes [44]. In line with the results from that study, we find that melanocyte 
adhesion to Fn is mediated by integrins а501 and αν/33. However, others have shown 
that in neonatal but not fetal melanocytes, a301 can be involved in adhesion to Fn [31]. 
Such subtle discrepancies may possibly be explained by differences in culture conditions 
that may effect the activity of the adhesion molecules. 
A marked effect of PMA is observed specifically on melanocyte adhesion to Ln and 
Co. In the absence of PMA, melanocytes adhere strongly to these basement membrane 
glycoproteins. Our finding that long term culturing of melanocytes in the presence of 
PMA abrogates adhesion to Ln and Co is in line with findings for keratinocytes [1]. 
However, opposite to its effect on melanocytes, PMA induces terminal differentiation of 
keratinocytes. Furthermore, in keratinocytes a general decrease of ß\-integrin expression 
is observed whereas melanocytes have a selective increase of аЗ/31 and a5/31 expression 
in the presence of PMA. Our immunoprecipitation data show that increased surface 
expression is accompanied by an increased level of synthesis. For other /31 integrins 
(a2/31, a4/31 and аб/31) we find the opposite effect, namely that PMA selectively 
downmodulates surface expression and synthesis. In addition, even though modulation of 
a2/31 expression was only observed in melanocytes from one individual, in all cases we 
observed a strong effect of PMA on a2j31-mediated adhesion to Co. This suggests that 
PMA influences the activity of a2/31 as well. This effect is opposite to the effect observed 
when T-cells are incubated for a period of only a few minutes with PMA [32]. Such a 
treatment enhances the affinity of/31 integrins on leukocytes, whereas long term exposure 
of melanocytes to PMA appears to reduce the affinity of a2/31. Thus, PMA-induced 
proliferation of melanocytes selectively up- and downmodulates expression, synthesis, and 
activity of integrins, which leads to a loss of adhesion to basement membrane components 
Ln and Co. 
Our finding that melanocytes can use E-cadherin for binding to keratinocytes is in line 
with the report from Tang et al. [36], but we find that E-cadherin and |81-integrins are 
involved to approximately the same extent whereas Tang et al. report a major role for E-
cadherin. Again, different culture conditions may influence the activity of the integrins. 
Even though a2/31 and аЗ/31 have been implicated in epidermal cell-cell interactions [21], 
up to 10 /ig/ml of inhibitory mAbs to these integrins have no effect on melanocyte-
keratinocyte interactions. This suggests that other ßl-integrins may be involved. No 
differences are observed between proliferative and non-proliferative melanocytes, 
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regarding adhesion to keratinocytes. For E-cadherin, this is in line with the finding that 
expression of E-cadherin is not influenced by PMA and it may suggest that expression 
and/or activation of the unidentified /31-integrin is not affected by PMA either. 
The differential modulation by PMA of melanocyte adhesion to basement membrane 
components and keratinocytes, may be paralleled in vivo by effects of keratinocyte-
derived cytokines [23]. One might speculate that by differentially affecting attachment to 
the basement membrane and to other cells, such modulation may influence proliferation 
and migration of melanocytes during embryogenesis, wound healing, and the initial steps 
of melanocytic tumor progression. 
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Loss of expression of E-cadherin, the major cell-cell adhesion receptor on 
keratinocytes, has been linked to tumor progression in various carcinomas. As E-
cadherin has been reported to be expressed in cultured human melanocytes, we 
questioned whether loss of E-cadherin expression may abo be related to melanocyte 
tumor progression. Flowcytometrical analysis demonstrated that E-cadherin was 
expressed on cultured normal melanocytes and nevus cells. Two non-invaslve/non-
metastatic melanoma cell lines showed low expression and 4 invasive/metastatic 
melanoma cell lines did not express E-cadherin. Immunohistochemistry on frozen 
sections of human melanocytic lesions, resulted in diffuse staining of 1/23 common 
nevocellular nevi and 1/13 dysplastic nevi, and no staining was observed in 7/7 early 
primary melanomas (<. 1.5 mm). Staining was observed in 4/20 advanced primary 
melanomas (> 1.5 mm) and 5/35 melanoma metastases. Thus, even though E-
cadherin is expressed in cultured melanocytes and nevus cells and lost in 
invasive/metastatic melanoma cells in vitro, it is rarely found in early stages of 
melanocytic tumor progression in situ, and surprisingly, some expression can be 
observed in 10-20% of lesions of advanced stages. 
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INTRODUCnON 
E-cadherin is a calcium-dependent epithelial cell adhesion receptor that is clustered in 
adherens junctions. In these regions, E-cadherin molecules on opposing cells bind to each 
other [6]. In addition to these homophilic interactions, E-cadherin can heterophilically 
bind integrin ae#7 on lymphocytes [8]. Binding of a complex of proteins called catenins 
to its cytoplasmic domain is crucial for the adhesive function of E-cadherin [28]. 
Reduction of intercellular adhesiveness is a prerequisite for the invasive behavior of 
carcinomas, and the breakdown of the adherens junctions is central in this process [29]. 
Indeed, antibodies to E-cadherin can induce invasiveness of otherwise non-invasive 
epithelial cells [3], and conversely, E-cadherin cDNA transfection into highly invasive, E-
cadherin negative carcinoma cells, greatly reduces their invasive capacity [37]. 
Furthermore, loss of (membrane-associated) E-cadherin expression was found to be 
correlated with lymph node metastasis of squamous cell carcinoma [25], with 
dedifferentiation of meningiomas [31], with high Gleason grade of prostate carcinomas 
[32], with infiltrative growth of basal cell carcinoma [24], with dedifferentiation and 
metastasis of breast carcinoma [15,20,21], with dedifferentiation, high Dukes stage, and 
metastasis of colon carcinoma [13,18], with poor prognosis of bladder cancer (in 
combination with gp78) [22], with dedifferentiation of thyroid carcinoma [7], and with 
lymph node metastasis, high grade, and advanced stage of pancreatic carcinoma [23]. 
Recently, it has been reported that E-cadherin is expressed on cultured melanocytes 
where it mediates adhesion to keratinocytes [30]. Therefore, in the present study, we 
investigated the hypothesis that loss of E-cadherin might also be related to melanocytic 
tumor progression. 
MATERIALS AND METHODS 
Cell lines and culture conditions 
The cutaneous melanoma cell lines included IF6 and 530 (non-metastatic in nude mice 
and non-invasive through a human amniotic basement membrane), and M14, Mel57, 
BLM, and MV3 (metastatic and invasive) [9,34,35]. Uveal melanoma cell lines included 
Mel202 [19], provided by Dr. BR Ksander, Boston, MA; 92-1 [11], provided by Dr. I de 
Waard-Siebinga, University Hospital, Leiden, The Netherlands; and OCM-1 [17], 
provided by Dr. GPM Luyten, Rotterdam, The Netherlands. All melanoma cell lines 
were cultured in Dulbecco's Modified Eagles Medium (DMEM) (Flow laboratories, 
Irvine, UK) supplemented with 10% fetal calf serum, penicillin, and streptomycin. 
Isolation and propagation of human foreskin melanocytes were performed as 
previously described [27]. Nevus cells were isolated from giant congenital nevi. 
Melanocytes and nevus cells were cultured for a maximum of 5 passages in Ham's FIO 
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(Flow laboratories) supplemented with 2% Ultroser-G synthetic serum (Gibco, Grand 
Island, NY), glutamate, penicillin, streptomycin, 0.1 mM IBMX (Sigma, St Louis, MO) 
and 16 nM phorbol 12-myristate 13-acetate (PMA) (Sigma). 
Flowcytometry 
Cells were harvested by short trypsinization of subconfluent monolayers, suspended in 
complete culture medium, and washed with phosphate buffered saline (PBS) containing 
0.5% BSA and 0.02% azide, and 1 mM CaCl2 and 0.5 mM MgCl2 to preserve E-cadherin 
integrity. Subsequently cells were incubated with 6F9 anti-E-cadherin mAb [14] 
(Eurodiagnostica, Apeldoorn, The Netherlands) in PBS/BSA/azide/CaI+/Mg2+ for 30 min 
at 4 eC. After washing, the cells were incubated with fluorescein-isothiocyanate (FITC)-
conjugated F(ab')2 fragments of rabbit anti-mouse Ig antibodies (Dako, Glostrup, 
Denmark). Analyses were performed on an Epics Elite flowcytometer (Coulter, 
Mijdrecht, The Netherlands). 
Lesions 
Lesions were obtained from patients at the University Hospital, Nijmegen, The 
Netherlands or provided by Dr. Ε-B Bröcker, Würzburg, Germany. Based on 
histopathologic examination of paraffin sections, lesions were divided into five classes: 
common nevocellular nevus (NN) (η=23), dysplastic [12] (atypical) nevus (DN) (n = 13), 
early primary melanoma (tumor thickness < 1.5 mm; ePM) (n=7), advanced primary 
melanoma (tumor thickness > 1.5 mm; aPM) (n=20), and melanoma metastasis (MM) 
(n=35). Representative samples were snap frozen in liquid nitrogen and stored at -80°C 
until sectioning. 
Immunohistochemistry 
Four μπι frozen sections were fixed in 3% paraformaldehyde for 20 minutes and 
permeabilized with 0.2% Triton X-100 for 5 minutes and subsequently incubated at room 
temperature with 6F9 E-cadherin mAb for 1 h. All buffers contained 1 mM CaCl2 and 
0.5 mM MgCl2 to preserve E-cadherin integrity. After washing with PBS, bound mAbs 
were visualized using the peroxidase-based Vectastain elite ABC kit (Vector Laboratories, 
Burlingame, CA) and 3-amino-9-ethylcarbazole as substrate. After counterstaining with 
Meyers hematoxylin sections were mounted with Kaisers glycerin/gelatin (Merck, 
Darmstadt, Germany). 
Melanocyte cells were identified in parallel HE-stained sections and by staining 
frozen sections with NKI-beteb anti-gplOO mAb [2]. 
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RESULTS 
To investigate if E-cadherin expression is inversely related to melanocyte tumor 
progression, we first analyzed expression on cultured human melanocytes isolated from 2 
individuals, on cultured nevus cells isolated from 2 individuals, and on a panel of 6 
human cutaneous melanoma cell lines with different invasive and metastatic potential. 
Both melanocyte cultures stained positive with the 6F9 E-cadherin mAb (Fig 1). The 2 
nevus cell cultures expressed E-cadherin as well, though the level of expression was 
somewhat lower than that found on melanocytes. Culturing melanocytes or nevus cells in 
the absence of PMA for 1 week, did not affect E-cadherin expression (Fig 1). Of the 
panel of cutaneous melanoma cell lines, only the non-invasive/non-metastatic cell lines 
IF6 and 530, expressed a very low amount of E-cadherin, whereas the invasive and 
metastatic cell lines M14, Mel57, BLM, and MV3 were negative (Fig 1). In addition, no 
E-cadherin could be detected on 3 uveal melanoma cell lines (Mel202, 92-1, and OCM-1) 
(not shown). 
Figure I. E-cadherin expression on cultured human melanocyte cells. Melanocytes βί), nevus 
cells (N), and cutaneous melanoma cell lines were stained with 6F9 E-cadherin mAb. Dashed 
graphs represent melanocytes and nevus cells cultured in the absence of PMA for 1 week. The 
dotted vertical line indicates the gate set with control Ig. One representative experiment of 3 is 
shown. 
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We next investigated E-cadherin expression on frozen sections of lesions from 
different stages of human melanocyte tumor progression. Epidermal keratinocytes, in all 
lesions that contained epidermis, stained strongly showing a membranous aspect. Because 
of the close contact of epidermal melanocytes with keratinocytes it was not possible to 
determine if melanocytes in normal skin expressed E-cadherin. We observed some diffuse 
staining with 6F9 mAb of melanocyte cells only in 1/23 NN (Fig 2a,b,c) and 1/13 DN. 
All 7 ePM tested lacked E-cadherin expression whereas 4/20 aPM and 5/35 MM did 
express E-cadherin. Heterogenous expression was observed in those lesions; some cells 
with membranous expression, some with cytoplasmic staining, and some being negative 
(Fig 2d,e,f). More than 50% of tumor cells stained in all positive lesions. The positive 
MM originated from liver, kidney, and lymph nodes. As E-cadherin can mediate binding 
of lymphocytes, we checked for enhanced lymphocyte infiltration in the positive aPM and 
MM lesions but no clusters of immune cells were present. 
Figure 2. Immunohistochemical E-cadherin staining in human melanocyte lesions. Frozen sections 
of common nevocellular nevi (А, В, С) and melanoma metastases (D,E,F) were stained with 6F9 
mAb. Note that in A, B, and С keratinocytes stain but only nevus cells (arrows) in С stain diffuse-
¡У-
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DISCUSSION 
Changes of adhesive properties are thought to play an important role in the process of 
tumor progression. Not only do metastatic tumor cells have to gain the capacity to adhere 
to basement membranes and to the extracellular matrix in the target organ, but loss of 
homotypic cell-cell adhesion is important for the initial invasion into surrounding tissues 
[4,16,36]. For invasive carcinomas, downmodulation of intercellular adhesion involves 
the breakdown of adherens junctions [29]. The cell-cell adhesion receptor E-cadherin is 
clustered in these structures on keratinocytes and its (membrane-associated) expression is 
lost with tumor progression in carcinomas [5]. E-cadherin is also expressed on cultured 
melanocytes where it can mediate adhesion to keratinocytes [30]. As keratinocytes control 
proliferation and differentiation of melanocytes [10,33], we hypothesized that loss of E-
cadherin may also occur in melanocyte tumor progression. 
Our finding that E-cadherin is expressed on cultured melanocytes and nevus cells and 
that it is lost on invasive and metastatic melanoma cell lines, confirms and extends the 
findings from an earlier report where expression was reported on cultured melanocytes 
[30]. Thus, in vitro, loss of E-cadherin seems to be related to melanocyte tumor 
progression. It is interesting in this respect that the 2 melanoma cell lines that are non-
invasive and non-metastatic [9,34] have some weak remaining expression. 
To the best of our knowledge, no studies have been published on E-cadherin 
expression on melanocyte cells in situ. Based on the in vitro findings it might be 
expected that melanocytes and nevi would express E-cadherin. However, we do not find 
expression in 22/23 NN and 12/13 DN. It is not possible to determine expression on 
normal melanocytes in situ since these cells are in close contact with surrounding 
keratinocytes which express high levels of E-cadherin at their surface. The fact that 
almost all NN and DN are negative whereas nevus cell cultures express E-cadherin, 
suggests that culturing the nevus cells induces expression. In analogy, the strong surface 
expression observed on cultured normal melanocytes may be a culture artefact as well. In 
this study, the melanocytes and nevus cells are cultured both in the presence and in the 
absence of the phorbol ester PMA, an agent that influences expression and function of 
another group of adhesion molecules called integrins [1,26]. We observe no effect of 
PMA on E-cadherin expression on these cell types. Possibly, other factors present in the 
culture medium may play a role. 
In contrast to the hypothesis that E-cadherin may be lost with melanocyte tumor 
progression, expression is observed in 10-20% of the aPM and MM. Melanoma cells may 
produce a transcription factor that induces abberant E-cadherin expression, but the 
heterogenous expression observed in these lesions (cells with some membranous staining 
and others negative) does not suggest any functional consequences for the adhesive 
behavior of the cells. Whether E-cadherin-mediated homotypic aggregation can enhance 
melanoma metastasis, i.e. by prolonging survival of melanoma cells in the blood stream, 
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is not known. As E-cadherin can also bind integrin aeßl on T-cells [8], its expression on 
melanoma cells may facilitate lymphocyte infiltration of the tumor. However, the E-
cadherin positive melanomas do not show increased numbers of tumor infiltrating 
lymphocytes compared to E-cadherin negative melanomas, suggesting that this interaction 
does not occur in the lesions tested. 
In conclusion, we find that loss of E-cadherin correlates with increased malignancy of 
cultured melanocytic cells, whereas E-cadherin is hardly detectable in early stages of 
melanocytic tumor progression in situ and emerges in a minor portion of advanced 
primary melanomas and melanoma metastases. 
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Emergence of aSßl fibronectin- and αν/33 vitronectin receptor expression 
in melanocyte tumor progression 
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Cell adhesion is crucial in the process of tumor progression. As integrins are 
important receptor molecules involved in cell adhesion, we studied the distribution of 
the αΐ-б, av, allb, /31, /33, and /34 integrin subunits in tissue sections of common 
nevocellular nevi (η=22), dysplastic nevi (η=16), thin- (η=24) and thick primary 
cutaneous melanomas (n=28), and melanoma metastases (n=25). Decrease of об and 
/34, and increase of a4 and αν were found to be correlated with melanocyte tumor 
progression. Furthermore, expression of <*5 and /33 was only detected in primary 
melanoma and melanoma metastasis. Our findings indicate that during melanocyte 
tumor progression alterations in integrin expression occur, the most striking being 
emergence of a5/31 fibronectin- and αν/33 vitronectin receptor. 
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INTRODUCTION 
Tumor progression can be considered to be composed of a series of discrete 
sequential steps leading to metastasis [29]. It may be expected that molecules that mediate 
homotypic or heterotypic interactions between cells or interactions between cells and their 
extracellular surrounding are involved in several of these steps [23]. Loss of adhesive 
properties for the normal location but also requirement of adhesive properties for foreign 
matrices and other cells may be important characteristics of malignant tumor cells. 
The last few years, a group of cell surface receptors, called integrins, has been 
extensively studied and characterized as summarized in several reviews [14,15,32]. 
Integrins are a-0 heterodimeric transmembrane glycoproteins and subsets can be formed 
on the basis of a common 0-subunit. So far, a 01, a 02, and a 03 subfamily have been 
described, and at least 5 additional 0-subunits have been discovered. Integrins mediate 
cell-cell and cell-extracellular matrix (ECM) interactions and the involvement of some of 
these or related molecules in tumor progression has been demonstrated. Thus, it has been 
shown that a) the VLA-5 fibronectin receptor (integrin a501) can suppress the 
transformed phenotype of Chinese hamster ovary (CHO) cells [11], b) the laminin and 
collagen receptor VLA-2 (integrin a201) has been demonstrated to be important in the 
metastatic process of rhabdomyosarcoma cells [4], c) the vitronectin receptor α-chain 
(integrin αν subunit) seems to be involved in human melanoma tumorigenicity [8], and d) 
E-cadherin, a cell-cell adhesion molecule, can act as an invasion suppressor molecule in 
certain epithelial tumor cells [3,44]. Finally, intercellular adhesion molecule ICAM-1 
[16,26], VLA-2 [2,19], and the vitronectin receptor 0-chain [1] (integrin 03 subunit) have 
been shown to be preferentially expressed in vertical growth phase primary melanoma 
lesions and melanoma metastases suggesting a role in melanocytic tumor progression. 
As only one study has been done with a large panel of monoclonal antibodies (mAbs) 
to look for integrin expression in melanocytic tumors [1], the purpose of this study was to 
investigate in a large number of lesions if there is a correlation between the stage of 
melanocytic tumor progression and the pattern of integrin expression. 
MATERIAL AND METHODS 
Lesions 
Lesions were obtained from patients at the University Hospital, Nijmegen, The 
Netherlands and at the Department of Dermatology of the Wilhelms University, Münster, 
Germany. Based on histopathologic examination of paraffin sections, lesions were divided 
into five classes: common nevus nevocellularis (NN) (η =22; 3 compound, 10 junctional 
and 9 intradermal), dysplastic nevus [7,40] (atypical nevus; DN) (n = 16), early primary 
melanoma (i.e. tumor thickness < 1.5 mm; ePM) (n=24), advanced primary melanoma 
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(i.e. tumor thickness> 1.5 mm; aPM) (n=28) and melanoma metastasis (MM) (n=25). 
Representative samples were snap frozen in liquid nitrogen and stored at -80°C until 
sectioning. 
Monoclonal antibodies 
The following anti integrin mAbs were used: TS2/7 anti-al [12] (T-cell Sciences, 
Cambridge MA, USA); Gi-14 anti-<*2 [34]; A1.43 anti-a2 [2,19]; Л43 anti-аЗ [9]; P1B5 
anti-аЗ [46] (Telios Pharmaceuticals Inc., San Diego CA, USA); HP2/1 anti-a4 [33] 
(Immunotech S.A., Marseille, France); P4G9 anti-o4 [48] (Telios Pharmaceuticals Inc., 
San Diego CA, USA); NKI-Saml anti-<*5 [42]; P1D6 anti-<*5 [47] (Oncogene Science 
Inc., Uniondale NY, USA); MT78 anti-a6 [20]; GoH3 anti-a6 [39]; NKI-M7 anti-av [6]; 
SZ.22 anti-allb [31]; Aj2 anti-/31 [17]; 4B4 anti-jSl [24] (Coulter Immunology, Hialeah 
FL, USA); C17 anti-03 [41]; and 3E1 anti-/34 [13] (Telios Pharmaceuticals Inc., San 
Diego CA, USA). 
Immunohistochemical staining 
Four μτη cryostat sections were fixed in acetone for 10 minutes and incubated at room 
temperature with mAbs for 1 h. After washing with phosphate buffered saline (PBS) 
bound mAbs were visualized using the peroxidase based Vectastain elite ABC kit (Vector 
Laboratories, Burlingame CA, USA) and amino-ethyl carbazole (AEC). After 
counterstaining with Meyers hematoxylin sections were mounted with Kaisers 
glycerin/gelatin. 
Score 
The intensity of staining of the melanocytic cells was scored semiquantitatively as: 
negative, positive or strongly positive. The percentage of stained melanocytic cells was 
estimated as: 0, 1-5, 6-25, 26-50, 51-75, 76-100% (Fig 1). Slides were read 
independently by two observers. Discrepancies exceeding one percentage class were found 
in less than 10% of the cases. These cases were reevaluated jointly until consensus could 
be reached. 
Logistic regression was used to detect antigen expression correlated with tumor 
progression. 
RESULTS 
The staining patterns for the various integrin subunits on different stages of 
melanocytic tumor progression are described below. Similar results were obtained for 
compound-, junctional- and intradermal nevi and these groups are therefore not mentioned 
separately. 
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Figure 1. Percentage of positive cells in each lesion stained with anti-integrin mAbs. 
NN= common nevus nevocellularis, DN=dysplastic nevus, PM1 = early primary melanoma (ePM), 
PM2=advanced primary melanoma (aPM), MM=melanoma metastasis. Staining intensity was 
scored as positive (open square) or strongly positive (filled square). 
a l . Most lesions did not show detectable α ϊ expression. However, 25% of the 
lesions, both benign and malignant, stained with TS2/7 mAbs (Figs 1,2a). 9 out of 22 NN 
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(41%) were positive, whereas only 1 out of 16 DN was found to contain positive cells. 
8% (2/24) of ePM and 24% (6/25) of aPM was found to be positive whereas 41% (9/22) 
of MM contained positive cells. 
a2. All lesions were incubated with A1.43 and Gil4 anti-a2 mAbs; similar results 
were found with both mAbs. There was a marked difference between the number of 
positive ePM (14%; 3/21) and the number of positive aPM (44%; 12/27) and MM (80%; 
20/25) (Fig 1). However, the number of positive NN (59%; 13/22) and DN (60%; 9/15) 
was in the same range as the number of positive aPM and MM. A membranous pattern of 
staining was observed in MM lesions whereas in NN, DN and PM this was not obvious 
(Fig 2b). 
a3. Staining with J143 and P1B5 anti-аЗ mAbs gave similar results. NN, DN, and 
ePM stained in variable percentages but staining was weak and 33% (7/21) of NN, 19% 
(3/16) of DN, and 38% (8/21) of ePM were negative (Fig 1). In the case of aPM and 
MM however, only few lesions were negative: 7% (2/27) and 8% (2/24) respectively. 
Furthermore a number of aPM and MM were strongly positive: 22% (6/27) and 33% 
(8/24) respectively. In contrast with nevi and PM, in MM usually a clear membranous 
staining pattern was observed (Fig 2c). 
a4. Approximately 10% of NN (2/21) and aPM (3/27) showed a4 expression while 
no expression was detected in DN and ePM (Fig 1). In MM, 55% (12/22) of the lesions 
were found to stain positive with HP2/1 mAbs (not shown). Expression of a4 appears to 
increase in MM (p=0.002). 
a5. Staining with P1D6 and NKI-SAM1 anti-a5 mAbs gave similar results but 
usually P1D6 stained less strongly than NKI-SAM1. In NN and DN, a5 expression could 
not be detected (Figs l,2d). Approximately 15% of ePM (4/23) and aPM (4/26) stained 
whereas 60% (15/25) of MM were a5 positive. No obvious membranous pattern of 
staining was observed (Figs 2e,f). These results show that expression of <*5 emerges 
during melanocytic tumor progression (p=0.0001). 
аб. Staining with MT78 and GoH3 anti-аб mAbs gave similar results. Almost all NN 
(19/21) were positive (Fig 1). Basal keratinocytes stained strongly at their basal surface 
whereas nevus cells showed no obvious membranous staining pattern (Fig 2g). Often, 
strong staining of keratinocytes was interrupted at the site of nevus cell nests. Even 
though not significant (p>0.05), more DN, ePM, aPM, and MM were negative; 38% 
(6/16), 54% (13/24), 32% (9/28) and 29% (7/24) respectively. Usually, staining in PM 
and MM was not strong (Fig 2h) whereas 57% of NN and 31% of DN was strongly 
positive. 
αν. 72% of NN (16/22), 56% of DN (9/16), 40% of ePM (6/15), and 63% of aPM 
(12/19) stained with NKI-M7 anti-av mAbs (Fig 1). All MM were positive and in all but 
two MM more than 75% of the cells stained. In addition, 58% (14/24) of MM stained 
strongly with NKI-M7. A partly cytoplasmic and membranous staining pattern was 
observed (Fig 2i). The αν subunit appears to be quantitatively upregulated during 
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melanocytic tumor progression (p=0.04). 
«IIb. No allb expression was detected in any of the lesions stained with SZ.22 
m Abs; internal control cells (platelets) were positive (not shown). 
/81. In all lesions except 2 PM more than 50% of cells stained with AJ2 and 4B4 anti­
mi mAbs (Fig 1). In general the lesions showed strong expression (not shown). 
/33. None of the NN and DN were stained positive with C17 anti-/33 mAbs (Fig l,2j). 
Out of 24 ePM only one showed expression of the /33 subunit in 26-50% of the cells. 
15% (4/26) of aPM and 58% (14/24) of MM stained positive with С17, three of which 
were strongly positive (Fig 2k). These results show that 03 emerges during melanoma 
progression (p=0.0001). 
ß4. 71% of NN (15/21) showed expression of the /34 subunit as detected with 3E1 
mAbs whereas less then 20% of the lesions from each of the other categories was found 
to be positive (Fig l,21,m). For keratinocytes, staining was similar to that observed with 
anti-o¡6 mAbs (not shown). It appears that /34 expression decreases with melanocytic 
tumor progression (p=0.0003). 
DISCUSSION 
From this study and two others [1,27] in which integrin expression in fresh human 
melanocytic lesions was investigated, it is clear that during melanocytic tumor progression 
a number of changes in integrin expression occur. Albelda et al. [1] detected emerged 
expression of the /33 subunit in vertical growth phase PM and in MM, and Natali et al. 
[27] who studied only o¡6/31//34 integrins found decreased expression of a6/31 to be a 
striking phenomenon in melanocytic tumor progression. In the present study, on a large 
number of cases and with a broad panel of mAbs we find both decreased and increased 
expression of integrins and also emergence of subunits which can not be detected in 
benign lesions, to occur during melanocytic tumor progression. 
Our finding that almost all NN express об whereas expression is absent in 30 to 50% 
of PM and MM, is in line with findings from Natali et al. [27] who reported 
downregulation of a6 expression associated with invasiveness. However, the decrease of 
скб expression during melanocytic tumor progression is not significant in our material and 
Albelda et al. [1] did not detect any correlation. These differences can not be explained 
by differences between the mAbs used as both Albelda et al. and we ued GoH3 anti-a6 
and the mAb used by Natali et al. recognizes the same epitope on the a6 molecule [18]. 
It may be partly explained by differences in classification of PM, i.e. thickness versus 
growth phase, and possibly by different sensitivities of the methods used. The fact that /34 
is present in NN and like a6, an increasing number of lesions is /34 negative with 
melanocytic tumor progression, may suggest that nevus cells express a6/34. The ligand 
for ск6/34 has recently been demonstrated to be laminin [22] and α6/34 seems to play an 
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important role in maintaining the epidermal structure as it is involved in keratinocyte 
adhesion to the basal membrane [38]. In keratinocytes /34 is localized in hemidesmosomes 
[38] and we find strong /34 expression only on the basal side of these cells. The fact that 
the strong /34 signal usually found in keratinocytes, is not detected where nevus cells 
appear to be in close contact with the basal lamina may indicate that even though /74 is 
expressed in nevus cells it does not play a role as a receptor for the basal lamina similar 
to its role in keratinocytes. 
Our finding that /33 emerges during melanocytic tumor progression is in line with 
findings reported by Albelda et al. [1]. The fact that we can not detect /33 expression in 
all of the MM may be explained by differences in the mAbs used or by the sensitivity of 
the methods. It may also be that 03 is not necessarily associated with melanocytic tumor 
progression though there are indications for a role for /33 in this process. Thus 03 has 
been demonstrated to play a role as a signal transducing molecule which is important for 
melanoma metastasis [35]. The fact that we detect αν expression in all lesions tested 
indicates that αν combines with other subunits than /33 in the benign lesions where /33 is 
absent. In fact, alternative /3 subunits have been shown to combine with αν [5,21,45]. 
Our finding that αν expression is upregulated in MM may indicate a role for αν in the 
metastatic process. There is evidence that αν is important in melanoma tumorigenesis [8] 
and it has also been implicated in the metastatic process of melanoma cells [10]. 
Our finding that a5 expression emerges in PM and is strongly increased in MM 
confirms and extends previous reports where a5 expression in melanoma was 
investigated: a) Mortarini et al. [25] did not detect any a5 expression on cells cultured 
from PM whereas cells cultured from two out of three MM expressed a5, and b) Albelda 
et al. [1] detected α5 expression only in vertical growth phase PM and in MM. These and 
our findings strongly suggest that expression of the classical fibronectin receptor VLA-5 
[30], is associated with melanocytic tumor progression and that its role in melanoma cells 
is different from CHO cells where VLA-5 has been demonstrated to suppress rather than 
enhance the transformed phenotype [11]. 
Figure 2. Immunohistochemical staining with anti-integrin mAbs on human melanocytic lesions. A: 
ePM stained with TS2/7 al mAbs. B: MM stained with Al.43 ct2 mAbs. Note that no a2 is 
detected in the liver parenchyma (L). C: MM stained with J143 ct3 mAbs. D: NN stained with 
NKI-Saml a5 mAbs. Some small vessels are positively stained (arrows). E: ePM stained with NK1-
Satnl a5 mAbs. Both regions of positive and negative melanoma cells were found. F: MM stained 
with NKI-Saml ct5 mAbs. G: NN stained with GoH3 ct6 mAbs. Note the strong basal staining of 
basal keratinocytes (arrow) and the cytoplasmic staining of nevus cells (Ν). H: MM stained with 
GoH3 a6 mAbs. I: MM stained with NKI-M7 av mAbs. J: DN stained with CI 7 β3 mAbs. Some 
blood cells are positively stained (arrow). K: MM stained with C17 β3 mAbs. L: DN stained with 
3E1 β4 mAbs. M: MM stained with 3E1 β4 mAbs. Blood vessel walls are positively stained 
(arrow), (see opposite page). 
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To date, little is known about the expression of integrins in normal melanocytes in 
situ. One immunoelectronmicroscopic study on epithelial cell suspensions [49] 
demonstrates expression of a3 and a6 but not αϊ, α2, or α4 in normal melanocytes. We 
and others [1] find expression of αϊ and a2 in NN which may indicate that formation of a 
nevus implies changes in the adhesive phenotype of melanocytes. The fact that we find 
increased a4 expression in MM but also in a small number of NN is in line with results 
reported by Albelda et al. [1]. In an earlier study, a2 expression has been described to 
correlate with melanocytic tumor progression [2]. In the present study we find strongly 
increased a2 expression in аРМ and MM compared with ePM but a large number of nevi 
shows a2 expression as well. As in both studies the same mAbs (Al.43) are used, these 
differences may be due to different sensitivity of the methods used or the fact that in the 
earlier study weak staining was scored negative. 
Finally, it is known that integrins can be present in an active or inactive state and that 
activation is often required for high affinity interaction with their ligands [28,37,42,43]. 
Therefore, the fact that changes in the expression of a number of integrins are observed 
during melanocytic tumor progression does not necessarily indicate that during this 
process cells loose or gain the functional properties known to be mediated by these 
integrins. 
In conclusion, we find a number of alterations in integrin expression during 
melanocytic tumor progression: decrease of a6 and /34, increase of a4/31, and the most 
striking being emergence of the a5j81 fibronectin- and αν/33 vitronectin receptor. In this 
respect it is interesting that signaling through both a5/31 [36] and αν/33 [35] can modulate 
the 72 kDa type IV collagenase during human melanoma cell invasion. Besides /33 which 
has been described before, a5 may be useful as a marker for malignant melanocytic 
lesions. 
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Chapter 5 
Integrin expression in uveal melanoma differs from 
cutaneous melanoma 
Invest Ophthalmol Vis Sci 34, 3635-3640, 1993 
Integrili expression in uveal melanoma differs from cutaneous melanoma 
Paul JM ten Berge1, Erik HJ Danen1, Goos NP van Muijen', Martine J Jager2, 
and Dirk J Ruiter' 
'The Department of Pathology, University Hospital, Nijmegen, and 2The Department of 
Ophthalmology, University Hospital, Leiden, The Netherlands 
During the process of metastasis changes in cell-cell and cell-matrix contacts 
occur and expression of integrins, a superfamily of adhesion molecules, may 
therefore be important. Expression of integrins has been extensively studied in 
cutaneous melanoma. Since it is known that uveal melanoma has a metastatic 
behavior different from cutaneous melanoma, we investigated integrin expression in 
uveal melanoma. We employed monoclonal antibodies recognizing integrin subunits 
al-6, orv, /31, /34, and integrins αν/33 and αν/35 on frozen sections of 32 human 
primary uveal melanomas and 4 metastases, followed by an ABC-immunoperoxidase 
technique. As in cutaneous melanoma a4 expression was rare whereas most lesions 
expressed a3 and аб. In contrast to cutaneous melanoma where al is well expressed 
in most lesions and a5 is expressed only in a low percentage of primary lesions, in 
uveal melanoma o2 expression was rare whereas a5 expression was found in all 
lesions. A major difference was observed with regard to the av/?3 vitronectin 
receptor. In contrast to cutaneous melanoma where αν/33 is expressed in advanced 
primary lesions, αν/33 was not detected in any of the primary uveal melanomas, 
irrespective of the thickness or cell type of the tumor. All lesions strongly expressed 
av/}5. Thus, integrin expression in uveal melanoma cannot be correlated with either 
cell type or invasiveness, and in contrast with cutaneous melanoma, determination of 
the integrin expression profile seems not to be suitable to subdivide uveal melanomas 
into low and highly malignant lesions. 
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INTRODUCnON 
In contrast to cutaneous melanoma, uveal melanoma metastasizes primarily to the 
liver. This difference in biological behavior cannot be explained on the basis of any 
known anatomic or physiologic factors [6]. Other sites where uveal melanomas may 
metastasize to are the brains, lungs, bone marrow, lymph nodes, pericardium, skin, and 
organs of the gastro-intestinal tract. As the eye lacks lymphatics, unlike cutaneous 
melanoma, uveal melanoma does not exhibit direct lymphatic spread. Besides direct 
hematogenous spread, uveal melanoma cells can invade the sclera and reach the orbital 
tissues, usually at sites where blood vessels and possibly lymph vessels pass through. 
In order for malignant cells to detach from their primary location, to attach to 
extracellular matrix (ECM) components of the surrounding stroma, to enter a blood 
vessel, and to metastasize, their adhesive properties must change repeatedly [18]. 
Receptors mediating cell adhesion may therefore be of great importance to metastasis 
[15,19]. Integrins, a family of cell-surface receptors, participate in cell adhesion and 
migration [11]. These heterodimeric glycoproteins consist of an α-chain noncovalently 
linked to a /3-chain, rendering ligand specificity. Integrins are divided into families on the 
basis of a common /3-chain. So far three subfamilies (/31, /32, /33) have been extensively 
studied and 5 additional /3-subunits have been described. In cutaneous melanocytic lesions 
the pattern of integrin expression has been reported to correlate with tumor progression 
[1,2,4,12,17]. 
As uveal melanoma differs biologically and clinically from cutaneous melanoma, 
uveal melanoma may express a different pattern of integrins. In this study we therefore 
investigated the expression pattern of a number of integrins in human uveal melanoma, 
using a panel of monoclonal antibodies (mAbs) for immunohistochemical staining of al-
6, αν, /31, /34, αν/33 and αν£5 in frozen specimens. 
MATERIALS AND METHODS 
Lesions 
Specimens of 32 primary uveal melanomas and 4 uveal melanoma metastases were 
obtained from patients at the Nijmegen University Hospital, the Leiden University 
Hospital, the Rotterdam University Hospital, the Academical Medical Center, 
Amsterdam, and the Foundation of Deventer Hospitals, The Netherlands. Methods for 
securing human tissue were humane, included proper consent and approval, and complied 
with the Declaration of Helsinki. Diagnosis of primary uveal melanomas was 
microscopically assessed on paraffin sections, discerning spindle (n = l l), mixed (n = 14), 
and epithelioid (n=7) cell types. Invasion of the sclera was graded as not (n=3), 
superficially (less than 25% of scleral thickness) (n=l l) , half (ca. 50% of scleral 
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thickness) (n=5), deep (ca. 75% of scleral thickness) (n=6), and episclerally (n=4) 
invaded. Bruch's membrane was regarded intact (n=9) or ruptured (n=20). From 3 
primary uveal melanomas invasion of sclera or Bruch's membrane could not be 
determined. Representative parts of all specimens were embedded in Tissue Тек OCT 
compound (Ames Company, Division of Miles Laboratories, Elkhart, IN) and snap frozen 
in liquid nitrogen. In a cryostat 4μπι sections were cut serially at -25°C, mounted on 
uncoated slides and stored at -80°C until use. 
Table 1. 
Integrin 
αϊ 
α2 
al 
α3 
α4 
о5 
α5 
об 
об 
αν 
Al 
αν/33 
αν/85 
/34 
Monoclonal antibodies. 
mAb 
TS2/7 
GÏ14 
A 1.43 
P1B5 
HP2/1 
NKI-Saml 
P1D6 
GoH3 
MT78 
NKI-M7 
4B4 
LM609 
P1F6 
3E1 
Source and reference 
T-cell Science, Cambridge, MA [9] 
Dr Santoso, Giessen, Germany [21] 
Dr Bröcker, Würzburg, Germany [2,12] 
Telios, San Diego, CA [26] 
Immunotech, Marseille, France [20] 
Dr Figdor, Amsterdam, The Netherlands [25] 
Oncogene Science, Uniondale, NY [27] 
Dr Sonnenberg, Amsterdam, The Netherlands [24] 
Dr Klein, Würzburg, Germany [13] 
Dr Figdor, Amsterdam, The Netherlands [5] 
Coulter, Hialeah, FL [16] 
Dr Cheresh, La Jolla, CA [3] 
Gibco, Gaithersburg, MD [28] 
Telios, San Diego, CA [10] 
Immunohislochemistry 
Integrin expression was detected by an indirect immunoperoxidase method using a 
panel of mAbs listed in Table 1. In brief, sections were air dried, fixed in acetone for 10 
min, and incubated with the mAbs at room temperature for 60 min. MAbs were diluted in 
phosphate buffered saline (PBS) containing 1 % bovine serum albumin (BSA) and optimal 
working dilutions had been determined on positive controls previously. After PBS rinsing, 
detection of the primary antibodies was achieved using the peroxidase-based Vectastain 
elite ABC system (Vector Laboratories, Burlingame, CA). This consisted of a biotinylated 
rabbit anti-rat Ig for mAb GoH3 and a biotinylated horse anti-mouse Ig for all other 
mAbs, followed by an avidin-biotin-peroxidase complex (ABC). As a substrate 3-amino-
78 
9-ethyl-carbazole (AEC) in acetate buffer pH 4.85 containing hydrogen peroxide was 
used. Finally, sections were counterstained with methyl green or hematoxylin and 
mounted with Kaiser's glycerol/gelatin (Merck, Darmstadt, Germany). Negative controls 
consisted of incubations replacing the primary antibodies by PBS/BSA. 
Score 
The intensity of staining of the melanocyte cells was scored semiquantitatively as: 
negative, positive or strongly positive. The percentage of stained melanocyte cells was 
estimated as: 0, 1-5, 6-25, 26-50, 51-75, 76-100%. Slides were read independently by 
two observers. Discrepancies exceeding one percentage class were found in less than 10% 
of the cases. These cases were reevaluated jointly until consensus was reached. 
RESULTS 
Staining results for the seven α subunits and four 0-subunits showed a consistent 
expression pattern among the 32 primary uveal melanomas (Fig 1). 
Uniformly positive staining was observed in all lesions when incubated with mAbs 
against the common β subunit of the ßl integrine. A low proportion of lesions stained 
with mAbs against the a l (5/32, 16%), α2 (3/32, 9%) and α4 (8/32, 25%) subunits. 
When expression of these integrin subunits was detected it usually was of moderate 
intensity and a low percentage of tumor cells stained. Al.43 and Gil4 anti-a2 mAbs 
showed identical staining patterns (not shown). 
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Figure 1. Percentage of positive cells in lesions stained with anti-integrin mAbs. P, primary uveal 
melanoma; M, uveal melanoma metastasis. Open and closed squares indicate moderately and 
strongly positive lesions respectively. 
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Expression of the α6 subunit was found in a majority of lesions (24/32, 75%) though 
a large variability in the number of positive tumor cells was observed; i.e. in 8/32 lesions 
no positive tumor cells could be detected (Fig 2c), whereas in 11/32 lesions 
approximately all melanoma cells were stained though staining was usually cytoplasmic 
and of moderate intensity (Fig 2d). A marked difference in reactivity was seen between 
GoH3 and MT78 anti-аб mAbs, as the latter detected expression in only two lesions (not 
shown). 
All lesions stained with mAbs directed against a3 (Fig 2a), a5 (Fig 2b), and αν (not 
shown). Usually a high percentage of tumor cells within a given lesion stained strongly 
with these mAbs though staining with NKI-M7 anti-av mAbs was of moderate intensity. 
Expression of a5 could always be detected with NKI-SAM1 mAbs, but with P1D6 mAbs 
only few lesions stained (not shown). 
The /34 subunit could not be detected on melanoma cells in any of the lesions though 
staining of bloodvessels was observed with 3E1 anti-/34 mAbs (not shown). 
No expression of αν/33 was observed in any of the primary lesions though staining of 
bloodvessels was observed with LM609 anti αν/33 mAbs (Fig 2e). In contrast all lesions 
strongly expressed αν/35 (Fig 2f). 
Similar to primary uveal melanoma, the metastatic lesions expressed the /31-subunit 
and none of them expressed the /34 subunit (Fig 1). Furthermore, the metastatic lesions 
expressed a3, α5, and αν and 3/4 expressed a6. In contrast to primary uveal melanoma, 
all metastatic lesions showed a2 and 3 out of 4 expressed a4 though a low percentage of 
cells within a given lesion stained and staining was of moderate intensity. Similar to the 
results in primary uveal melanoma, 76-100% of the cells in all three uveal melanoma 
metastasis lesions expressed αν/35. In two lesions strong staining was observed and in one 
lesion staining was of moderate intensity (Fig 2h). Expression of αν/33 which was not 
detected in any of the primary lesions, could be detected in most cells of one of the 
metastatic lesions (Fig 2g) and in some cells of another metastatic lesion. 
Some sections from one of the metastatic lesions showed mainly necrotic tumor tissue 
and no more material was available. Therefore, staining with anti-аЗ, -a5, -/31, -av/33, -
av05, and -/34 mAbs could be investigated in only three metastatic lesions. 
Within our series of primary tumors neither the cell type nor the invasion of sclera or 
Bruch's membrane correlated with an expression preference for any of the integrin-
subunits. 
DISCUSSION 
Integrins in cutaneous melanoma have been the subject of a number of studies 
investigating the pathogenesis of metastasis [8]. Clinical and biological differences 
between cutaneous and uveal melanoma led us to the question whether different integrin 
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expression patterns could be found for these tumors. To the best of our knowledge this 
study is the first to investigate the expression pattern of a large number of integrins in 
human uveal melanoma. In our panel of primary uveal melanomas all cell types and 
stages are represented. As patients with metastases of uveal melanoma usually die at 
home, it is difficult to collect a set of metastases. Nevertheless we gathered 4 uveal 
melanoma metastases, but none located in the liver. Due to this low number, no 
significant conclusions can be drawn regarding integrin expression in uveal melanoma 
metastasis. The results of our survey have no diagnostic nor prognostic implications, 
though they may enhance understanding of biological processes with respect to uveal 
melanoma. 
g Q; ··«· h ' 
Figure 2. Uveal melanomas stained with anti-integrin mAbs. A: Primary uveal melanoma stained 
with P1B5 anti-аЗ. B: Primary uveal melanoma stained with NKI-Saml anti-ct5. C,D: Primary 
uveal melanoma lesions stained with GoH3 anti-аб. Note that С contains no positive tumor cells 
(vessel walls stain strongly) whereas in D all melanoma cells are positive. E,F: Primary uveal 
melanoma stained with (E) LM609 anti-avß3, or with (F) P1F6 anti-avßS. Identical regions in 
sequential sections are shown. G,H: Uveal melanoma metastasis stained with (G) LM609 anti-
avß3, or with (H) P1F6 anti-avßS. Identical regions in sequential sections are shown. 
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Comparison of integrili expression in this study and in studies on cutaneous melanoma 
indicates some differences. In uveal melanoma we find that all lesions express aS but 
only a few are <*2 positive whereas most cutaneous melanoma lesions express the a2-
subunit and a5 can only be detected in about 20% of them [1]. Furthermore, even though 
no /34 can be detected in uveal melanoma, a small number of cutaneous melanomas 
express this subunit [17]. The fact that only few lesions are a4 positive whereas аЗ, α6, 
and αν can be detected in the majority of lesions is similar to the findings in cutaneous 
melanoma [1,17]. The different staining profile using different m Abs against the same 
integrin subunit, as seen with mAbs against a5 and a6, is most probably due to 
differences in avidity of the mAbs or masking of specific epitopes. We have recently 
confirmed and extended the data on integrin expression in cutaneous melanoma in a large 
set of 115 melanocyte lesions [4]. The most striking difference between cutaneous and 
uveal melanoma concerns the αν/33 vitronectin receptor. In cutaneous melanoma αν/33 is 
expressed in metastases and in vertical growth phase primary lesions but not in nevi or in 
the relatively benign radial growth phase primary lesions [1]. In this study on uveal 
melanoma no αν/33 expression can be detected in any of the primary lesions, including 
those which may have metastatic potential such as those of the mixed and epithelioid cell 
types where Bruch's membrane is broken and sclera invaded. This indicates that the av-
subunit in uveal melanoma combines with an alternative subunit. We show that αν/35 is 
the vitronectin receptor expressed in primary uveal melanoma. In uveal melanoma 
metastasis both αν/33 and αν/85 may be expressed. It is known that αν can combine with 
/31, /33, /35, /36, or /38 [11]. Since no mAbs recognizing the αν/31, αν/36, or αν/38 
complexes were available, we can not exclude the possibility that either of these integrins 
are present in uveal melanoma as well. Integrin αν/35 appears to be restricted to 
vitronectin in its ligand binding specificity whereas αν/33 interacts with multiple ligands 
[23]. Furthermore, αν/33 and αν/35 promote distinct cellular responses to vitronectin in 
vitro [14]. These findings indicate that the difference in expression of av-integrins 
between cutaneous and uveal melanoma may lead to a different biological behavior. Since 
av-integrins are thought to play a role in both proliferation [7] and invasion [22] of 
melanoma cells, the lack of αν/33 in primary uveal melanoma may have consequences for 
its growth and for its metastatic behavior. The fact that histological differences in cell 
type, and scleral and Bruch's membrane invasion cannot be correlated with a difference in 
integrin expression suggests that determination of the integrin expression profile is not 
suitable to subdivide uveal melanomas into low and highly malignant lesions. In contrast, 
this seems possible in cutaneous melanomas [1,4,17]. 
In conclusion we find integrin expression in human uveal melanoma not to be 
correlated with either cell type or invasiveness. Furthermore, we find that the αν/33 
vitronectin receptor, which is associated with cutaneous melanoma progression, is not 
expressed in primary uveal melanoma. In uveal melanoma we demonstrate that the αν 
subunit combines with /35. 
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Chapter 6 
Regulation of integrin-mediated adhesion to laminin and 
collagen in human melanocytes and non- and highly 
metastatic melanoma cells 
Int J Cancer 54, 315-321, 1993 
Regulation of integrin-mediated adhesion to laminin and collagen in 
human melanocytes and non- and highly metastatic melanoma cells 
Erik HJ Danen1, Goos NP van Muijen1, Elly van de Wiel-van Kemenade2, 
Kees FJ Jansen', Dirk J Ruiter1, and Carl G Figdor2 
'Department of Pathology, University Hospital, Nijmegen, and 'Department of 
Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands 
We compared ¡ntegrin-mediated adhesion to extracellular matrix (ECM) 
components of cultured human melanocytes and six human melanoma cell lines with 
different metastatic capacities in nude mice. Cultured melanocytes, and most 
melanoma cell lines adhered strongly to fibronectin (Fn), whereas only highly 
metastatic cell lines adhered to laminin (Ln) and collagen type one (Col) and type 
four (СоГ ). Adhesion to Ln was blocked by mAbs to a2 and об, and adhesion to Co 
by mAbs to a2. This observation was consistent with the finding that expression of 
Ln receptor α6βί and Ln/Co receptor ct2ßi was low on melanocytes and non - or 
poorly metastatic cell lines whereas these integrine were strongly expressed on highly 
metastatic cell lines. In addition, immunoprecipitation from [3SS]-methionine labeled 
cells demonstrated increased synthesis of об, o¡2, and /31 in highly metastatic cell 
lines, and immunohistochemistry showed expression of аб/31 and alßl only in 
xenograft lesions from highly metastatic cell lines. Furthermore, the observation that 
a201/a601-mediated adhesion of melanocytes and non - or poorly metastatic cell 
lines to Co/Ln could be induced with stimulatory anti-/31 mAbs, demonstrates that 
these receptors, on these cells, are expressed in an inactive state. Our results suggest 
that a201 and tx6ßl may play a role in human melanoma metastasis in nude mice 
and demonstrate that interactions of these integrins with their ligands can be 
regulated at the level of synthesis, surface expression, and activation state of the 
receptor. 
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INTRODUCnON 
Crucial steps in the process of metastasis are the release and migration of cells from 
the primary tumor, penetration of the vessel wall, arrest in the microcirculation of distant 
organs and subsequent extravasation [29]. During this process the malignant cells interact 
several times with the ECM components of basal lamina and stroma including Ln, Co, 
and Fn through specific receptors on the cell membrane termed integrins. 
Integrins consist of a family of transmembrane receptors. Structurally each integrin is 
a heterodimer consisting of an α subunit noncovalently bound to a β subunit. Based on 
the type of β subunit present in the dimer the integrin family can be subdivided into 
several groups [17]. Most extensively studied are the /31, the /32, and the /33 integrins. 
Beta-1 integrins (very late antigens, VLA's) play an important role in mediating cell-ECM 
contacts, /32 integrins are exclusively expressed on leukocytes and mediate cell-cell 
contacts, whereas /83 integrins have a broader distribution and mediate cell-ECM 
interactions. In order to mediate their functions integrins have to be in an activated state. 
This has been shown for /31 [31], /32 [39], and /33 integrins [13]. 
Integrin expression and adhesive behavior of cells can change after transformation. 
F2408 rat fibroblast and normal rat kidney (NRK) cells show reduced adhesion to Fn 
after viral transformation [28] and certain human osteosarcoma cells show a changed 
pattern of integrin expression and of adhesive properties after further chemical 
transformation [8]. Highly metastatic tumor cells have been shown to be more adherent to 
basement membrane than tumor cells with low metastatic capacity [26]. Transfection of 
the a5 gene has been demonstrated to suppress the transformed phenotype of Chinese 
hamster ovary (CHO) cells [11] whereas transfection of the αν gene in M21 human 
melanoma cells that lack αν/ЗЗ expression restored their tumorigenicity [9] and 
transfection of the a2 gene has demonstrated the importance of VLA-2 in the metastatic 
process of rat rhabdomyosarcoma cells [6]. Finally, expression of a2/31 [4,21], the /33 
subunit [1], and intercellular adhesion molecule ICAM-1 [18], a ligand for integrin al/32, 
has been shown to be related to melanocytic tumor progression. 
The purpose of this study is to investigate whether a correlation exists between the 
metastatic potential of human melanoma cell lines and their capacity to adhere to ECM 
components, and to study the mechanism of adhesion. 
MATERIAL AND METHODS 
Cell lines and culture conditions 
The melanoma cell lines used, included: IF6 [41], 530 [43], M14 [19], Mel57 [5], 
BLM [41], and MV3 [42]. All cell lines were cultured in Dulbecco's Modified Eagles 
Medium (DMEM) (Flow laboratories, Irvine, UK) supplemented with 10% fetal calf 
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serum (FCS), gentamycin, glutamate and pyruvate. Isolation and propagation of human 
foreskin melanocytes were performed as previously described [32] and melanocytes were 
cultured for a maximum of 10 passages in Ham's FIO (Flow) supplemented with 2% 
Ultroser-G synthetic serum (Gibco, Grand Island, NY), glutamate, penicillin, strepto-
mycin, 0.1 mM IBMX (Sigma, St Louis, MO) and 16 nM Phorbol 12-myristate 13-
acetate (PMA) (Sigma). 
Monoclonal antibodies 
The following anti-integrin subunit m Abs were used. TS2/7 anti-al [15] (T-cell 
Sciences, Cambridge, MA); Al.43 anti-a2 [4,21] (Cell Diagnostica GmbH, Münster, 
Germany); 5E8 anti-a2 [45]; J143 anti-a3 [10]; GoH3 anti-o6 [33]; 4B4 anti-01 [24] 
(Coulter Immunology, Hialeah, FL); 8A2 anti-01 [22]; TS2/16 anti-/31 [15]; 3E1 anti-04 
[16] (Telios Pharmaceuticals Ine, San Diego, CA). As negative control in flowcytometry 
WT31 anti-CD3 [34,35] mAbs were used. As negative control in the adhesion inhibition 
assays W6/32 anti-МНС class I [3] mAbs were used. MHC class I is strongly expressed 
on all cell lines [41] and on cultured melanocytes (not shown). 
Flowcytometry 
Cells were harvested by short trypsinization of subconfluent monolayers. After 
washing with DMEM containing 10% FCS they were incubated with mAbs in phosphate 
buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) and 0.02% azide for 
30 min at 0°C. After washing three times with PBS/BSA/azide the cells were incubated 
with fluorescein-isothiocyanate (FITC)-conjugated F(ab')2 fragments of rabbit anti-mouse 
Ig (Dako, Glostrup, Denmark), or in the case of GoH3 mAbs, with FITC-conjugated 
rabbit anti-rat Ig (Dako). Analyses were performed on a Coulter Epics Elite (Coulter 
Electronics, Mijdrecht, The Netherlands). 
Immunoprecipitation 
Subconfluent monolayer cell cultures (75 cm2) were labeled overnight at 37CC with 
0.3 mCi [35S]-methionine (Amersham, Houten, The Netherlands) in methionine-free 
medium (Flow) containing 10% dialysed FCS. The cells were washed 2 times with PBS 
and incubated with NP40 lysis buffer (0.5% NP40, 0.015 M NaCl, 0.01 M Tris pH 7.5, 
1.0 mM phenyl-methyl-sulphonyl-fluoride and 4 μg/ml Aprotinin) at 4°C for 10 min. 
Subsequently the cells were scraped off the culture flask, repeatedly aspired into syringes 
and forced through needles with decreasing diameter. Glycoproteins were isolated from 
NP40 solubilized cell extracts by adsorption to concanavalin A (Con A) Sepharose 
(Pharmacia Ine, Uppsala, Sweden). Immunoprecipitations were performed as described 
before [20]. To compare the amount of glycoproteins in the various cell lines, equal 
numbers of counts of the Con Α-bound fractions were used for immunoprecipitation. 
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Immunohistochemistry 
After acetone fixation 4 μτη frozen sections were incubated with mAbs for 1 h at 
room temperature. After washing with PBS, bound mAbs were visualized using 
peroxidase-conjugated rabbit anti-mouse Ig (Dako), or in the case of GoH3 mAbs, 
peroxidase-conjugated rabbit anti-rat Ig (Dako), and amino-ethyl carbazole (AEC). After 
counterstaining with hematoxylin the sections were mounted with Kaizers glycerin/gelatin. 
Cell adhesion assay 
Ln and CoIV, both isolated from Englebreth-Holm-Swarm mouse sarcoma cells, were 
purchased from Gibco. Col isolated from rat tail was a gift from Dr E. Klein, Ulm, 
Germany. Fn isolated from human plasma, was purchased from Sigma. Polystyrene 
microtiterplates (96 wells, flatbottom, Greiner, Alphen a/d Rijn, The Netherlands) were 
coated by incubation overnight at 4°C with 50 μ\ of a solution containing 20 μg/ml of the 
appropriate adhesive protein in PBS. Unbound protein was removed by washing with PBS 
and free binding sites were blocked by incubation for 1 h at 37°C with DMEM containing 
0.25% BS A. Cells were harvested by short trypsinization of subconfluent monolayers, 
washed with DMEM containing 0.25% BS A and labeled in a volume of approximately 
100 μΐ with 50 μα Na3
51CrO for 90 min at 37°C. Subsequently the cells were washed 
three times, diluted to a concentration of lxlO5 cells/ml in DMEM containing 0.25% BSA 
and seeded into the wells (5000 cells/well). Cells were allowed to attach for 30 min at 
37°C in a 5% C0 2 atmosphere; non-adhered cells were removed by washing three times 
with DMEM containing 0.25% BSA; the attached cells were lysed with Triton- X-100 
and radioactivity was measured in a gamma-counter. In adhesion inhibition/stimulation 
assays, labeled cells were incubated with the appropriate mAbs for 30 min at 4°C before 
seeding into the wells. 
RESULTS 
Metastatic behavior of human melanoma cell lines in nude mice 
The rate of tumor take and the frequency of experimental and spontaneous metastasis 
of the human melanoma cell lines studied in nude mice has been described previously 
[41,42]. Although after subcutaneous inoculation all cell lines gave a good tumor take, 
only BLM and MV3 were found to be highly metastatic. IF6 and 530 did not metastasize 
at all and M14 and Mel57 were only poorly metastatic. 
Adhesion to ECM components 
In order to investigate whether the capacity to metastasize was reflected by the 
capacity to adhere to ECM components, we investigated adhesion to Ln, Col, CoIV and 
Fn. Melanocytes, and the non- (IF6, 530) and poorly metastatic cells (M14, Mel57) 
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adhered weakly to Ln, Col and CoIV whereas the highly metastatic BLM and MV3 
melanoma cells adhered strongly to these ECM components (Fig 1). A different pattern 
was found for adhesion to Fn. Most cells exhibited strong binding to Fn and only 530 
cells adhered weakly to Fn. 
These results indicate that highly metastatic melanoma cells adhere to Ln and Co 
much stronger then non- or poorly metastatic cells. 
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Figure 1. Adhesion of cultured melanocytes ßiCT) and 6 human melanoma cell lines to Ln, Col, 
CoIV, and Fn. Control adhesion to BSA was less than 5%. One experiment of 4 is shown. Means 
± s.d. from triplicate wells are shown. 
Expression ofLn/Co receptors 
As adhesion to Ln and Co was strongly increased in highly metastatic cell lines, 
surface expression of integrins, known to mediate adhesion to Ln (a 1/31, c2ß\, a3/31, 
a6/31, a6|34) or Co (al/31, o¡2/31, a3/31) was investigated by means of flowcytometry. 
Melanocytes and all 6 cell lines expressed 01 integrins (Fig 2). Beta-1 expression was 
high on melanocytes and the highly metastatic BLM and MV3 cells, and low on the other 
cell lines. Alpha-1 expression was low, both on melanocytes and on all cell lines. 
Notably, expression of oil and a6 was high on the highly metastatic BLM and MV3 cells 
whereas melanocytes and all other cell lines showed no or only weak expression. The a3 
subunit was highly expressed on melanocytes and the highly metastatic BLM and MV3 
cells, moderately on IF6 and Mel57 but not or hardly detectable on 530 and M14. No 04 
expression was found on melanocytes or any of the cell lines even though 3E1 anti-04 
mAbs stained control cells (keratinocytes; not shown). 
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Figure 2. Expression of Co/Ln receptors on cultured human melanocytes and 6 human melanoma 
cell lines. Cells were incubated with WT31 anti-CD3 control mAbs (c) or with TS2/7 anti-al, 
Al.43 anti-a.2, J143 anti-аЗ, GoH3 anti-аб, 4B4 anti-ßl, or 3E1 anti-ß4. The fluorescence 
intensity of 5000 cells was determined. One experiment of 2 is shown. 
To establish whether differences in cell surface expression were reflected by 
differences in the level of biosynthesis of integrin subunits, immunoprecipitation was 
performed on the glycoprotein fraction of [35S]-methionine labeled melanoma cells. No αϊ 
or /34 could be precipitated from any of the cell lines and o¡3 synthesis was detected in all 
cell lines except for S30 and M14 (Fig 3). Consistent with the surface expression data the 
level of synthesis of /31, a2, and a6 was increased in the highly metastatic BLM and 
MV3 cells compared with the other cell lines. 
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Figure 3. Synthesis of Ln/Co receptors 
in 6 human melanoma cell lines. 
Glycoproteins were isolated from ^SJ-
methionine-labeled cells with Con A-
Sepharose. Equal numbers of counts 
were used for immunoprecipitation with 
TS2/7 anti-al, Al.43 anti-a2, J143 
anti-аЗ, GoH3 anti-ab, 4B4 anti-ßl, or 
3EI anti-ß4. 
Finally we determined whether increased expression of Ln/Co receptors was also 
found in situ. Immunohistochemistry was performed on subcutaneous xenograft lesions 
from the non-metastatic cell lines IF6 and 530 and from the highly metastatic cell lines 
BLM and MV3. Expression of a2 and a6 was only detected in lesions of the highly 
metastatic BLM and MV3 cells (Fig 4), similar to the results on cultured cells. 
Thus, synthesis and expression of <*6j31 and a2/31 in culture and in situ is strongly 
increased in highly metastatic melanoma cells compared to non- or poorly metastatic 
melanoma cells and normal melanocytes. 
Ö.' Figure 4. lmmunohistochemical 
staining of s. e. xenografi lesions from 
A: IF6 with A 1.43 anti-a.2, B: 530 with 
GoH3 anti-a6, C: BLM with Al.43, or 
D: MV3 with GoH3. 
The role of a2ßl and oc6ßl in adhesion to Ln and Co 
To further demonstrate the role of «2/31 and «6/31 in adhesion to Ln, Col, and CoIV, 
we performed antibody blocking studies. Since adhesion of normal melanocytes and the 
non- (IF6, 530) or poorly metastatic melanoma cells (M14 and Mel57) to Ln, Col, or 
CoIV was absent or low (Fig 1), we only examined the highly metastatic BLM and MV3 
cells. Adhesion of BLM and MV3 to Ln was inhibited for 60% by m Abs to α2, for 90% 
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by mAbs to ab, and the combination of these m Abs (Fig 5) or a m Ab to /31 (not shown) 
completely blocked adhesion of these cells to Ln (Fig 5). Adhesion to Col and CoIV was 
almost completely inhibited by mAbs directed to al or 01. 
These results indicate that a2/31 and a6/31 are the major receptors for Co and Ln 
respectively on highly metastatic melanoma cells. 
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Figure 5. Inhibition of adhesion to Ln/Co of BLM and MV3. Cells were allowed to adhere to 
wells coated with Ln, Col, or CoIV in the absence or presence of W6/32 anti-МНС class 1 control 
mAbs (c) or 5E8 anti-a2, GoH3 anti-аб, 4B4 anti-ßl, or combinations. Adhesion to BSA was less 
then 5%. One experiment of 3 is shown. Means ± s.d. from triplicate wells are shown. 
Effect of stimulatory anti-ßl mAbs on adhesion to Ln and Co 
In order to determine whether differences in adhesion to Ln and Co between cells of 
varying metastatic capacities were not only due to differences in expression of Ln/Co 
receptors but also to the activation state of these receptors, we performed adhesion assays 
in the presence of 8A2 or TS2/16 anti-/31 mAbs. Both mAbs have been described to 
stimulate integrin-mediated adhesion, probably by inducing a conformational change of 
the receptors. Following incubation with these mAbs, normal melanocytes and non- and 
poorly metastatic melanoma cells adhered strongly to Ln and Col (Fig 6). No or only 
minor stimulatory effects were observed with the highly metastatic BLM and MV3 cells 
(not shown). The effect was inhibited by mAbs to <*6 for Ln and by mAbs to a2 for Col, 
demonstrating that a6/31 and a2/31 had been activated by the stimulatory /31 mAbs. 
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From these results we conclude that a6/31 and a2/31 on normal melanocytes and non-
and poorly metastatic melanoma cells are expressed in an inactive state whereas these 
receptors are constitutively active in highly metastatic melanoma cells. 
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Figure 6. Stimulation of adhesion of cultured human melanocytes (MCT) and 4 human melanoma 
cell lines to Ln and Col with 8A2 anti-ßl mAbs and inhibition with G0H3 anti-a6 or 5E8 anti-a.2 
mAbs. Control adhesion to BSA was less then 5%. One experiment of 3 is shown. Means ± s.d. 
from triplicate wells are shown. 
DISCUSSION 
During metastasis, tumor cells interact at several sites with the ECM components of 
basal lamina and stroma. Therefore, we have compared the capacity of cultured human 
melanocytes and human melanoma cell lines with different metastatic capacities in nude 
mice to adhere to Ln, Co, and Fn. 
No correlation between adhesion to Fn and the metastatic capacity of the cell lines 
was found. Since most cells bound well to Fn, a crucial role for Fn in the metastatic 
process would not be expected. This observation, confirms and extends the findings of a 
number of previous studies where no positive correlation between the capacity of cells to 
adhere to Fn and their tumorigenic and/or metastatic behavior was reported; a) chemical 
transformation of human osteosarcoma cells leads to changes in integrin expression but 
not of the a3j81 and e*5j31 Fn receptors [8], b) mouse osteosarcoma cells with different 
metastatic capacities show similar interactions with Fn [2], and c) overexpression of the 
a5/31 Fn receptor has even been demonstrated to result in loss of tumorigenicity in CHO 
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cells [11]. For melanoma cells, adhesion to Fn has been shown not to correlate with 
metastatic behavior in a nude mouse model [27,37] and cultured normal human 
melanocytes have been demonstrated to adhere very weakly to Ln and Co but strongly to 
Fn [12, this paper]. 
An important role for Ln in the metastatic behavior of melanoma cells has been 
demonstrated in several studies [2,36,37]. Our data confirm these findings and show that 
a) highly metastatic melanoma cells adhere strongly to Ln, b) this adhesion is mediated 
through аб/31, and c) expression of the Ln receptor VLA-6 α-chain is markedly upre-
gulated in highly metastatic human melanoma cells. Furthermore our results indicate that 
adhesion of human melanoma cells to Ln is not exclusively mediated through VLA-6 but 
also through alßl. Adhesion to Col and CoIV has been demonstrated to be a property of 
various metastatic melanoma cell lines [7,23,30]. Our data confirm and extend these 
findings: the highly metastatic cells adhere strongly to Col and CoIV whereas the non- or 
poorly metastatic cells and normal melanocytes adhere only weakly to these ECM 
components. Adhesion to both Col and CoIV is mediated through alßl which is strongly 
upregulated in highly metastatic cells. These results are in agreement with findings from 
Mortarini et al. [25] who reported high a2 and об expression on tumor cells cultured 
from human melanoma metastases but not on tumor cells cultured from primary 
melanomas. Finally, increased a2 expression in fresh human melanocytic lesions has been 
shown to correlate with malignant progression [4,21]. Our immunoprecipitation data 
indicate that elevated expression of al and a6 in highly metastatic cell lines is not only 
due to increased cell surface expression but also to increased biosynthesis. Furthermore, 
from our immunohistochemical data on subcutaneous xenograft lesions we conclude that 
the difference in expression of alß\ and аб/31 between non- and highly metastatic cell 
lines is not only found in vitro but also in vivo. 
It is well known that in order to interact with their ligands, integrins have to be in an 
active state [13,31,39]. For /31 [38,44], 02 [40], and 03 integrins [14], mAbs have been 
described which induce a high avidity state of these receptors. Wayner and Kovach [44] 
have shown that U937 cells, Τ and В lymphoblastoid cells or PHA-stimulated Τ cell 
blasts require expression of the activated state of a4/31 in order to bind the cell adhesion 
site in Fn, LDV, whereas A375 melanoma cells do not require such activation. These 
findings suggest that on certain melanoma cells integrins may be expressed in a 
constitutively active state. Our results extend these findings and show that non- or poorly 
metastatic melanoma cells require induction of a high avidity state of /31 integrins in order 
to adhere to Ln and Co whereas highly metastatic cells do not. Even though only a very 
low amount of alßl and аб/31 is expressed on the non- or poorly metastatic cells, once 
these receptors are activated the cells adhere to Ln or Co as strong as the highly 
metastatic cells. This suggests that the number of receptors is less important than the state 
of activity they are in. 
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In conclusion, we show that a2j31- and a6/31-mediated adhesion to Co and Ln is 
strongly increased in highly metastatic human melanoma cell lines and that this adhesion 
can be regulated at the level of expression and activation of the a201 and аб/31 integrins. 
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Chapter 7 
Alpha-y integrins in human melanoma: gain of av/S3 and 
loss of ct\ß5 are related to tumor progression in situ 
but not to metastatic capacity of cell lines 
Int J Cancer 61, 491-496, 1995 
Alpha-v integrins in human melanoma: gain of αν/53 and loss of αν/35 
are related to tumor progression in situ but not to 
metastatic capacity of cell lines 
Erik HJ Danen, Kees FJ Jansen, Annemieke A Van Kraats, Ine MHA Cornelissen, 
Dirk J Ruiter, and Goos NP van Muijen 
Department of Pathology, University Hospital, Nijmegen, The Netherlands 
We investigated the expression of av-integrins in different stages of human 
cutaneous melanocytic tumor progression. We observed that αν/35 was the av-
integrin expressed in all common nevocellular nevi, in 78% of dysplastic nevi, in 63% 
of early primary melanomas, in 43% of advanced primary melanomas, and in 33% 
of melanoma metastases. Hence, loss of αν/35 expression was related to melanocytic 
tumor progression. In line with earlier reports, αν/33 was exclusively detected in 
advanced primary melanomas and metastases (24% and 50% respectively). Staining 
with anti-av mAbs on lesions where both av/33 and αν/35 were absent, showed that 
alternative av-integrins were expressed in advanced primary melanomas and 
metastases. By FACS analysis, we determined expression of αν/35 and αν/33 on 4 
human melanoma cell lines with different metastatic capacities after subcutaneous 
inoculation into nude mice. One of the non-metastatic and both highly metastatic cell 
lines expressed αν/35 at their surface. Surprisingly, αν/33 was detected exclusively on 
the non-metastatic cell lines. Absence of αν/33 in the highly metastatic cell lines was 
confirmed by lack of immunoprecipitation from [35S]-methionine labeled cells and by 
absence of immunohistochemical staining on primary and metastatic xenograft 
lesions. Our findings indicate that αν/35 expression is often lost in advanced stages of 
melanocytic tumor progression in situ while αν/33 is acquired, but that decrease of 
αν/35 and increase of αν/33 expression is not necessarily related to the metastatic 
behavior of human melanoma cells in nude mice. 
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INTRODUCTION 
The extracellular matrix (ECM) regulates a number of cellular processes and integrins 
link the ECM to structural elements in the cell and play a role as signaling receptors [9]. 
Therefore, it is likely that integrins can mediate ECM control of cell growth, migration, 
and invasion. These processes play an important role in tumorigenicity and metastasis 
formation and integrins have indeed been shown to be involved in both phenomena [10]. 
In human melanoma, integrins have been demonstrated to be involved in tumor 
growth and metastatic spread [14]. For melanocytic tumor progression in situ, changes in 
the expression of several integrins have been reported, including acquired expression of 
αν/33 in the vertical growth phase of primary melanomas and in metastases [2]. The αν 
subunit of this integrin, however, can be associated with several different β subunits in 
melanoma cells in vitro [12] and is expressed in all stages of melanocytic tumor 
progression in situ [4]. In this study we have investigated expression of av-integrins in 
cutaneous melanocytic lesions and in a panel of human melanoma cell lines with different 
metastatic capacities in nude mice. 
MATERIAL AND METHODS 
Lesions 
Lesions were obtained from patients at the University Hospital, Nijmegen, The 
Netherlands and at the University Hospital, Würzburg, Germany. Based on 
histopathologic examination of paraffin sections, lesions were divided into five classes: 
common nevocellular nevus (NN) (η = 19), dysplastic [7] (atypical) nevus (DN) (n=9), 
early primary melanoma (tumor thickness < 1.5 mm; ePM) (n=8), advanced primary 
melanoma (tumor thickness>1.5 mm; aPM) (n=21) and melanoma metastasis (MM) 
(n=24). Representative samples were snap frozen in liquid nitrogen and stored at -80°C 
until sectioning. 
Cell lines and culture conditions 
The melanoma cell lines used, included: IF6 [19], 530 [21], BLM [19], MV3 [20] 
and Mel57 [19]. All cell lines were cultured in Dulbecco's Modified Eagles Medium 
(DMEM; Flow laboratories, Irvine, UK) supplemented with 10% fetal calf serum (FCS), 
penicillin and streptomycin. 
Monoclonal antibodies 
Anti-integrin mAbs were 4B4 anti-/?l [13] (Coulter, Hialeah, FL), LM142 anti-αν 
and LM609 anti-av/33 [3] (Dr. David Cheresh, La Jolla, CA), 13C2 anti-αν and 23C6 
anti-av/33 [6] (Dr. Michael Horton, London, UK), and P1F6 anti-av/35 [22] (Telios, San 
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Diego, CA). In flowcytometry, WT31 anti-CD3 mAbs [17] (Dr. Wil Tax, Nijmegen, The 
Netherlands) were used as a negative control. NKI-beteb anti-gplOO [1] (Dr. Carl Figdor, 
Nijmegen, The Netherlands) was used to identify melanocytic cells in human lesions. 
Immunohistochemistry 
Identical procedures were used for immunohistochemistry on frozen sections of 
human melanocytic lesions and melanoma cell line xenograft lesions. Four μπι frozen 
sections were fixed in acetone for 10 min and incubated at room temperature with mAbs 
for 1 h. After washing with phosphate buffered saline (PBS) bound mAbs were visualized 
using the peroxidase-based Vectastain elite ABC kit (Vector Laboratories, Burlingame, 
CA) and 3-amino-9-ethylcarbazole as substrate. After counterstaining with Mayer's 
hematoxylin sections were mounted with Kaisers glycerin/gelatin (Merck, Darmstadt, 
Germany). 
Melanocytic cells were identified in HE stained sections and by staining with NKI-
beteb mAbs. The percentage of stained melanocytic cells was estimated as 0, 1-25%, 51-
75%, or 76-100%. Slides were read independently by two observers. Discrepancies 
exceeding more than one percentage class were found in less than 10% of the cases. 
These cases were revaluated jointly until consensus was reached. Logistic regression was 
used to determine a correlation between antigen expression and tumor progression. 
Flow cytometry 
Cells were harvested by short trypsinization of subconfluent monolayers and 
suspended in DMEM/10% FCS. After washing with PBS containing 0.5% BSA and 
0.02% azide, they were incubated with mAbs in PBS/BSA/azide for 30 min at 4°C, 
washed with PBS/BSA/azide, and incubated with fluorescein-isothiocyanate (FITC)-
conjugated F(ab')2 fragments of rabbit anti-mouse Ig antibodies (Dako, Glostrup, 
Denmark). Analyses were performed on an Epics Elite flowcytometer (Coulter, 
Mijdrecht, The Netherlands). 
Immunoprecipitation 
Immunoprecipitations were performed as described before [5]. In short, cells were 
labeled overnight with 0.3 mCi [35S]-methionine (Amersham, Houten, The Netherlands), 
washed and lysed with 0.5% NP40 lysis buffer. Glycoproteins were isolated from NP40 
solubilized cell extracts by adsorption to concanavalin A (Con A) Sepharose (Pharmacia, 
Uppsala, Sweden). To compare the amount of glycoproteins in the different cell lines, 
equal numbers of counts of the Con Α-bound fractions were used for 
immunoprecipitation. MAbs, rabbit anti-mouse Ig (Dako, Glostrup, Denmark) and Prot A 
beads (Pharmacia) were subsequently added and the volume was adjusted to 1 ml with 
0.5% NP40. Samples were tumbled overnight at 4°C. Beads were washed 3 times with 
0.5% NP40, 5 times with 0.5% NP40/0.1% SDS, resuspended in sample buffer 
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containing 2-mercaptoethanol, boiled, and run on SDS-PAGE. 
RESULTS 
Expression of otvß5 in situ 
In order to investigate which av-integrins are expressed in benign melanocytic lesions 
and to see whether other av-integrins besides av/33 are expressed in malignant melanoma 
we stained a series of NN, DN, ePM, aPM and MM with P1F6 anti-av/35 mAbs. Besides 
staining of fibroblast-like cells in stroma of all lesions, staining of melanocytic cells was 
found in 100% of NN (19/19), in 78% of DN (7/9), in 63% of ePM (5/8), in 43% of 
aPM (9/21) and in 33% of MM (8/24) (Figs 1,2). Hence, loss of expression of αν/35 was 
related to tumor progression (p=0.0001). In the lesions that were positive for αν/35, a 
variable heterogeneous staining pattern was observed with 25-100% positive melanocytic 
cells. 
avb5 avb3 
Figure 1: Expression ofavß5 and αν/33 
in different stages of human 
melanocytic tumor progression. 19 NN, 
9 DN, 8 ePM, 21 aPM, and 24 MM 
were stained with P1F6 anti-avß5 and 
23C6 and LM609 anti-avß3 mAbs. 
Percentage of lesions whith positive 
melanocytic cells are indicated. In the 
lesions that were positive, 25-100% of 
melanocytic cells stained. 
% positive lesions 
Expression of other av-integrins in situ 
In contrast to αν/35, staining for αν/33 was absent in NN, DN and ePM whereas 24% 
of aPM (5/21) and 50% of MM (12/24) were positive, indicating that αν/33 emerged in 
aPM and MM (p=0.0001) (Figs 1,2). Incubation with 23C6 or LM609 anti-av/33 mAbs 
gave similar results. In all lesions staining of bloodvessels was observed. In 2 DN, 4 
ePM, 10 aPM and 6 MM neither αν/33 nor αν/35 could be detected and we incubated 
these lesions with 13C2 and LM142 anti-av mAbs. Staining was negative for the 2 DN 
and 4 ePM lesions, whereas 5/10 aPM and 5/6 MM lesions were positive indicating that 
other αν integrins were expressed (not shown). Incubation with 4B4 anti-/31 mAbs 
resulted in staining of all melanocytic cells in all lesions (not shown), indicating that αν/31 
may possibly be the αν integrin expressed in aPM and MM lesions. 
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Figure 2: Microphotographs of melanocytic lesions stained with anti-av-integrin mAbs. 
Melanocytic lesions were stained with 23C6 and LM609 anti-avß3 or P1F6 anti-avßS mAbs. 
Arrowheads indicate nevus (Α-D) or melanoma (Ε-J) cells. A&B: NN negative for αν/35 (A) and 
positive for αν/35 (В). C&D: DN negative for αν/35 (C; arrow =positive bloodvessel) and positive 
for avßS (D). E&F: ePM negative for ανβ3 (E; arrow—positive bloodvessel) and positive for 
avß5 (F). G&H: aPM positive for αν/35 (G) and negative for ανβ5 (Η) (s=stroma cells). I&J: 
MM positive for αν/35 (I) and negative for αν/35 (J) (s=stroma cells). Bars are 20μιη. (see 
opposite page). 
Figure 3: Surface expression of av-integrins on human melanoma cell lines. IF6 (thin line), 530 
(thin dotted line), BLM (thick line) and МУЗ (thick dotted line) were incubated with P1F6 anti-
αν/35 (A) or LM609 anti-avß3 mAbs (B) followed by FITC-labeled second antibodies. 
Fluorescence was measured on an Epics Elite flowcytometer. The vertical line indicates the gate 
set with control anti-CD3 mAbs. Results with 23C6 mAbs were identical to those with LM609. 
Expression of αν/35 and avß3 in human melanoma cell lines 
We next examined whether decreased expression of αν/35 and increased expression of 
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αν/33 also correlated with the metastatic potential of cultured human melanoma cells. 
Therefore we used a panel of 4 human melanoma cell lines. After subcutaneous 
inoculation into nude mice all 4 cell lines have been shown to be tumorigenic but IF6 and 
530 do not or only in a very low percentage of mice give rise to metastases whereas BLM 
and MV3 very frequently metastasize [19,20]. FACS analysis showed that comparable 
levels of αν/35 were expressed on IF6, BLM and MV3 whereas no αν/35 could be 
detected on 530 cells. (Fig 3a). Surprisingly, no αν/33 was detected on the highly 
metastatic cell lines BLM and MV3 whereas the non-metastatic cell lines IF6 and 530 
expressed αν/33 at their surface (Fig 3b). Hence, the relation of decreased αν/85- and 
increased αν/33 expression with melanocyte tumor progression in situ, was not paralleled 
by a relation with the metastatic capacity of human melanoma cells in nude mice. 
In order to investigate whether the absence of αν/33 from the surface of BLM and 
MV3 cells was reflected by a lack of biosynthesis of αν/33 in these cells, 
immunoprecipitations were performed on [35S]-methionine labeled cells. Consistent with 
the surface expression data, synthesis of αν/33 was extremely low for the highly 
metastatic BLM and MV3 cells. For the non-metastatic IF6 and 530 cells, a clear 125 
kDa band corresponding to αν and a 105 kDa band corresponding to /33 were detected, 
whereas these bands were barely visible for BLM and MV3 cells (Fig 4). The 90 kDa 
and 150 kDa bands were non-specific since they could be detected even after incubation 
with normal mouse serum (NMS). 
Figure 4: Biosynthesis of avß3 in 
human melanoma cell lines. IF6, 530, 
BLM and MV3 were metabolically 
labeled with fsS]-methionine, lysed, 
and glycoproteins were isolated on Con 
A-Sepharose. Equal numbers of Con A-
bound counts were used for immuno-
precipitation with 23C6 anti-avß3 mAbs 
or NMS as a negative control. Identical 
results were obtained with LM609 
mAbs. 
Expression of αν/33 in xenograft lesions 
In order to exclude the possibility that absence of αν/33 in the highly metastatic cell 
lines in vitro was due to culture conditions, we stained xenograft lesions of these cell 
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lines with anti-av/33 mAbs. No αν/33 was detected in primary tumors or metastases of 
BLM and MV3 cells, whereas control anti-ßl mAbs stained all tumor cells (Fig 5). For 
IF6 and 530 cells that expressed αν/33 in vitro, we could not detect αν/33 in xenograft 
lesions (not shown), suggesting that the level of expression was too low to detect 
immunohistochemically or, alternatively, culturing the cells may influence the expression 
of αν/33. Therefore, as a positive control, we stained subcutaneous xenograft lesions of 
Mel57 melanoma cells that strongly express αν/33 in vitro (our unpublished data). As 
shown in figure 5, Mel57 melanoma cells stained strongly with LM609 mAbs in 
xenograft lesions. Hence, in line with the findings in vitro, subcutaneous tumors and lung 
metastases in nude mice of the highly metastatic human melanoma cell lines BLM and 
MV3 do not show αν/33 expression. 
DISCUSSION 
Cutaneous melanoma is characterized by proliferative and invasive growth in the 
dermis and is often followed by widespread metastasis. Interactions of tumor cells with 
the ECM, which are mainly mediated by integrins [9], are thought to play an important 
role in the malignant behavior of melanoma [14] and other human tumors [10]. In the 
present study, we investigated the expression of av-integrins in human melanocyte tumor 
progression in situ, and in a panel of human melanoma cell lines with different metastatic 
capacities after subcutaneous inoculation into nude mice. 
Acquired expression of αν/33 in the vertical growth phase of primary melanomas and 
in melanoma metastases has been reported [2] whereas the αν subunit is expressed in all 
stages of melanocytic tumor progression [4]. In vitro, melanoma cells have been shown to 
express αν/33, αν/31 [12] and αν/35 [22]. In this study we have investigated which of the 
αν integrins are expressed in situ in nevi and in primary melanomas and metastases. Our 
data concerning αν/33 expression confirm the findings from previous studies [2,4] and 
show that αν/33 emerges in aPM and MM. Regarding αν/35 we find that expression is 
often lost with melanocytic tumor progression. Since no mAbs have yet been generated 
recognizing the αν/31 complex we could not investigate expression of this integrin. For 
the lesions with αν/33 and/or αν/35 expression we cannot exclude that other αν integrins 
are expressed as well. For those lesions where neither αν/33 nor αν/35 was detected we 
investigated whether alternative av-integrins are expressed. The fact that alternative αν 
integrins were not detected in DN or ePM whereas a number PM and MM did express 
other αν integrins, suggests that additional αν integrins may emerge in aPM and MM 
besides αν/33. Thus, in NN, DN and ePM αν/35 can be expressed whereas in aPM and 
MM αν/35, αν/33 and/or other αν integrins can be expressed. Since all lesions were /31 
positive, and since αν/31 can be expressed by melanoma cells in vitro [12], αν/31 may be 
the alternative av-integrin emerging. 
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figure 5: Expression ofavß3 in xenografi lesions. Frozen sections from MV3 subcutaneous tumor 
(A,B,C), MV3 lung metastasis (D,E,F), and Mel57 subcutaneous tumor (G,H,I), were stained 
either in the absence of primary mAbs (A,D,G), with 4B4 anti-ßl (Β,Ε,Η), or with LM609 anti-
ανβ3 mAbs (C,F,I). Results for BLM were identical to those shown for MV3. Bar is 20μ/η. 
The fact that αν/35 expression is lost in most MM and that expression of αν/33 
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emerges may have functional consequences for the melanoma cells. The ligand binding 
specificity of αν/35 seems to be restricted to vitronectin whereas αν/33 recognizes multiple 
ligands including vitronectin and fibronectin [16]. In addition, αν/35 and αν/33 promote 
distinct cellular responses to vitronectin in vitro [11]. We have recently shown that for 
melanomas originating from the uvea, αν/33 is absent in all primary lesions including 
those of the aggressive type, and that αν/35 is the αν integrin expressed [18]. This may 
indicate that the microenvironment of the melanoma cells is important in determining 
which av-integrins are expressed. The fact that a role in proliferation [8] and invasion 
[15] of melanoma cells has been attributed to αν/33, seems to be in line with the 
emergence of avf?3 in аРМ and MM. In our panel of human melanoma cell lines, IF6 
and 530 express αν/33 in vitro but no αν/33 can be detected in the primary xenograft 
tumors, and these tumors grow slowly. On the other hand, BLM and MV3 tumors lack 
αν/33, and these tumors grow fast. All 4 cell lines develop tumors upon s.c. inoculation 
into nude mice [19,20]. This suggests that αν/33 is not necessarily involved in melanoma 
tumor growth. Furthermore, the fact that for the highly metastatic cell lines, αν/33 
expression is absent in vitro, in subcutaneous xenograft lesions, and in lung metastases, 
suggests that they use alternative integrins for metastasizing in nude mice. 
In conclusion, we show that αν/35 is often lost in advanced stages of melanocytic 
tumor progression in situ while αν/33 emerges, but that decrease of αν/35 and increase of 
αν/33 is not necessarily related to the metastatic potential of human melanoma cell lines in 
nude mice. 
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Chapter 8 
Requirement for the synergy site for cell adhesion to 
fibronectin depends on the activation state 
of integrili α5/31 
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Requirement for the synergy site for cell adhesion to fibronectin 
depends on the activation state of integrin aSjSl 
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We investigated the influence of the activation state of integrin «501 on its 
dependence on the PHSRN synergy site for binding to RGD in fibronectin. K562 and 
MV3 cells lacked αν/33 expression and adhered to fibronectin through «5/31. Mel57 
cells adhered through αν/33 and α5/31. K562 showed no adhesion to mono- or 
polymeric GRGDSP peptides and MV3 adhered only weakly to the polymeric 
peptide. RGD-containing peptides promoted Mel57 adhesion to the same extent as 
fibronectin. Soluble GRGDSP blocked Mel57 adhesion to fibronectin but had no 
effect on adhesion of K562 and MV3. A recombinant fibronectin polypeptide 
containing 3Fn6-3FnlO, and a mutated polypeptide lacking the synergy site, were 
equally effective in promoting Mel57 adhesion. For K562 and MV3 the mutated 
polypeptide was not or poorly active compared to the control polypeptide. Expression 
of αν/33 in MV3 cells induced strong adhesion to the mutated polypeptide. TS2/16 or 
8A2 stimulatory /31-integrin antibodies or Mn2+ induced a5/31-mediated adhesion of 
K562 and MV3 to GRGDSP. In the presence of TS2/16 or Mn2+, «5/31-mediated 
MV3 adhesion to the mutated polypeptide was equally strong as adhesion to the 
control polypeptide. Mn2+ or TS2/16 induced weak K562 binding to the mutated 
polypeptide, and in the presence of a combination of PMA, Mn ! t , and TS2/16, a5/31-
mediated K562 adhesion to the mutated and control polypeptide was equally strong. 
Our findings demonstrate that requirement for the PHSRN synergy site for a5/31-
mediated adhesion to RGD in fibronectin depends on the activation state of the 
integrin. 
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¡NTRODUCnON 
Fibronectin (Fn) is an extracellular matrix (ECM) glycoprotein that functions in cell 
adhesion and migration in wound healing, embryonic development, and malignant 
transformation [27,37]. The Fn molecule is composed of three types of repeating 
modules, termed type I, II, and III repeats [43] which are organized into functional 
domains. Proteolytic cleavage yields several fragments containing domains that promote 
cell adhesion, including the carboxyterminal НерП domain [35], the alternatively spliced 
type ΙΠ connecting segment [25], and the central cell binding domain (CCBD). 
The CCBD consists of type III repeats, each containing approximately 90 amino acids 
[31]. Cells bind to the CCBD via receptors of the integrin family [26]. Integrins are aß 
heterodimeric transmembrane molecules mediating cell-cell adhesion and attachment of 
cells to the ECM [28]. Integrins that bind the CCBD include «3/31 [19], a5/31 [2,48], 
αν/31 [60], αν/33 [13], allb03 [22,23], and αν/36 [11]. 
The Arg-Gly-Asp (RGD) sequence in the 10* type III repeat (3Fnl0) is the key 
attachment site for binding of these integrins to the CCBD as demonstrated by inhibition 
of cell adhesion with synthetic RGD-containing peptides [47,64]. Furthermore, two 
synergistic regions in the CCBD besides RGD have been identified that are required for 
cell adhesion through aIIb/33 [8] and a5/31 [3,30,38,40]. For a5/31 binding to Fn, the 
synergy region in 3Fn9 is the most important of these two regions [3], and recently, a 
short amino acid sequence Pro-His-Ser-Arg-Asn (PHSRN) was identified in this repeat 
that synergistically enhances the cell adhesion promoting activity of the RGD sequence 
[4]. This sequence is also present in an 11 amino acid integrin binding site from 3Fn9 
that is recognized by aIIb/33 [9]. 
Integrins do not always constitutively bind to their ligands with high affinity. Integrin 
adhesiveness can be stimulated by phorbol esters and other more physiologically relevant 
agonists [18,28]. In addition, antibodies have been described to integrin /31 [5,32,39,57], 
/32 [50], and /33 [42] subunits, that induce a high affinity state of the integrins. Studies 
with stimulatory /31 antibodies on hematopoietic cells have demonstrated modulation of 
binding to natural ligands [5,32,57], modulation of ligand specificity [12], modulation of 
binding to different regions in one ligand [52], and modulation of the minimal sequence 
of a binding site required for adhesion [62]. 
In the present study, we have investigated the role of the PHSRN synergy site in 
a5/31- and avj33-mediated cell adhesion to the CCBD in Fn. We show that requirement 
for the PHSRN synergy site for cell adhesion to the CCBD depends on the integrins 
expressed and on the activity of the integrins involved. 
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MATERIAL AND METHODS 
Fibronectin, fragments, and peptides 
Plasma Fn was purchased from Sigma (St Louis, MO). A polymeric Arg-Gly-Asp 
(RGD) peptide and a 120 kDa chymotryptic Fn fragment containing the CCBD [46,51], 
were purchased from Life Technologies (Gaithersburg, MD). For adhesion assays, 
synthetic peptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) was obtained from the Department 
of Organic Chemistry, Faculty of Science, University of Nijmegen, The Netherlands, and 
covalently bound to bovine serum albumin (BSA) as previously described [44]. For 
adhesion inhibition assays, GRGDSP and Gly-Arg-Gly-Glu-Ser-Pro (GRGESP) were 
obtained from Life Technologies. 
PHSRN RGD 
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Figure 1. Recombinant FN polypeptides. A: Schematic representation of a recombinant Fn 
polypeptide 3Fn6-10 consisting of 5 type III Fn repeats from 3Fn6 through 3Fnl0, and of a 
mutated Fn polypeptide 3Fn6-10(SPSDN) where the region containing PHSRN in 3Fn9 has been 
substituted by the corresponding region from 3Fn8 (hatched bar). B: In 3Fn6-10(SPSDN), 16 
amino acid residues from 3Fn9 were substituted with the corresponding residues from 3Fn8 to 
disrupt the PHSRN site in 3Fn9. Boxed sequences are from 3Fn6-10(SPSDN). The region with 
italicized nucleotides differs from the original sequence in 3Fn8 for technical reasons to alter 
restriction sites but this does not alter the amino acid sequence. 
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Production of recombinant fibronectin polypeptides 
In order to avoid the artifactual losses of adhesive activity known to result from 
adsorbing short polypeptides on substrates (e.g. see [38]), we used recombinant Fn 
polypeptides containing five type III Fn repeats from 3Fn6 through 3FnlO. The 3Fn6-10 
wildtype expression construct was generated based on the T7 phage promotor and a Fn 
cDNA fragment encoding Fn type III repeat numbers 6-10 produced using the polymerase 
chain reaction method [4]; the PHSRN sequence was present in repeat 9 and RGD in 
repeat 10 (Fig la). The N-terminal sequence of 3Fn6 starts immediately after an initiation 
codon for methionine. To create substitution mutants, two complementary 
oligonucleotides with appropriate sequences were synthesized, annealed, and then cloned 
between the BamHl and EcoRl sites of 3Fn9. This yielded a mutated polypeptide 3Fn6-
lO(SPSDN) where the PHSRN sequence from 3Fn9 was substituted by SPSDN from 
3Fn8 (Fig la,b). 
Protein expression was induced by 1 raM ITPG treatment of E. coli strain BL21 
(DE3, pLysS) containing the expression plasmid. The expressed recombinant polypeptides 
were purified by sequential DEAE and hydroxyapatite column chromatography. The 
polypeptide was eluted from a DEAE column (DE52, Whatman) using a linear gradient of 
0 to 0.5 M NaCl in 10 mM sodium phosphate (pH 7.4), 1 raM EDTA, 0.02% sodium 
azide, then applied to a hydroxyapatite column (Bio-Rad) and eluted using a linear 
gradient from 5 mM sodium phosphate (pH6.5), 0.4 mM EDTA, 0.02% sodium azide to 
250 mM sodium phosphate (pH 6.5), 0.4 mM EDTA, 0.02% sodium azide. The fractions 
with peak absorbance were evaluated for purity by SDS-PAGE, pooled, dialysed against 
PBS without Ca2+ or Mg2+ and with 0.02% sodium azide, and stored at - 8 0 ' С 
Cell lines and culture conditions 
The human melanoma cell lines used included Mel57 [10] and MV3 [59]. The K562 
erythroleukemic cell line was provided by Dr. Nancy Hogg. All cell lines were cultured 
in Dulbecco's modified Eagles medium (DMEM) (Flow, Irvine, UK) supplemented with 
10% fetal calf serum, penicillin, and streptomycin. 
Antibodies 
Anti-integrin antibodies included P1B5 anti-аЗ [61], purchased from Telios 
Pharmaceuticals Inc. (San Diego, CA); HP2/1 anti-a4 [53], provided by Dr. Francisco 
Sanchez-Madrid; NKI-Saml anti-a5 [57], provided by Dr. Carl Figdor; 4B4 anti-01 [36], 
purchased from Coulter Immunology (Hialeah, FL); AJ2 anti-/31 [29], provided by Dr. 
Eberhard Klein; C17 anti-/33 [56], provided by Dr. Amoud Sonnenberg; A109 polyclonal 
anti-av [54], purchased from Life Technologies; 10E5 anti-orllb [15], provided by Dr. 
Barry Coller; and LM142 anti-av and LM609 anti-av/33 [14], provided by Dr. David 
Cheresh. The stimulatory anti-integrin /31 mAbs were 8A2 [32], provided by Dr. 
Nicholas Kovach; and TS2/16 [24], provided by Dr. Francisco Sanchez-Madrid. Anti-Fn 
115 
mAbs were 16G3 and 13G12 [38]. 
Cell adhesion 
Cell adhesion assays were performed as described previously [16]. In short, 
polystyrene microtiter plates (Greiner, Alphen a/d Rijn, The Netherlands) were coated 
overnight with the appropriate adhesive ligands and blocked for 1 h at 37°C with DMEM 
containing 0.5% wt/vol BSA. Subsequently, lxlO4 51Cr-labeled cells in 50 μΐ 
DMEM/BSA were added to the wells and incubated for 30 min at 37°C in 5% C0 2. 
Unbound cells were removed by washing with DMEM/BSA, bound cells were lysed by 
detergent, and radioactivity of the lysate was measured in a gamma counter. Results are 
presented as the mean percentage of cell binding from triplicate wells. For induction of 
adhesion, radiolabeled cells were either preincubated with TS2/16 or 8A2 mAbs for 30 
min at 4°C before seeding in the wells, or 1 raM MnCl2, or 100 ng/ml phorbol 12-
myristate 13-acetate (PMA) was added to the cells prior to seeding in the wells. For 
adhesion inhibition studies, cells were preincubated with the appropriate mAbs or peptides 
for 30 min at 4°C before seeding into the wells. 
Flow cytometry 
Cells were incubated with mAbs in PBS containing 0.5% wt/vol BSA and 0.02% 
wt/vol sodium azide for 30 min at 4°C. After washing with PBS/BSA/azide, the cells 
were incubated with fluorescein-isothiocyanate (FITC)-labeled F(ab')2 fragments of rabbit 
anti-mouse Ig antibodies (Dako, Glostrup, Denmark) for 30 min at 4°C. After washing, 
fluorescence was measured on an Epics Elite flow cytometer (Coulter, Mijdrecht, The 
Netherlands). 
Transfection 
The full-length cDNA for the integrin /33 subunit [58], a kind gift from Dr. Erkki 
Ruoslahti, was cloned in the polylinker of the mammalian expression vector pBJlneo 
[33], kindly provided by Dr. René de Waal-Malefijt. Twenty μg of this construct was 
used for stable transfection of MV3 cells according to the calcium phosphate precipitation 
method [63], using the Calcium Phosphate Transfection System (Life Technologies). 
After 48h, stably transfected cells were selected by culturing in the presence of 1 mg/ml 
G418 (Life Technologies) for 2 weeks. Cell populations were enriched for αν/33 
expression by cell sorting in an Epics Elite flow cytometer using LM609 mAbs. After 
three cycles of sorting, transfected cell lines contained >95% αν/33 positive cells. Cells 
were maintained in culture in medium containing 200 Mg/ml G418 and regularly 
monitored for αν/33 expression. 
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RESULTS 
K562, MV3, and MelS7 differentially adhere to the CCBD 
We investigated adhesion of K562 human erythroleukemic cells and MV3 and Mel57 
human melanoma cells to the CCBD. Of the integrine known to be involved in adhesion 
to Fn, K562 exclusively expressed a5/31 (Table 1). MV3 and Mel57 expressed a3/31, 
a4/31, and a5/31. In addition, Mel57 but not MV3 expressed а /33. MV3 and Mel57 
expressed other αν integrins including αν/35 [17] and possibly αν/31 that may bind to Fn. 
Table 1. Fn-binding 'integrins on K562, MV3 and Mel57 cells. 
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MV3 
Mel57 
control 
4 
4 
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69 
41 
mean fluorescence 
a4 
4 
31 
17 
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23 
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Figure 2. Inhibition of adhesion to Fnl20kDa with integrin mAbs. Cells were allowed to adhere to 
wells coated with 20 ßg/ml of a 120 kDa fragment ofFn (Fnl20kDa) in the absence (no) or in the 
presence of inhibitory mAbs to integrin subunits as indicated. Adhesion to BSA was less than 5%. 
One experiment of 4 is shown. 
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In order to exclude influences from domains outside the CCBD that are known to 
have cell adhesive activity (HepII, IIICS), we used a 120 kDa Fn fragment that lacks the 
heparin-binding domain and the V-region but includes the CCBD. K562 adhered weakly 
to Fnl20kDa, whereas MV3 and Mel57 both adhered strongly (Fig 2). As expected from 
the surface expression data, adhesion of K562 was completely blocked by mAbs to a5 or 
/31. Even though MV3 expressed several Fn-binding integrins, adhesion was fully blocked 
by mAbs to a5 whereas mAbs to a3 or a4 or polyclonal anti-av had no effect. Adhesion 
of Mel57 was inhibited approximately 35% by mAbs to a5 or /81, and about 50% by 
mAbs to /33 or αν/33 or by polyclonal anti-av. The combination of mAbs to a5 and αν/33 
completely blocked adhesion of Mel57. 
Thus, K562 adheres weakly to the CCBD through a5/31, MV3 binds strongly through 
a5/31, and Mel57 binds strongly through a5/31 and αν/33. 
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Figure 3. Adhesion to RGD-containing ligands. A: Cells were allowed to adhere to 20 ßg/ml of 
GRGDSP peptide coupled to BSA, to polymeric RGD, or to Fnl20kDa. Adhesion to BSA was less 
than 4%. One representative experiment of three is shown. B: Cells were incubated in the absence 
(no) or presence of 500 ßg/ml GRGDSP, a control peptide GRGESP, or 16G3 or 13G12 anti-Fn 
mAbs as indicated, and allowed to adhere to wells coated with 20 ßg/ml Fnl20kDa. Adhesion to 
BSA was less than 4%. One experiment of3 is shown. 
KS62 and MV3 require the PHSRN synergy site whereas for MelS7 RGD is sufficient 
To study binding of these cells to the cell recognition site RGD, we used a GRGDSP 
peptide and polymeric RGD as adhesive ligands. K562 did not adhere to either of the 
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ligands and MV3 bound only weakly to polymeric RGD (Fig 3a). In contrast, Mel57 
adhered strongly to both ligands. When soluble GRGDSP was used to inhibit adhesion to 
Fnl20kDa, it only blocked adhesion of Mel57 whereas adhesion of K562 and MV3 was 
not influenced (Fig 3b). A control GRGESP peptide had no effect. Inhibition with the 
16G3 anti-Fn m Ab, which binds in close proximity to the RGD site [38], demonstrated 
that all cell lines bind to that region in the CCBD (Fig 3B). A control anti-Fn mAb, 
13G12, which binds at greater distance from the RGD site [38], had no effect. 
To further study the mechanism of binding to the CCBD, we used a recombinant Fn 
polypeptide containing 3Fn6-3FnlO and a mutated polypeptide lacking the recently 
described PHSRN synergy site [4] (Fig 1). As shown in figure 4, K562 did not adhere to 
the mutated polypeptide and weakly to the control polypeptide. Only very low adhesion of 
MV3 cells was observed to the mutated polypeptide whereas adhesion of MV3 to the 
control polypeptide was 5 times higher. In contrast, Mel57 cells adhered strongly to both 
polypeptides. 
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Figure 4. Adhesion to recombinant Fn polypeptides. K562, MV3, or Mel57 cells were allowed to 
adhere to wells coated with increasing concentrations of 3Fn6-W(SPSDN) (dotted line) or 3Fn6-10 
(line) as indicated. Adhesion to 0.1 mg/ml BSA was less than 4%. One experiment of 4 is shown. 
To investigate if the different adhesive characteristics of MV3 and Mel57, were due 
to differential expression of αν/33, we transfected MV3 cells with /33 cDNA, resulting in 
αν/33 surface expression (Fig 5a), and used these cells in adhesion assays. Expression of 
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αν/33 provided MV3 cells with the capacity to adhere to GRGDSP (not shown) and to the 
mutated polypeptide, and this adhesion could be inhibited by C17 anti-/33 mAbs (Fig 5b). 
A similar level of inhibition was found with LM609 anti-av/33 (not shown). 
From these results, we conclude that the differential requirement for the PHSRN 
synergy site for adhesion to RGD in the CCBD of MV3 versus Mel57, is due to the 
different binding mechanisms of a5/31 versus αν/33. 
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Figure S. Expression of αν/33 on MV3 induces adhesion to 3Fn6-10(SPSDN). A: MV3 cells were 
either untransfected (dotted line), transfected with pBJlneo alone (thin line), or transfected with 
pBJlneo including integrin β3 cDNA followed by sorting with LM609 anti-avß3 mAbs (thick line). 
Shown is the relative fluorescence after incubation with LM609 and a FITC-labeled second 
antibody. В: М Зпео or MV3-ß3 cells were allowed to adhere to wells coated with increasing 
concentrations of 3Fn6-10(SPSDN) (dotted line) or 3Fn6-10 (line) as indicated. Filled bars 
represent remaining adhesion to wells coated with 32 \Lglml of 3Fn6-I0(SPSDN) in the presence of 
inhibitory anti-integrin mAbs as indicated. Adhesion to BSA was less than 3%. One experiment of 
3 is shown. 
Stimulation of aSßl-mediated RGD binding with anti-ßl mAbs, PMA, and manganese 
The fact that K562 did not adhere to the mutated polypeptide whereas MV3 did to a 
low extent (Fig 4), even though both cell lines used a5/31, suggested that binding of a5/31 
to RGD in 3FnlO might depend on the activation state of the integrin. To investigate this, 
we treated both cell lines with 8A2 and TS2/16 stimulatory /31 mAbs, with Mn2+, or with 
PMA, prior to using them in adhesion assays to a GRGDSP peptide. PMA had no effect, 
8A2 and TS2/16 induced weak adhesion of K562 to GRGDSP, and treatment of MV3 
cells with these mAbs resulted in 25% adhesion to GRGDSP (Fig 6a). A control /31-
integrin mAb AJ2 had no effect (not shown). The strong binding of Mel57 was not 
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enhanced by 8A2 or TS2/16. Mn2+ was less effective for K562 but induced adhesion of 
MV3 cells up to 35%. We performed adhesion inhibition assays to examine whether the 
effect of 8A2 and TS2/16 was due to activation of a5/31 or to the recruitment of other 
integrins. Induced adhesion of K562 to GRGDSP in the presence of 8A2 (Fig 6b) or 
TS2/16 (not shown) was blocked by m Abs to α5 and not by any of the other m Abs. In 
addition, even though 8A2 and TS2/16 may activate аЗ/31, а4/31, aS/31, and possibly 
av|31 on MV3 cells, induced adhesion of MV3 to GRGDSP was completely blocked by 
m Abs to а5 whereas m Abs to аЗ, а4, and αν had no effect (Fig 6b). The fact that the 
4B4 anti-01 mAb did not inhibit adhesion in the presence of 8A2, is in line with the 
report that activating and inhibiting antibodies share a common epitope on the ßl subunit 
[55]. 
Thus, the strength of a5/31 binding to RGD can be increased by Mn2+ and by 
activating 01 antibodies. 
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Figure 6. Stimulation of ci5ßl-mediated adhesion to RGD. A: Cells were incubated in the absence 
(no) or in the presence of PMA, 8A2 or TS2/16 stimulatory ßl mAbs, or manganese (Mn) and 
allowed to adhere to wells coated with 20 \iglml BSA-GRGDSP. B: Cells that had been previously 
incubated in the absence (x) or in the presence of 8A2 stimulatory ßl mAbs (8A2), were incubated 
in the absence (no) or in the presence of inhibitory anti-integrin mAbs as indicated and allowed to 
adhere to wells coated with 20 ßg/ml BSA-GRGDSP. Adhesion to BSA was less than 5%. One 
experiment of3 is shown. 
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Requirement f or the PHSRN synergy site depends on the activation state ofaSßl 
As stimulatory ßl m Abs and Mn2+ induced a5/?l -mediated adhesion to GRGDSP, we 
hypothesized that the activation state of a5ßl determines the requirement for the PHSRN 
synergy site for cell adhesion to the CCBD. Therefore, we treated K562 and MV3 cells 
with PMA, TS2/16, or Mn2+, and allowed them to adhere to the mutated and control Fn 
polypeptides. TS2/16 and, to a lesser extent, Mn2+, induced adhesion of K562 cells to the 
mutated polypeptide and enhanced adhesion to the control polypeptide (Fig 7). PMA 
enhanced adhesion of K562 cells to the control polypeptide but had no effect on adhesion 
to the mutated polypeptide. For MV3 cells, no effect of PMA was observed but the low 
adhesion to the mutated polypeptide was enhanced 5-fold by TS2/16 and Mn2+, resulting 
in a level of adhesion that was similar to that observed with the fully active control 
polypeptide. 
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Figure 7. Stimulation of adhesion to recombinant Fn polypeptides. Cells were incubated in the 
absence (Я) or in the presence of PMA (*), 132/16 (*•), or manganese (•*), and allowed to adhere 
to wells coated with increasing concentrations of 3Fn6-10(SPSDN) (dotted line) or 3Fn6-10 (line) 
as indicated. Adhesion to BSA was less then 4%. One experiment of3 is shown 
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The fact that in the presence of TS2/16 or Mn2+, no difference was observed between 
the mutated and control polypeptide regarding adhesion of MV3 cells, whereas for K562 
the mutated polypeptide was still poorly active, could suggest a) that stimulation of MV3 
cells resulted in recruitment of other RGD-binding integrins, or b) that a501 on K562 
cells was not maximally activated by these agents. To exclude possibility a, we used 
mAbs to o¡3, o¡4, a5, av, ßl, /33, av/33, or the combination of these mAbs in the absence 
of anti-a5, for inhibition of TS2/16-stimulated adhesion of MV3 cells to the mutated 
polypeptide. Stimulated adhesion was blocked by the anti-a5 mAb and not by any of the 
other mAbs or their combination (Fig 8), suggesting that induction of adhesion to the 
mutated polypeptide of MV3 by TS2/16 was due to activation of a5/31 and not to 
recruitment of other integrins. 
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Figure 8. Inhibition of stimulated adhesion ofMV3 to 3Fn6-10(SPSDN) with integrin mAbs. MV3 
cells were incubated in the absence or in the presence of TS2/16 and allowed to adhere to wells 
coated with 32 μξ/ml 3Fn6-10(SPSDN). Inhibitory mAbs to integrin subunits were added as 
indicated. Adhesion to BS A was less then 3%. One experiment of3 is shown. 
To investigate possibility b, we incubated K562 cells with PMA, TS2/16, or Mn2+, 
and the various combinations, and allowed the cells to adhere to the mutated and control 
polypeptide. In the presence of the combination of TS2/16 and Mn2+, adhesion to the 
mutated polypeptide was more than half the level of adhesion to the control polypeptide 
(Fig 9). PMA had no effect by itself on adhesion to the mutated polypeptide but enhanced 
adhesion to the control polypeptide more than twofold. Finally, in the presence of the 
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combination of PMA, TS2/16, and Mn2+, the control and the mutated polypeptide were 
equally effective in promoting adhesion of K562 cells. This adhesion was blocked by a5 
m Abs (not shown). 
From these results we conclude that requirement of the PHSRN synergy site for 
a5|81-mediated adhesion to RGD in the CCBD, depends on the activation state of <*5/31. 
DISCUSSION 
In line with earlier reports, we find that αν/83 does not require the PHSRN site. We 
base this conclusion on 3 observations. First, in contrast to K562 and MV3 that lack 
αν/33 expression, Mel57 cells express αν/83 and adhere equally well to all molecules 
tested containing RGD, i.e. GRGDSP, polymeric RGD, the mutated polypeptide lacking 
the synergy site 3Fn6-10(SPSDN), the control polypeptide 3Fn6-10, and Fnl20kDa. 
Second, soluble GRGDSP blocks adhesion to Fnl20kDa of Mel57 but not of K562 or 
MV3 cells. Third, MV3 cells do not adhere to RGD-containing ligands that lack the 
PHSRN site, and transfection with /33 cDNA resulting in av03 surface expression leads 
to binding of these cells to GRGDSP and 3Fn6-10(SPSDN). 
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Figure 9. Stimulation of adhesion of K562 to recombinant Fn polypeptides. K562 cells were 
incubated in the absence or in the presence of various combinations of FM A, TS2/16, and Mri~* 
as indicated and allowed to adhere to wells coated with 32 pglml 3Fn6-10(SPSDN) (dotted bars) 
or 3Fn6-10 (filled bars). Adhesion to BSA was less then 4%. One experiment of3 is shown. 
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These findings confirm and extend the observations that αν/33 can be retained on an 
RGD column [49] whereas a5/31 cannot [48]. Furthermore, these data are in agreement 
with the recent report that αν- and a3- but not a5-containing integrins are bound by a 
column containing a Fn-fragment lacking the synergy region [1]. Similarly, it has been 
reported that aIIb/33 but not av/33 binding to Fn can be inhibited by an 11 amino acid 
peptide from 3Fn9 that also contains the PHSRN sequence [9]. Thus, RGD is sufficient 
for binding to Fn through αν/33, whereas a5/31 and aIIb/33 require the synergy region for 
efficient binding to Fn [4,9]. 
Parenthetically, it has been reported that crosstalk between αν/33 and a5/31 can occur 
[6,7]. Therefore, the induced adhesion to 3Fn6-10(SPSDN) upon expression of αν/33 in 
MV3 cells did not necessarily have to be due to αν/33-mediated adhesion. Even though 
Blystone et al. [7] show that αν/33 regulates only a5/31-mediated phagocytosis, in our 
system αν/33 might influence a5/31-mediated adhesion. Ligation of αν/33 with LM609 
mAbs might induce a signal that inhibits a5/31. To exclude this possibility, we used C17 
anti-/33 for adhesion inhibition assays. The fact that these mAbs inhibit adhesion of /33-
transfected MV3 cells to 3Fn6-10(SPSDN) suggests that direct binding through а ^З 
rather than signalling to a5/31 is involved. 
The major conclusion from this study is that the requirement for the PHSRN synergy 
site for a5/31-mediated adhesion to the CCBD depends on the activation state of a5/31. 
This is based on 3 findings. First, stimulation of K562 cells that express only a5/31, with 
Mn2+ or stimulatory /31-integrin mAbs, induces adhesion to GRGDSP and 3Fn6-
lO(SPSDN). Second, in the presence of the combination of PMA, TS2/16, and Mn2+, the 
mutated and control polypeptide are equally effective in promoting K562 cell adhesion. 
Third, treatment of MV3 cells with these agents induces adhesion to GRGDSP and 
enhances adhesion to 3Fn6-10(SPSDN) to the level of adhesion to 3Fn6-10, and this 
effect is completely blocked by antibodies to a5 but not by mAbs to аЗ, а4, or αν, or 
the combination. 
Even though the αν/33-negative K562 and MV3 cells express similar levels of a5/31, 
they differ dramatically in binding to Fnl20kDa through this receptor. The view of cell 
type specific regulation of a5/31 affinity proposed by O'Toole et al. [43] suggests that the 
default low affinity state of the integrin as observed in K562 is switched to a high affinity 
state in MV3. As a result, MV3 but not K562 cells bind strongly to Fnl20kDa. Our 
finding that K562 cells bind poorly to Fnl20kDa and that 8A2 increases that adhesion 2-3 
times is in line with earlier findings [20]. As expected, Mn2+ and stimulatory /31 mAbs do 
not affect the strong adhesion of MV3 to Fnl20kDa. However, our findings demonstrate 
that these agents do in fact alter the avidity of a5/31 in MV3 cells, but that this change 
can only be observed in the absence of the PHSRN synergy site. One interpretation of 
these findings is that intracellular factors (induced by PMA for K562 and factors already 
present in MV3) can increase the affinity of a5/31 to a level where RGD is recognized in 
the Fn molecule, and that additional extracellular events are required for the final 
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activation of or5/31 leading to full adhesion to RGD in Fn. The synergy site could be 
involved in the last step by locking the RGD site in the a5/31 binding pocket, and in the 
presence of TS2/16 or Mn2+ that last step seems to be no longer required. Our finding 
that PMA enhances K562 adhesion to the control polypeptide whereas by itself it has no 
effect on adhesion to the mutated polypeptide, is in line with this idea. Furthermore, the 
fact that K562 cells in the presence of TS2/16 bind strongly to the control polypeptide 
without the need for PMA, demonstrates that optimal extracellular stimulation (the 
synergy site plus stimulatory /31 m Abs) can abrogate the need for intracellular activation 
(PMA). 
It is of interest that comparable observations have been reported for a4/31 [62]. Even 
though Jurkat and Ramos cells express an active form of a4/31 in the sense that they are 
capable of binding to the CSI domain of Fn, they only bind to a peptide containing the 
EILDV recognition sequence from CSI in the presence of stimulatory /31 mAbs. The 
authors suggest that sequences may be present in the NH2-terminal portion of CSI that 
strengthen o¡4/31 binding to EILDV, although none have yet been identified. Thus, the 
presence of sites that synergistically enhance binding of integrins to their recognition 
sequence might be a general mechanism, and activation by stimulatory /31 mAbs and 
Mn2+ may bypass the dependence on such sites. Our report, however, provides the first 
example of substitution of the function of a well-characterized synergy site by agents that 
activate the integrins involved. 
For leukocytes, stimulatory /31 mAbs also increase the affinity of a4/31 for CSI 
[34,62] and for VCAM-1 [32], and they can even induce a4/31 binding to the RGDS 
sequence [52]. MV3 cells adhere to CSI and TNFa-stimulated endothelial cells in the 
absence of stimuli (not shown) indicating the expression of active a4/31 on these cells. 
For MV3 cells in the absence or presence of stimuli, we do not observe any inhibition of 
binding to the CCBD with HP2/1 anti-a4 mAbs, whereas these mAbs inhibit binding to 
CSI (not shown). Thus, the reported recognition of RGD by stimulated a4/31 does not 
play a role in our assay. This difference may be explained by the fact that Ramos cells, as 
used by Sánchez-Aparicio et al. [52], do not express a5ßl. In MV3, the effect of TS2/16 
on of4/31 may be masked by the binding to RGD through a5ßl. Alternatively, as reported 
previously [21], stimulatory /31 mAbs may selectively activate a5/31 while leaving a4/31 
unaffected. 
A possible interpretation of our findings may be that the PHSRN synergy site binds 
to the same epitope as recognized by the stimulatory /31 mAbs. It has been suggested 
previously that the epitope where these mAbs bind may physically interact with 
extracellular proteins [55]. However, the fact that binding of K562 to 3Fn6-10 can be 
enhanced in the presence of 8A2 or TS2/16 when PMA is absent, indicates that the 
synergy site and stimulatory mAbs can have additional combined stimulatory effects. 
Therefore these data seem to support a model where the synergy site and stimulatory 
mAbs have different binding sites on <x5/31. This is in agreement with the recent report 
126 
that the mechanism of binding of integrin a5/Sl to Fn seems to be through binding of the 
a5 subunit to the synergistic regions and of the /31 subunit to RGD [41]. 
In conclusion, our data demonstrate that a501 but not av/33 requires the PHSRN 
synergy site for cell adhesion to RGD in the CCBD of Fn, but that induction of a high 
affinity state of a5#l with PMA, stimulatory mAbs, and/or Mn2+, abrogates this 
dependence on the PHSRN sequence. 
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Chapter 9 
Inhibition of metastasis of an avj83-negative human 
melanoma cell line by expression of αν/53 and 
by the disintegrin eristostatin 
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RGD-containing ligands can inhibit melanoma metastasis though the integrine 
affected are unknown. For human melanoma, aSßl and αν/ЗЗ are candidates. They 
emerge in melanocyte tumor progression and have been implicated in melanoma 
growth and invasion. We studied the role of these integrine in an experimental 
metastasis assay using a highly metastatic human melanoma cell line MV3 that lacks 
αν/33 but expresses aSßl. As differential expression of these 2 integrins has been 
reported to modulate in vitro melanoma cell invasiveness, we transfected MV3 with 
03-cDNA resulting in av03 surface expression and adhesion to fibrinogen via this 
receptor. MV3-/J3 and two of its clones with high av03 expression were no longer 
metastatic upon i.V. injection in nude mice. Thus, in line with an earlier report on 
melanoma cell invasion, αν/33 can inhibit metastasis of certain human melanoma cell 
lines. To investigate if a5/31 was critical for MV3 metastasis, we next tested the effect 
of an anti-a5/31 mAb and peptides specifically binding to this ¡ntegrin. All reagents 
blocked adhesion to fibronectin but none of them affected metastasis. Thus, a5/?l-
mediated adhesion to fibronectin does not seem to be critical for metastasis of av/33-
negative MV3 melanoma cells. In contrast, the disintegrin eristostatin efficiently 
blocked MV3 lung metastasis. Eristostatin bound to MV3 cells in vitro and RGD-
dependent MV3 adhesion to eristostatin was partially inhibited by anti-«4 mAbs. 
Eristostatin did not affect a5/?l-mediated MV3 adhesion to the central cell binding 
domain of fibronectin, a4/31-mediated adhesion to the CS-1 domain of fibronectin or 
to VCAM-1 on stimulated endothelial cells, a2/?l-mediated adhesion to collagen, or 
аб/31-mediated adhesion to laminin. Thus, eristostatin probably does not act by 
inhibiting the initial attachment of MV3 to endothelial cells or to the subendothelial matrix. 
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INTRODUCTION 
Cell adhesion events are critical in tumor metastasis [55] and integrins play an 
important role in adhesion of cells to other cells and to the extracellular matrix (ECM) 
[26]. Many integrins recognize the RGD sequence in their ligands, and it has been shown 
that synthetic RGD peptides, non-peptide RGD mimetics, or RGD peptides isolated from 
snake venom called disintegrins, can inhibit experimental metastasis of B16 murine 
melanoma cells [3,21,24,33,46,54]. α2/31 [η, аЗ/31 [17], α401 [4η, α5/31 [1,42], αν01 
[63], αν/33 [43], αν05 [10], αν/36 [6], and αν/38 [36] recognize RGD but it is not known 
which of these integrins is affected. In addition, in contrast to human melanoma cells, B16 
cells can express aIIb/33 [8,38] an integrin that also binds RGD and has been shown to 
play a role in metastasis of these cells [23]. 
In one study, a disintegrin was shown to block experimental metastasis of human 
melanoma cells [57]. Integrins a4/31, a5/31, and αν/33, are interesting candidates in 
human melanoma since: a) they are strongly upregulated with melanocyte tumor 
progression in situ [2,16,49,50], b) antibodies to a4 can inhibit human melanoma cell 
metastasis [19,37], and c) a5|31 and αν/33 have been implicated in growth [18,34] and 
invasion [51,52] of human melanoma cells. Conversely, expression of a4/31 has been 
reported to inhibit the early stage of murine melanoma cell metastasis [44] and 
downmodulation of expression of αν03 has been demonstrated to enhance the invasive 
capacity of certain human melanoma cells [52]. 
In the present study we investigated the role of αν/33 and a5/31 in human melanoma 
cell metastasis by transfection and inhibition assays. As the disintegrin eristostatin, that 
does not bind to a5/31, blocked metastasis of an αν/33-negative melanoma cell line, we set 
out to investigate its mode of action in in vitro assays. 
MATERIALS AND METHODS 
Proteins, peptides, and antibodies 
Plasma fibronectin (Fn) was purchased from Sigma (St Louis, MO). A 120 kDa 
chymotryptic Fn fragment containing the central cell binding domain and synthetic 
peptides Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) and Gly-Arg-Gly-Glu-Ser-Pro (GRGESP) 
were purchased from Life Technologies (Gaithersburg, MD). A Fn CS-1 peptide coupled 
to IgG was provided by Dr. Martin Humphries (Manchester, U.K.). Laminin (Ln), 
isolated from Englebreth-Holm-Swarm mouse sarcoma cells was purchased from Life 
Technologies, and collagen (Co) type I, isolated from rat tail, was provided by Dr. 
Eberhard Klein (Würzburg, Germany). Fibrinogen (Fg) type 1 and type 3 were purchased 
from Sigma and mixed before use. Isolation of disintegrins from crude viper venoms and 
their affinities for various RGD-binding integrins have been described [41]. Echistatin 
133 
binds а501, αν03, and aIIb/83 with the same high affinity, while bitistatin moderately 
affects only av#3 and aIIb/33, and eristostatin is a very potent inhibitor of aIIb/33. The 
cyclic peptide cRRETAWA that binds specifically to a5/31 [28] was generated as 
described previously [40]. 
Anti-integrin mAbs included 5E8 anti-a2 [68], provided by Dr. Richard Bankert 
(Buffalo, NY); P1B5 anti-аЗ [64], purchased from Life Technologies; HP2/1 anti-a4 [48], 
provided by Dr. Francisco Sanchez-Madrid (Madrid, Spain); NKI-Saml anti-a5 [58], 
provided by Dr. Carl Figdor (Nijmegen, The Netherlands); GoH3 anti-аб [53], provided 
by Dr. Amoud Sonnenberg (Amsterdam, The Netherlands); 4B4 anti-/81 [32], purchased 
from Coulter Immunology (Hialeah, FL); TS2/16 anti-01 [22], provided by Dr. Francisco 
Sanchez-Madrid; LM142 anti-av and LM609 anti-av/33 [9], provided by Dr. David 
Cheresh (La Jolla, CA); P1F6 anti-av/35 [65] purchased from Life Technologies; SN1 
anti-av/38 [36], provided by Dr. Steven Nishimura (San Francisco, CA); and 10E5 anti-
allb [12], provided by Dr. Barry Coller (Stoneybrook, NY). A109 polyclonal anti-av [56] 
was purchased from Life Technologies. 
E1/6 anti-VC AM-1 and H18/7 anti-E-selectin [45] were provided by Dr. Michael 
Bevilacqua [La Jolla, CA] and G250 [39], an isotype matched (IgG2b) control m Ab for 
NKI-Saml, was provided by Dr. Egbert Oosterwijk (Nijmegen, The Netherlands). 
Nude mice and ceil culture 
BALB/c athymic nude mice (nu/nu) were purchased from The Laboratory Breeding 
and Research Center, Gl, Bomholtgaard, Ry, Denmark and kept in separate rooms in 
cages covered with air filters under specific pathogen-free conditions. Mice were used 
when 6-8 weeks old. Within a single experiment mice were sex and age matched. The 
highly metastatic human melanoma cell line MV3 [61] was cultured in Dulbecco's 
modified Eagles medium (DMEM; Flow, Irvine, UK), supplemented with 10% fetal calf 
serum (Life Technologies) and antibiotics. Human umbilical vein endothelial cells 
(HUVEC) were provided by Dr. Hans Westphal, Nijmegen, The Netherlands. 
Flowcytometry 
Cells were incubated with mAbs in PBS containing 0.5% wt/vol BSA and 0.02% 
wt/vol sodium azide for 30 min at 4°C. After washing with PBS/BSA/azide, the cells 
were incubated with fluorescein-isothiocyanate (FITC)-labeled F(ab')2 fragments of rabbit 
anti-mouse Ig antibodies (Dako, Glostrup, Denmark) for 30 min at 4°C. After washing, 
fluorescence was measured on an Epics Elite flow cytometer (Coulter, Mijdrecht, The 
Netherlands). For the disintegrin binding assay, eristostatin was labeled with FITC as 
described [31]. FITC-eristostatin, separated by gel filtration, fully retained its platelet 
aggregation inhibitory activity. 
134 
Transfection 
The full-length cDNA for the integrin /33 subunit [59], provided by Dr. Erkki 
Ruoslahti (La Jolla, CA), was cloned in the poly linker of the mammalian expression 
vector pBJlneo [29], provided by Dr. René de Waal-Malefijt (La Jolla, CA). Twenty μg 
of this construct was used for stable transfection of MV3 cells according to the calcium 
phosphate precipitation method [66], using the Calcium Phosphate Transfection System 
(Life Technologies). After 48h, stably transfected cells were selected by culturing in the 
presence of 1 mg/ml G418 (Life Technologies) for 2 weeks. Bulk- or single cell sorting 
was done on an Epics Elite flow cytometer using LM609 mAbs. Cells were cultured in 
medium containing 200 /tg/ml G418 and regularly monitored for av/33 expression. 
Experimental metastasis assay 
To determine the capacity of cells to metastasize, 2xl06 tumor cells in 200 μΐ 0.9% 
NaCl were injected intravenously (i.v.) into the lateral tail vein. For inhibition assays, 
cells were mixed with mAbs or peptides 15 min before injection. Mice were killed after 1 
month, lungs were formalin fixed and embedded in paraffin, and HE-stained 4 μπι 
sections of 3 levels of the lungs were microscopically examined for lung metastases. In 
our experience, no other organs are colonized [60,61]. 
Cell adhesion assay 
Cell adhesion assays were performed as described previously [14]. In short, 
polystyrene microliter plates (Greiner, Alphen a/d Rijn, The Netherlands) were coated 
overnight with the appropriate adhesive ligands and blocked for lh at 37°C with DMEM 
containing 0.5% wt/vol BSA. For adhesion to HUVEC, wells were precoated with 2 
μg/ml gelatin for lh at 37°C followed by 5x10s HUVEC that were allowed to grow for 2-
3 days and were incubated for 24h with 10 nM rTNFa (kind gift from Boehringer, 
Ingelheim, Germany) to induce VCAM-1 expression. Subsequently, lxlO4 "Cr-labeled 
MV3 cells in 50 μΐ DMEM/BSA were added to the wells and incubated for 30 min at 
37°C in 5% C02. Unbound cells were removed by washing with DMEM/BSA, bound 
cells were lysed by detergent, and radioactivity of the lysate was measured in a gamma 
counter. Results are presented as the mean percentage of cell binding from triplicate wells. 
For adhesion inhibition studies, radiolabeled cells were preincubated with the appropriate 
mAbs or peptides for 30 min at 4°C before seeding into the wells, or HUVEC were 
preincubated with mAbs for 30 min at 37°C. For induction of adhesion, radiolabeled cells 
were preincubated with TS2/16 mAbs that induce a high affinity state of /îl-integrins [55] 
for 30 min at 4°C before seeding in the wells. 
Statistical analysis 
Fisher's Exact Test (two-sided) was used for comparison of percentages of mice that 
developed metastases. 
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Expression of avß3 in MV3 cells inhibits metastasis 
The highly metastatic human melanoma cell line MV3 expresses several RGD-bim 
integrins but it lacks αν/83 (Table 1). 
Table 1. Expression ofRGD-binding integrins on MV3. 
subunit clg2 Ô2 Ö3 04 a5 
m.f.1 4 20 69 31 62 
~/SÎ αν αν/33 αν/35 αν/38 allb 
107 13 2 19 4 3 
mean fluorescence (arbitrary units), xontrol Ig. 
A 
MV3 
М Зпео 
MV3-j83 
MV3-jS3.c4 
MV3-/33.C5 
0 1000 
fluorescence 
В 
% adhesion 
12/15 
7/15 
0/5 
0/10 
0/10 
80 
47 
0 
0 
0 
metastasis 
Figure 1. Expression of αν/35 in MV3 inhibits experimental metastasis. A: MV3 cells were e 
untransfected or transfected with pBJlneo alone (М Зпео), or with pBJlneo including β3-α 
followed by bulk sorting (MV3-ß3) or single cell sorting ßfV3-ß3.c4 and MV3-ß3.c5) with LS 
anti-avß3 mAbs. Shown is the relative fluorescence after incubation with LM609 and FITC-lal 
second antibody. The dotted vertical line is the gate set with control Ig. В: Adhesion of eel 
wells coated with 100 )iglml Fg in the absence (filled bars) or presence (hatched bars) of Lb 
anti-avß3. С: Number and percentage of mice developing lung metastases after i.v. injection. 
136 
In order to investigate the effect of αν/33 expression on MV3 metastasis, we 
transfected /33-cDNA into these cells. This resulted in αν/33 surface expression (Fig la) 
and it slightly reduced the level of av/J5, while no effect was seen on the expression of 
any of the other integrins (not shown). MV3-/33 and 2 clones (MV3-/33.c4 and c5), but 
not the parental or the neo-transfected cell line adhered to Fg, and this adhesion was 
inhibited by αν/33 mAbs (Fig lb). In vitro proliferation rates of MV3, М Зпео, and 
MV3-/33 were identical; growth of the 2 clones was slightly slower (not shown). In an 
experimental metastasis assay, 80% of mice injected i.v. with MV3 cells and 47% of mice 
injected with М Зпео developed lung metastases. In contrast, in the case of MV3-/33, 
MV3-/33.C4, or MV3-/33.C5, no lung metastasis was observed (Fig lc). 
Thus, expression of αν/33 inhibits experimental metastasis of MV3 cells (p< 0.005 for 
MV3-/33, М З-03.С4, and MV3-/33.c5 compared with parental MV3; ρ < 0.01 for MV3-
/33.c4 and MV3-/33.c5 compared with М Зпео). 
Table 2. Inhibition of experimental metastasis ofMV3. 
treatment μg/mouse exp. 1 exp. 2 exp. 3 total % ρ 
no 
eristostatin 
bitistatin 
echistatin 
NKI-Saml 
clg1 
cRRETAWA 
25 
25 
25 
100 
100 
1000 
5/5* 
1/5 
5/5 
4/5 
5/5 
4/5 
3/5 
4/5 
0/5 
5/5 
3/5 
4/5 
n.d.3 
4/5 
3/5 
1/5 
5/5 
3/5 
n.d. 
n.d. 
n.d. 
12/15 
2/15 
15/15 
10/15 
9/10 
4/5 
7/10 
80 
13 
100 
67 
90 
80 
70 
0.0007 
>0.05 
>0.05 
>0.05 
>0.05 
>0.05 
'control Ig G250, dumber of mice with lung metastases, 3not done. 
Inhibition of aSßl does not affect MV3 metastasis 
To test the hypothesis that a5/Jl may be critical for MV3 metastasis, we injected MV3 
cells in the tail vein of nude mice in the presence or absence of reagents that block the 
adhesive function of a5/31. Incubation for lh in vitro with each of these reagents, did not 
affect the viability of the cells. MV3 lung metastasis formation was not affected by a5 
mAbs or by the a5/31-specific cyclic peptide cRRETAWA in 2 experiments with 5 mice, 
or by the a5/31-binding disintegrin echistatin in 3 experiments with 5 mice (p>0.05 for 
all treatments) (Table 2). Amounts of mAbs and disintegrins were similar or larger than 
those described to be effective in previous studies [3,19,37,54]. All 3 reagents blocked in 
vitro adhesion of MV3 to Fn and to a 120 kDa Fn fragment containing the central cell 
binding domain (Fig 2). 
These results suggest that blocking a5/31 -mediated adhesion to Fn does not inhibit 
MV3 metastasis. 
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Figure 2. Inhibition of a5ßl-mediated 
adhesion. MV3 cells were allowed to 
adhere to wells coated with 20 \Lglml 
Fn (filled bars) or Fn 120 kDa (hatched 
bars) in the absence or presence of 10 
ßg/ml of the dis inte grins eristostatin, 
bit ¡statin, or echistatin; 5 \iglml NKI-
Saml anti-a5 mAb or G250 control Ig 
(clg); or 100 \Lglml of the cyclic peptide 
cRRETAWA. S.d. of triplicate determi-
nations did not exceed 5%. One experi-
ment of3 is shown. 
Eristostatin inhibits MV3 metastasis and binds MV3 cells in vitro 
In contrast to these reagents, the disintegrin eristostatin which is known to bind with 
high affinity to /33 integrins but poorly to a5/31, clearly reduced lung metastasis in all 
three experiments (p=0.0007) (Table 2). A third disintegrin, bitistatin, that also binds /33 
integrins but not aSßl, had no effect (Table 2). As MV3 lacks /33 integrins, we tested if 
these cells could bind eristostatin. As shown in figure 3a, FITC-labeled eristostatin bound 
to MV3 cells in a concentration-dependent manner. Adhesion of MV3 cells to eristostatin 
could be inhibited by GRGDSP while a control GRGESP peptide had no effect, but the 
effect of RGD was low compared to the complete block of adhesion to echistatin and 
bitistatin (Fig 3b). To identify the RGD-binding integrin on MV3 that was involved in 
adhesion to eristostatin, we incubated MV3 cells with function-blocking mAbs to various 
subunits of integrins known to recognize RGD. Some inhibition was observed with HP2/1 
anti-a4 mAbs but not with 4B4 anti-01 (Fig 3c). None of the other mAbs directed to a2, 
аЗ, α5, αν/33, αν/35, or polyclonal anti-av had any effect, nor did they enhance inhibition 
in combination with HP2/1 (not shown). 
From these results we conclude that eristostatin binds an RGD-recognizing integrin(s) 
on MV3, possibly including a4/31, and that it inhibits MV3 experimental metastasis. 
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Figure 3. MV3 binds eristostatin. A. MV3 cells were incubated with increasing concentrations of 
FITC-labeled eristostatin or with FITC-labeled BSA (open circle) as a negative control, and 
fluorescence was measured. В. MV3 cells were allowed to adhere to wells coated with 25 ßg/ml of 
disintegrins as indicated, in the absence or presence of 1 mg/ml GRGDSP or GRGESP. С. MV3 
cells were allowed to adhere to wells coated with 25 μg/ml eristostatin in the absence or presence 
of5E8 anti-a.2, P1B5 anti-аЗ, HP2/1 anti-a4, NKI-Saml anti-a5, 4B4 anti-ßl, LM609 anti-avß3, 
P1F6 anti-avß5 mAbs, or A109 polyclonal anti-av. S.d. of triplicate determinations did not exceed 
5%. One experiment of 2 is shown. 
Eristostatin does not affect in vitro adhesion of MV3 cells 
Eristostatin did not affect MV3 adhesion to Fn through a501 (Fig 2). As a4/31 in its 
active conformation has been reported to bind RGD, and as we observed some inhibition 
of adhesion to eristostatin with HP2/1 anti-a4 mAbs, we next investigated if eristostatin 
affected a4/31 -mediated MV3 adhesive events. Adhesion of MV3 cells to TNFa-stimulated 
HUVEC that could be blocked with an anti-VC AM-1 m Ab and not with a m Ab to E-
selectin, was not affected by eristostatin (Fig 4a). Similarly, eristostatin did not interfere 
with adhesion to the CS-1 domain from Fn that was blocked by a4 and /31 mAbs (Fig 4b). 
As eristostatin-binding to o4j31, and thus its capacity to inhibit a4/31 -mediated adhesion, 
may depend on the activation state of the integrin, we performed the same experiments in 
the presence of TS2/16 stimulatory /31 m Ab. However, incubation of MV3 cells with 
TS2/16 did not result in eristostatin inhibition of adhesion to HUVEC or CS-1 (not 
shown). 
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Figure 4. Inhibition of a4ßl-mediated adhesion. A: MV3 cells were allowed to adhere to a 
monolayer of unstimulated HUVEC (filled bars) or TNFa-stimulated HUVEC (hatched bars) in the 
absence or presence of 10 pg/ml eristostatin or El/6 anti-VCAM-1 or H18/7 anti-E-selectin. B: 
MV3 cells were allowed to adhere to wells coated with 2 pg/ml CS-l-lg in the absence or presence 
of 10 pg/ml eristostatin or HP2/1 anti-a4 or 4B4 anti-ßl. S.d. of triplicate determinations did not 
exceed 10% (for A) or 5% (for B). One experiment of 2 is shown. 
Figure 5. Inhibition of a2ßl-/ce6ßl-
mediated adhesion. MV3 cells were 
allowed to adhere to wells coated with 
20 ixg/ml Co (filled bars) or Ln 
(hatched bars) in the absence or 
presence of 10 ßg/ml eristostatin or 5E8 
anti-a.2, Golii anti-аб, or 4B4 anti-ßl. 
S.d. of triplicate determinations did not 
exceed 5%. One experiment of 2 is 
shown. 
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In order to investigate if eristostatin affected adhesion of MV3 to basement membrane 
components, we performed adhesion assays to Co and Ln. Eristostatin did not interfere 
with a2/31 -mediated adhesion to Co (Fig 5). Similarly, a6/31-mediated adhesion to Ln was 
not affected by eristostatin. Again, incubation with TS2/16 stimulatory /31 mAb did not 
induce an inhibitory effect of eristostatin (not shown). 
From these results we conclude that eristostatin does not affect <*2/31, or4/31, «5/31, or 
a601-mediated adhesion of MV3 in vitro. 
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DISCUSSION 
The fact that MV3 is highly tumorigenic and metastatic [61] and lacks αν/33 [15], 
confirms earlier reports that certain melanoma cell lines can grow and metastasize in the 
absence of this integrin [5,52]. In contrast, strong expression of αν/83 is related to 
tumorigenicity, invasiveness, and metastatic potential of several other melanoma cell lines 
[18,20,30,35] and αν/ЗЗ emerges with melanocyte tumor progression in situ in part of the 
melanoma cases [2,15,16,49]. Together, these reports demonstrate that αν/ЗЗ may be 
important for growth, invasion, and metastasis of some melanoma cell lines, while other 
melanoma cell lines use alternative mechanisms that do not involve αν/33. Moreover, 
downmodulation of αν/33 expression has been shown to enhance A375M melanoma cell 
invasiveness [52], indicating that αν/33 can actually inhibit invasion of some cell lines. 
Our observation that /33-transfected MV3 cells, which express αν/33, fail to produce lung 
metastases, extends this finding and demonstrates that αν/33 can inhibit metastasis of 
certain melanoma cells. A possible explanation for these findings may be that the firm 
αν/33-mediated adhesion to Fn, overrules /31-integrin-mediated interactions involved in cell 
migration on Fn [67]. Alternatively, αν/33 signaling may affect the function of other 
integrins, i.e. a5/31 [4], or it may interfere with the complex of signals derived from other 
integrins that regulates protease expression and cell proliferation [11,13,27]. For both 
hypotheses, it is important to realize that in our experiments, αν/33 expression is forced 
onto cells that have adopted a strategy for metastasis in the absence of this integrin. In 
such a cellular background (integrin/protease profile, etc.) αν/33 can be obstructive while 
it can be part of the metastatic design in other melanoma cells. 
Another RGD-recognizing integrin that emerges with melanocyte tumor progression is 
a5/31. We have recently shown that a5/31 in its active state can bind RGD as strong as 
αν/33 [14], suggesting that it can be a candidate integrin for RGD-inhibition of melanoma 
metastasis. In benign melanocyte lesions a5/31 is absent while it can be detected in 
melanomas, with increased expression in advanced stages of tumor progression [2,16,49]. 
Furthermore, triggering a5/31 can stimulate invasion of αν/33-negative C8161 melanoma 
cells [52]. These findings, and the report that a5/31-binding to Fn stimulates in vitro 
melanoma cell proliferation [34], suggest that a5/31 may be important for invasion and 
growth of melanoma cells that lack αν/ЗЗ. It may thus be expected that a5/31 plays a role 
in MV3 metastasis. However, NKI-Saml, cRRETAWA, and echistatin do not affect lung 
metastasis of MV3 cells, while they all bind a5/31 [28,41,58] and inhibit MV3 adhesion to 
Fn which is exclusively mediated by a5/31 [14]. Thus, our data suggest that binding to Fn 
through a5/31 is not critical for MV3 metastasis but they do not exclude a possible role 
for a5/31, as other integrins may take over its Fn-binding function. It has been reported 
that unoccupied a5/31 inhibits proliferation, while upon Fn-binding, a5/31 generates a 
growth stimulatory signal [62]. Binding of cRRETAWA and echistatin may mimic Fn-
binding but the absence of inhibition with the a5 mAb suggests that neither adhesion nor 
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proliferative signaling through aSßl is critical. 
Earlier studies have shown that eristostatin inhibits murine melanoma cell metastasis 
[3,33]. Our study extends these findings and demonstrates that eristostatin can also inhibit 
metastasis of human melanoma cells in a nude mouse model. It has been reported that 
eristostatin in a dose of 500 ng per mouse provided almost complete protection against 
metastases and that it was 80 times more potent than echistatin on a molar basis [3]. In 
that study, eristostatin appeared to be an extremely potent inhibitor of B16F10-induced 
murine platelet aggregation, and it had little effect on adhesion to ECM components. 
Beviglia et al. [3] suggested that eristostatin may prevent metastasis by disrupting 
melanoma-platelet aggregates, formed by fibrinogen bridging aIIb/33 on platelets and other 
fibrinogen-binding integrins on B16F10 cells. Our current study suggests that the anti-
metastatic activity of eristostatin does not involve a platelet-dependent mechanism since 
MV3 cells lack /33 integrins that are implicated in melanoma-platelet interaction [8,23]. 
Accordingly, Morris et al. [33] excluded that the inhibition of B16F1 liver metastasis 
observed with eristostatin, involved inhibition of platelet aggregation. Further evidence 
against a role for inhibition of tumor-platelet interactions in the effect of RGD-containing 
ligands, is the fact that RGD-peptides have been demonstrated to inhibit B16 metastasis in 
platelet-depleted mice [25]. 
There is one previous report on inhibition of human melanoma cell metastasis by a 
disintegrin [57]. The M24met cells used in that study expressed av#3, but binding of 
contortrostatin was found to be a5/81-mediated, indicating that blocking a5/31 might have 
been involved in its in vivo effect. Our findings suggest that such a mechanism is unlikely 
for eristostatin. We hypothesized that interference with or4/31 -mediated adhesion to 
endothelial cell VCAM-1 might be an alternative mechanism, as it was recently observed 
that FITC-eristostatin, in contrast to FITC-echistatin, binds a4- (but not mock-) 
transfected CHO cells [C. Marcinkiewicz and S. Niewiarowski, unpublished 
observations]. M Abs to α4 have been reported to inhibit TNFa- or ILI-augmented murine 
melanoma cell metastasis [19,37], and «4/31 -expression is associated with poor prognosis 
in melanoma patients [50], indicating the importance of this integrin for melanoma 
metastasis. Even though mAbs to a4 partially inhibit MV3 adhesion to eristostatin, /31 
mAbs have no effect, and MV3 cells do not express j37 (not shown). At present we have 
no explanation for these findings. If a4/31 is involved in binding of eristostatin to MV3, 
our in vitro adhesion assays suggest that inhibition of a4/31-mediated adhesion to VCAM-
1 on endothelial cells or to the Fn CS-1 domain does not play a role in the inhibition of 
metastasis. As eristostatin does not inhibit in vitro adhesion to Ln and Co either, it does 
not seem to act by preventing the initial adhesion to vascular endothelial cells or to 
components of the subendothelial basement membrane. Our findings may support the 
earlier notion that inhibition of B16F1 liver metastasis by eristostatin is not due to 
prevention of platelet binding or to interference with extravasation or subsequent invasion 
of the tumor cells, as was determined by in vivo video-microscopy [33]. Similar to what 
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was suggested in that study for B16F1 cells, eristostatin might inhibit the outgrowth of 
individual MV3 cells in the lungs. Studies on the inhibition of MV3 proliferation, 
migration, and invasion should provide more insight in the mode of action of eristostatin. 
In conclusion, our findings demonstrate that a) expression of αν/33 can inhibit 
metastasis of certain human melanoma cells, b) blocking a5/31 on αν/33-negative 
melanoma cells does not result in obstruction of metastasis, and c) the disintegrin 
eristostatin can block metastasis of human melanoma cells though its mode of action 
remains to be determined. 
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Changes in glycoconjugate production have been reported for tumor cells. In this 
study we investigated the glycoconjugate expression pattern in normal human 
melanocytes and in a panel of 6 human melanoma cell lines with different metastatic 
capacity after subcutaneous inoculation into nude mice. Glycoconjugates were labeled 
in vitro with [35S] sulphate and [3H] glucosamine, purified from cells and culture 
medium by column chromatography and identified by treatment with specific 
glycosidases. Characterization of the purified glycoconjugate fractions as well as 
Alcian blue staining of xenograft lesions revealed that hyaluronic acid (HA) is the 
main glycoconjugate produced by all cell lines. Highly metastatic cell lines expressed 
higher levels of HA than melanocytes and non or low metastatic cell lines. In 
addition, a shift from chondroitin sulphate proteoglycan to heparan sulphate 
proteoglycan dominancy was observed with increasing metastatic capacity. We also 
studied the expression and binding activity of the HA receptor CD44. 
Immunoprecipitation experiments indicated a high CD44 synthesis only in highly 
metastatic cell lines, but flowcytometry demonstrated about the same surface 
expression in melanocytes and all cell lines. Adhesion assays to immobilized HA 
showed that CD44 can be present in an inactive or active conformation. Our data 
suggest that a combination of increased HA production and the expression of CD44 
on the cell surface may be associated with a high metastatic potential of human 
melanoma cell lines in nude mice. 
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INTRODUCTION 
The composition of the cell surface and the microenvironment plays an important role 
in tumor progression, especially metastasis formation. To create an environment that is 
conductive to tumor cell invasion, a balance has to be reached between extracellular 
matrix (ECM) degradation and production of new ECM components. Local disintegration 
of the ECM network results in expansion and subsequent hydration of the ground 
substance. In this environment glycosaminoglycans bind water accumulating at the tumor 
invasion zone due to vascular perturbation [7]. This process is often accompanied and 
enhanced by the deposition of excessive amounts of hyaluronate (HA) [14,15] and/or 
chondroitin sulphate (CS) [3,11,19]. 
In tumors, changes in glycoconjugate expression are prominent at the invasion zone. 
Not only the production of excessive quantities of various types of normal 
glycoconjugates by tumor cells has been reported, but also the deposition of chemically 
altered glycoconjugates, finally resulting in a pathologic ECM [22]. A number of studies 
have been performed on animal tumor cell lines with different metastatic capacity derived 
from the same parental line [13,23,24,25,31]. Strongly increased expression of HA was 
found in highly-metastatic sublines compared with the low-metastatic variants [13,31]. An 
important and specific role in tumor cell invasion was reported for heparan sulphate 
proteoglycans (HSPGs) in highly metastatic animal carcinoma and melanoma cell lines 
[23,24,31], and for chondroitin sulphate proteoglycans (CSPGs) in a highly metastatic 
lymphoma cell line [25]. Until now only few studies have been published on 
glycoconjugate expression by human tumor cell lines with different metastatic capacity 
[3,19,29]. A human melanoma subline with an eight- to tenfold higher capacity to form 
liver colonies after intrasplenic injection than its parental counterpart, was found to have a 
dominance of HSPG over CSPG at the cell surface [31]. 
CD44 can function as a receptor for HA [1,28]. Moreover, it has recently been 
shown that CD44 and some isoforms of CD44 are associated with tumor cell 
dissemination in several human malignancies [2,10,33] and in animal tumor model 
systems [8]. Regarding the involvement of CD44 in melanocytic tumor progression, it has 
been reported that intravenous (i.v.) inoculation of nude mice with human melanoma cell 
variants expressing high levels of CD44, gives rise to more extensive lung colonization 
than with cell line variants expressing low levels of CD44 [2]. However, in a recent study 
the same group was unable to confirm that association after testing a broad spectrum of 
different melanoma cell lines [5]. 
The purpose of this study was to investigate whether a correlation exists between the 
metastatic potential of human melanoma cell lines and their glycoconjugate expression 
pattern. Since we found that the level of HA was markedly increased in the frequently 
metastasizing cell lines, we also studied the expression and functional activity of the HA 
receptor CD44. 
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MATERIALS AND METHODS 
Cell lines and tissue culture conditions 
All cell lines were derived from human melanoma metastases and included: IF6; 530; 
M14; Mel57; BLM and MV3 [4]. All cell lines were cultured in Dulbecco's Modified 
Eagles Medium (Flow, Irvine, UK) supplemented with 10% heat-inactivated fetal calf 
serum and antibiotics. Isolation and propagation of normal human foreskin melanocytes 
was performed as described [26] in Ham's FIO (Flow) supplemented with 2% Ultroser-G 
synthetic serum (GIBCO, Grand Island, NY), antibiotics, 0.1 mM IBMX (Sigma, St. 
Louis, MO), and 16 nM phorbol 12-myristate 13- acetate (PMA) (Sigma). 
/*5S/ sulphate and fHJ glucosamine labeling of cells 
For radioactive labeling of the glycoconjugates, cells were grown to about 80% 
confluency in ISO cm2 tissue culture flasks and incubated with 20 ml medium containing 
20 μΟί/πιΙ [35S] sulphate and 10 μ<Ζί/πι1 [3H] glucosamine (Amersham, Houten, The 
Netherlands) for 24 h at 37°C. At the end of the labeling culture medium was removed, 
centrifuged to remove cell debris, and further processed for glycoconjugate analysis. 
After washing (3x) with phosphate buffered saline (PBS) cells were harvested using a 
rubber policeman and stored at -80°C until further analysis. 
Isolation of glycoconjugates f rom cells and culture medium 
All extractions and subsequent fractionations were performed in the presence of a 
mixture of protease inhibitors [1 mM phenylmethylsulphonylfluoride (PMSF)/5 mM 
benzamidine-HCl/10 mM n-ethylmaleimide/0.1 M 6-aminohexanoic acid/5 mM iodo-
acetamide/10 mM sodium EDTA]. 
Labeled human melanoma cells were extracted with 4 M guanidine-HCl/50 mM 
sodium acetate (pH 5.8) and stirred for 16 h at 4°C. The residue obtained after 
centrifugation (20,000 χ g for 30 min at 4°C) was extracted for an additional 16 h. The 
combined supematants were extensively dialyzed at 4°C against 7 M urea/50 mM Tris-
HC1 (pH 6.8). 
Secreted glycoconjugates were isolated from the culture medium. The culture medium 
was evaporated to dryness and the residue dissolved in 4 ml 7 M urea/50 mM Tris-HCl 
(pH 6.8). Unincorporated label was removed by gel filtration on a Bio-Gel P2 column 
(72.0 χ 1.6 cm). The peak eluting in the void volume of the column was used for further 
purification. 
Purification of glycoconjugates by Q-Sepharose-HL chromatography 
Urea extracts from the melanoma cells or culture medium were chromatographed 
after centrifugation (100,000 χ g for 30 min at 4°C) and filtration through a 0.2 /im filter 
on a column (1.6 χ 10.0 cm) of Q-Sepharose-HL. The following solvents were used for 
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this FPLC column: A: 7 M urea/50 mM Tris-HCl (pH 6.8) and B: 7 M urea/1 M 
NaCl/50 mM Tris-HCl (pH 6.8). After application of the sample, a linear gradient was 
used with a flow rate of 2 ml/min. The gradient started at 0% В for 10 min and rose to 
100% В at 60 min. The solvent composition was held at 100% В for 10 min, followed by 
equilibration back to 0% B. Fractions of 1 ml were collected and glycoconjugates were 
monitored by determination of the radioactivity in the fractions. The glycoconjugate-
containing fractions were pooled, dialyzed against distilled water and stored at -20°C. 
Identification of glycoconjugates 
Glycoconjugates were identified according to established procedures [32]. Enzymes 
used were: heparitinase (Seikagaku Kogyo Co, Tokyo, Japan), chondroitinase AC and 
ABC, and (Streptomyces) hyaluronidase (Sigma). The specificity of the glycosidases was 
first checked on glycosaminoglycan standards. Heparitinase digestion was performed at 
43°C for 18 h in 0.1 M sodium acetate/10 mM calcium acetate (pH 7.0). The enzyme was 
used at a concentration of 1 U/ml. Chondroitinase ABC digestion was performed at 37°C 
for 18 h in 0.1 M Tris-HCl (pH 8.0) at an enzyme concentration of 0.25 U/ml. 
Hyaluronidase digestion was performed at 37°C for 16 h in 50 mM sodium phosphate (pH 
5.0); the enzyme was used at a concentration of 10 U/ml. Quantitative proportions of 
glycosaminoglycans were determined by analyzing the radioactivity after BioGel P100 
chromatography. 
To test for the presence of glycoconjugates in xenograft lesions, formalin-fixed and 
paraffin-embedded sections from s.c. tumors and from lungs containing metastases were 
stained using the Alcian blue technique at pH 2.8. To determine the glycoconjugate 
profile present in Alcian blue-positive xenograft lesions, sections from s.c. tumors and 
from lungs containing metastases were preincubated for 1 h (and overnight) with various 
glycosidases before Alcian blue staining as described above. Parallel sections were treated 
with HN02 for specific chemical degradation of heparan sulphate (HS). 
Analytical procedures 
Protein content was determined using the Bio-Rad Protein Assay using BSA as a 
standard. 
Antibodies 
Control mAbs were WT31 anti-CD3 [26], provided by Dr. Wil Tax (Nijmegen, The 
Netherlands) for flowcytometry, and 4B4 anti-/?l-integrin [20], purchased from Coulter 
Immunology (Hialeah, FL) for adhesion assays. Anti-CD44 mAbs were NKI-P2 [21], 
provided by Dr. Carl Figdor (Nijmegen, The Netherlands); 5F12 [18], A1G3 [17], and 
A3D8 [9], provided by Dr. Barry Haynes (Durham, NC); KM201 [18] from the ATCC; 
and R7166.7 (Lesley et al., unpublished). 
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Subconfluent monolayer cell cultures (75 cm2) were labeled overnight at 37°C in 
methionine-free Eagle's minimum essential medium supplemented with 0.3 mCi [35S] 
methionine and 10% dialyzed FCS. Before harvesting cells were washed twice with PBS. 
Subsequently NP40-lysis buffer (0.5% NP40, 15 mM NaCl, 10 mM Tris (pH 7.5), 1.0 
mM PMSF and 4 /ig/ml Aprotinin) was added for 10 min at 4°C resulting in lysis of the 
labeled cells. Cell debris were scraped out of the culture flask, repeatedly aspirated into 
syringes and forced through needles with decreasing diameters. Adsorption to Con A-
Sepharose (Pharmacia, Uppsala, Sweden) was performed to isolate the glycoprotein 
fraction from the total cell lysate. Equal numbers of counts of the Con Α-bound fraction 
were used for immunoprecipitation as described earlier [4]. Immunoprecipitates were 
analyzed on a 10% SDS-polyacrylamide gel; gels were dried and exposed to X-ray films 
(Eastman Kodak, Arnhem, The Netherlands) at -70°C using intensifying screens. 
Flowcytometry 
After short trypsinization of subconfluent monolayers, cells were incubated for 30 
min at 4°C with purified mAbs diluted in PBS containing 0.5% BS A and 0.02% sodium 
azide. After washing with PBS/BSA/azide, cells were incubated with fluorescein-
isothyocianate (FITC)-conjugated F(ab')2 fragments of rabbit anti-mouse Ig antibodies 
(Dako, Glostrup, Denmark) and analyzed on an Epics Elite flowcytometer (Coulter 
Electronics, Mijdrecht, The Netherlands). 
Adhesion assay 
HA isolated from human umbilical cord was purchased from Sigma. Polystyrene 
microtiter plates (Greiner, Alphen a/d Rijn, The Netherlands) were precoated with 150 μ\ 
protamine chloride (200 ¿tg/ml) (KABI AB, Stockholm, Sweden) for 2 h at room 
temperature. After washing with PBS, 100 μΐ HA solution (200 ¿tg/ml carbonate buffer, 
pH 9.6) was added and incubated overnight at room temperature. The plates were then 
washed with PBS. To avoid non-specific binding, plates were subsequently coated for 2 h 
at 37°C with 1% (w/v) BSA in PBS and then again washed with PBS. MCr-labeled cells 
[4] were allowed to adhere to the wells for 30 min at 37°C. Non-adhered cells were 
washed away, attached cells were lysed, and the radioactivity of the lysates was measured 
in a gamma counter. In adhesion inhibition assays cells were incubated with the 
appropriate mAbs for 30 min at 4°C before seeding into the wells. 
RESULTS 
To study the expression of glycoconjugates in relation to metastatic potential, a set of 
human melanoma cell lines with different metastatic behavior was used. This set included 
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4 cell lines that are non- or sporadically metastasizing (IF6, 530, M14, Mel57) and 2 cell 
lines that are frequently metastasizing (BLM, MV3) upon s.c. inoculation into nude mice 
[4]. In addition, cultured normal human melanocytes were included. 
Figure 1. Histology of BLM xenografts (A,B) and visualization of glycoconjugates in a BLM 
xenograft (Q and in cultured BLM cells (D). HE-stained sections of tumor lesions show some 
compact areas of tumor cells (A), while other parts (of the same lesion) contain dispersed tumor 
cells with large intercellular spaces (B). Alcian blue positivity suggests the presence of 
glycoconjugates, mainly in the large intercellular spaces (C). Bar = 50 \¡m. Similar results were 
observed with MV3 cells. 
Expression and identification of glycoconjugates in tumors 
Macroscopic examination of s.c. tumors of the 6 melanoma cell lines, demonstrated a 
marked difference in the consistency of the tumors. While the xenografts of the non- or 
poorly metastatic cell lines demonstrated a solid aspect, the lesions of the frequently 
metastatic cell lines showed a mucin-like aspect. Conventionally stained histological 
sections of the s.c. tumors exhibited exclusively compact areas of tumor cells in IF6, 530, 
M14 and Mel57 xenograft lesions. In contrast, s.c. tumors and tumor lesions in the lungs 
of the highly metastatic cell lines BLM and MV3 exhibited besides compact areas (Fig 
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la) also parts showing dispersed tumor cells with large intercellular spaces (Fig lb) 
containing a mucin-like substance. Alcian blue staining of sections from lesions of all 6 
cell lines showed a marked positivity in BLM and MV3 tumors indicating large quantities 
of glycoconjugates (Fig lc). No or very weak positivity was seen in tumors derived from 
the other melanoma cell lines (not shown). 
To determine whether the glycoconjugates in BLM and MV3 lesions were produced 
by the tumor cells or by the tumor stromal cells Alcian blue stainings were performed on 
cells cultured on coverslips. About half of the tumor cells of both cell lines contained 
markedly positive intracellular vacuoles (Fig Id). 
Figure 2. Alcian blue staining of sections ofs.c. lesions of highly metastatic MV3 (A,B) and non-
metastatic IF6 (C,D) cells without (A,C) and after (B,D) treatment with chondroitinase ABC. Note 
the Alcian blue positivity in the MV3 tumor (A) and the disappearance of positivity after 
chondroitinase ABC treatment (B). Similar results as with chondroitinase ABC were found with 
chondroitinase AC and Hyaluronidase. No disappearance of Alcian blue-positivity was found after 
pretreatment with heparitinase. No Alcian blue positivity was found in the IF6 tumor (C). Bar = 
50 μ/η. Similar results as with MV3 tumors were observed with BLM tumors; 530, M14 and Mel57 
tumors showed similar results as 1F6 tumors. 
Separate sections were treated with various glycosidases (chondroitinase AC, 
chondroitinase ABC, hyaluronidase, and heparitinase) to determine the composition of the 
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glycoconjugates in BLM and MV3 xenograft lesions (Fig 2). Incubation with all enzymes 
except heparitinase resulted in disappearance of Alcian blue staining. Similar to 
heparitinase, HN02 treatment had no effect. These results indicate that the 
glycoconjugates in the intercellular spaces of BLM and MV3 lesions represent mainly 
HA. 
Expression and identification of glycoconjugates in vitro 
Metabolic labeling with [35S] sulphate and [3H] glucosamine was used to identify the 
glycoconjugates produced by normal human melanocytes and the different melanoma cell 
lines in vitro. Purification of the cellular extract on Q-Sepharose-HL resulted in a 3H-peak 
separated from a 35S-peak for all cell lines (Fig 3). The 3H-peak eluted as a broad peak 
between 0 and 0.40 M NaCl from the column and the 35S-peak eluted between 0.60 and 
0.80 M NaCl. Chromatography of urea extracts from culture media on Q-Sepharose-HL 
resulted in elution profiles comparable to those observed for the cellular fractions (Fig 3), 
demonstrating that glycoconjugates were secreted in the culture medium. 
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Figure 3. Chromatography of urea extracts from cells (A,B) and culture media (C,D) on Q-
Sepharose-HL after labeling with F5S] sulphate and ¡Ή] glucosamine of IF6 (A,C) and MV3 
(B,D) cells. Elution was performed with 7 M urea/50 mM Tris-HCl (pH 6.8) followed by a 
gradient of 0-1 M NaCl in the same buffer. Fractions (2.0 ml) were analyzed for radioactivity. 
Fractions from the 35S- and 3H-peak were pooled for further analysis. 
155 
Table 1. Œycosaminoglycan composition of the 'H and "S peaks. 
melanocytes 
IF6 
530 
M14 
Mel57 
BLM 
М З 
259 
299 
365 
301 
460 
623 
928 
cellular fraction culture medium 
cell line [Ή]ΗΑι ratio [33S]CS/HS2 [Ή]ΗΑ ratio [3,S]CS/HS 
ЗІ5 Í62 3~8 
2.6 293 3.2 
2.2 291 1.7 
1.8 438 2.0 
1.3 561 1.4 
0.6 726 0.8 
0.4 786 0.5 
'Values are given in dpm^g protein as means of 3 flF6, BLM) or 2 (melanocytes, 530, M14, 
Mel57, MV3) experiments. HA content was determined by Hyaluronidase digestion of the 'ri-
peak. 
^atio CS/HS was determined by digestion of the MS-peak with chondroitinase ABC and 
heparitinase. Values are given as means of 2 experiments. 
The composition of the 35S-labeled glycoconjugates, from the cellular fraction as well 
as the culture medium, showed differences between the cell lines studied. A clear change 
from CS to HS dominancy was observed in the 35S-peak with increasing metastatic 
capacity of the cell line. This suggests similar changes in the ratio CSPG/HSPG (Table 
1). As the 3H-peak, contains other products besides HA originating from [3H] 
glucosamine, this fraction was treated with Hyaluronidase to determine the production of 
HA. As shown in Table 1, in line with the findings in xenograft lesions, the highly 
metastatic cell lines showed increased HA production. 
Expression of CD44 
As the production of HA was elevated in the frequently metastasizing cell lines and as 
CD44 may function as a receptor for HA, we investigated the presence of CD44. To 
determine its level of biosynthesis, we performed immunoprecipitation experiments with 
[35S] methionine-labeled melanocytes and melanoma cells using mAb NKI-P2 which 
recognizes an epitope present on all CD44 isoforms. As shown in figure 4, a 90 kDa 
CD44 protein was precipitated from all cell lines, including melanocytes, but synthesis 
was high in BLM and MV3, intermediate in melanocytes, Mel57 and IF6, and very low 
in 530 and M14. In addition, we studied surface expression of CD44 using the same mAb 
in flowcytometry. As shown in figure 5, BLM and MV3 but also the other melanoma cell 
lines and normal melanocytes had a high level of CD44 surface expression. These data 
indicate that in addition to the increased synthesis and secretion of HA, synthesis of the 
CD44 HA-receptor is increased in the highly metastatic cell lines as well, whereas CD44 
surface expression is high on all cell lines tested. 
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Figure 4. Biosynthesis of CD44 in 
human melanocytes (MCI) and melano­
ma cell lines. Subconfluent monolayers 
were labeled with r~5S] methionine. 
After isolation of glycoproteins from 
cell lysates with Con A-Sepharose equal 
numbers of counts were used for 
immunoprecipitation with mAb NKI-P2. 
Adhesion to hyaluronic acid 
To investigate whether the expression of CD44 was reflected by the capacity to 
adhere to HA, we performed adhesion assays to immobilized HA. Two melanoma cell 
lines, 530 and M14, did not adhere to HA while the other cell lines, including 
melanocytes, adhered moderately (Mel57) or strongly (melanocytes, IF6, BLM, MV3) 
(Fig 6). Pretreatment of all cell lines with hyaluronidase or chondroitinase did not alter 
their binding capacity (data not shown). 
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Figure 5. Expression of CD44 on cultured human melanocytes (MCT) and melanoma cell lines. 
Cells were tested in indirect immunofluorescence with NKI-P2 (anti-CD44) or with WT31 (anti-
CD3) as a negative control (dotted line). Following mAb incubation, the cells were exposed to 
FITC-conjugated rabbit anti-mouse Ig and analyzed by flow cytometry. The fluorescence intensity 
of 5,000 cells was determined. One representative experiment out of 3 is shown. 
157 
To demonstrate that binding to HA was CD44-mediated, adhesion inhibition assays 
were performed with a panel of 6 different CD44 mAbs. As a negative control 4B4, an 
adhesion blocking ßl integrin m Ab [20] was used. As shown in figure 6, two CD44 
mAbs gave partial (5F12) or nearly complete to complete (R7166.7) inhibition of 
adhesion. No inhibition of adhesion of melanocytes and all melanoma cell lines was found 
with CD44 mAb KM201 (data not shown) and with the /31 integrin m Ab 4B4 although all 
cells markedly express ßl integrins on their surface [4]. 
From these results we conclude that even though all cells express CD44 on their 
surface, CD44-mediated adhesion to HA is highly variable. 
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Figure 6. Adhesion and inhibition of adhesion of human melanocytes (MCT) and melanoma cell 
lines to HA. BSA= adhesion to wells coated only with B5A. Cells were incubated in the absence 
(control) or in the presence of mAbs against CD44 (NKI-P2, R7166.7, 5FI2, A1G3. A3D8) or ßl 
integrin (4B4). S.d. of triplicate determinations did not exceed 10%. One experiment of3 is shown. 
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DISCUSSION 
Glycoconjugates are involved in various normal cellular processes, such as cell 
growth, migration, and adhesion. They may also be involved in various steps of the 
metastatic cascade. Transformed cells and tumor cells frequently demonstrate altered 
glycoconjugate patterns, decreased HS and increased HA and CS expression [11]. In 
addition, both rodent as well as human tumor cell lines with different metastatic capacity 
express altered glycoconjugate patterns [3,19] especially increased HS/CS ratios with 
increased metastatic potential [29,30]. Since little is known about glycoconjugate 
expression by human melanoma cell lines in relation to spontaneous metastasis, in the 
present study we investigated the expression pattern of melanocytes and a panel of 6 
human melanoma cell lines with different metastatic behavior after s.c. inoculation into 
nude mice [4]. 
Similar to other studies using low and highly metastatic mouse lymphoma cell lines, 
Lewis lung tumor cell lines, mouse melanoma cell lines, and various rodent cell lines 
[23,24,25,31], we find that the production of glycoconjugates is enhanced in highly 
invasive and metastatic cell lines. In accordance with other studies [30] a shift is observed 
from CSPG to HSPG dominancy with increasing metastatic capacity. 
Enhanced glycoconjugate synthesis has been reported for smooth muscle cells that are 
cocultured with colon carcinoma cells [12], and for fibroblasts that are cultured in the 
presence of tumor-conditioned-medium [6]. However, our findings and similar 
observations by other groups [13,31], indicate that most glycoconjugates in the xenografts 
are synthesized by the melanoma cells, as only few stromal cells are present in the tumor 
lesions and as the melanoma cells show a marked production in vitro. 
Our finding that the HA receptor, CD44, is expressed on melanocytes and on all 
melanoma cell lines tested irrespective of their metastatic potential, confirms previous 
findings [5]. A possible explanation for the higher synthesis in the frequently 
metastasizing cell lines BLM and MV3, may be that CD44, possibly after binding of 
"endogenous" HA, is shedded into the culture medium, inducing a continuous synthesis of 
CD44, but this still has to be proven. It has been reported that CD44 mRNA levels in 
melanoma cell lines do not correlate with the levels of surface expression [5], suggesting 
that the control of surface expression is regulated post-transcriptionally. In line with that 
study, we find that melanoma cells express the standard 90 kD CD44 isoform and that 
they adhere to immobilized HA through this receptor as proven by inhibition with anti-
CD44 mAbs. Regarding the mechanism of inhibition of adhesion by the R7166.7 mAb we 
know that this is not due to direct blocking of the HA binding site, since the mAb does 
not block binding of fluorescein-labeled soluble HA to the cell lines (data not shown). 
Our interpretation of these data is that binding to immobilized HA might be blocked by 
mAb R7166.7 by restricting CD44 mobility or distribution. Alternatively, steric hindrance 
may be involved. Our results with the KM201 mAb conflict with the report that this mAb 
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should inhibit binding of HA to human cells [28]. However, we and others (Kincade; 
Neame and Isacke, personal communication) were unable to demonstrate KM201 binding 
to human CD44. 
In accordance with East et al. [5] we do not find a correlation between the level of 
CD44 cell surface expression and the ability of the cells to adhere to HA. Pretreatment of 
the non or poorly adhering cell lines with hyaluronidase or chondroitinase does not induce 
or enhance binding to HA, excluding that absence of adhesion is due to binding of 
"endogenous" HA to the receptor. One explanation for these results is that CD44 is 
present in an inactive state on the non-adhering cell lines. For murine cells that express 
CD44 it has been shown that they do not constitutively bind HA, but binding activity can 
be induced by mAbs recognizing specific epitopes [16]. As activating antibodies to human 
CD44 were not available to us we could not prove this supposition. Interestingly, East et 
al. [5] reported a reproducible but not significant increase of the binding capacity of 
CD44-positive human melanoma cells to HA with 2 different CD44 mAbs. 
In conclusion, we found that 1) melanocytes and non- or low metastatic human 
melanoma cells secrete low levels of glycoconjugates compared with highly metastatic cell 
lines, 2) there is a shift from CSPG to HSPG dominancy with increasing metastatic 
capacity, 3) HA is the main glycoconjugate produced by all melanoma cell lines, 4) the 
synthesis of HA and its receptor, CD44, are markedly higher in the frequently 
metastasizing cell lines, and S) CD44 is strongly expressed on all cell lines but seems to 
be present in an inactive conformation on some cell lines. Our results confirm the 
potential role of HA and its receptor in the metastatic process. 
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Chapter 11 
Expression of CD44 splice variants in human cutaneous 
melanoma and melanoma cell lines is related to tumor 
progression and metastatic potential 
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Expression of CD44, particularly of certain splice variants, has been linked to 
tumor progression and metastasis formation in a number of different animal and 
human cancers. As human cutaneous melanoma is among the most aggressive human 
cancers, we explored expression of CD44 isoforms (CD44v) in lesions of melanocyte 
tumor progression. In addition, by RT-PCR and FACS analysis we assessed CD44v 
RNA species and cell surface expression of CD44v in cultured melanocytes isolated 
from human foreskin and in a panel of two non-, two sporadically-, and two highly 
metastatic human melanoma cell lines. We observed that all melanocyte lesions 
examined, showed strong uniform expression of standard CD44 (CD44s) epitopes. 
We did not detect CD44v6 expression in the melanocyte lesions. However, CD44 
isoforms containing v5 or vlO were differentially expressed. V5 was expressed in 16, 
0, 20, 67, and 58% of common nevi, atypical nevi, early primary melanomas 
( i 1.5mm), advanced primary melanomas (> 1.5mm), and metastases respectively 
and hence was related to tumor progression. In contrast, CD44vlO was expressed in 
all common nevi whereas part of the atypical nevi and most primary melanomas and 
metastases lacked vlO. CD44v RNA patterns were closely similar in cultured 
melanocytes and all melanoma cell lines. Melanocytes expressed high levels of CD44s 
but no CD44v, whereas all melanoma cell lines expressed CD44v at their surface. 
Interestingly, expression of v5 was strongly increased in the highly metastatic cell 
lines. Our results may suggest a role for CD44 variant domains, particularly v5 and 
vlO, in human melanocyte tumor progression. 
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INTRODUCTION 
During tumor progression, a subset of cells acquires metastatic properties, presumably 
through a series of genetic alterations. As a result, cells detach from the primary tumor, 
penetrate the basement membrane, and invade the connective tissue including lymph- and 
blood vessels. The tumor cells are subsequently transported to sites of metastatic 
outgrowth via lymph and/or blood. Loss of existing adhesive functions and gain of new 
adhesive functions are thought to play a crucial role in this metastatic cascade [12]. 
CD44, a heterogenous family of molecules with putative functions in cell-cell and 
cell-matrix interaction has recently been linked to tumor progression in a number of 
malignancies. In human non-Hodgkin's lymphomas [16,17,29] and in adenocarcinomas of 
the colon [15,36,42], stomach [23], and breast [18], expression of CD44 was found to be 
related to tumor dissemination and/or unfavorable prognosis. In a rat model, highly 
metastasizing adenocarcinoma cell lines express splice variants of the CD44 glycoprotein. 
These variants differ from the standard CD44 molecule in that they contain additional 
peptide domains, inserted into the extracellular portion of the transmembrane protein by 
alternative splicing. Some of these variants play a causal role in the metastatic process. 
Co-injection of variant-specific mAbs with the metastasizing cells led to retardation or 
even complete block of metastatic spread in vivo [33]. Moreover, overexpression of 
specific CD44 variants in non-metastasizing tumor cell lines induced metastatic behavior 
[11]. CD44 variants, including homologues of those that confer a metastatic phenotype to 
rat carcinomas, have been found to be overexpressed in human tumors including 
aggressive non-Hodgkin's lymphomas and colorectal carcinoma [15,22,36,42]. 
The fact that malignant melanomas are among the most aggressive human tumors, 
prompted us to explore the expression of CD44 splice variants in human cutaneous 
melanocyte tumor progression in situ and in cultured normal human melanocytes and 
melanoma cell lines with different metastatic properties after subcutaneous (s.c.) 
inoculation into nude mice. 
MATERIALS AND METHODS 
Antibodies 
MAbs directed against the variant portions of CD44 were VFF4 anti-CD44v6 
(IgG2b); VFF7 and VFF18 anti-CD44v6 (both IgGl); VFF8 anti-CD44v5 (IgGl); and 
VFF14 and VFF16 anti-CD44vlO (both IgGl) [22,42]. The mAb against the standard 
portion of CD44 was NKI-P1 [28]. The specificity of the mAbs is schematically shown in 
figure 1. 
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Figure 1. A: Schematic representation of the CD44 gene. Open boxes indicate exons that are 
spliced out of the "standard" type of CD44. ΊΜ, transmembrane region. B: Schematica! 
representation of the CD44 protein with location of the epitopes which are recognized by the mAb 
NKI-P1, VFF4, VFF7, VFF8, VFF14, VFF16, and VFF18. Anti-variant antibodies were raised 
against a bacterially expressed fusion protein encoded by pGEX CD44v HPKII (v3 to vlO). Dark 
area, "standard CD44"; vl-vlO, domains encoded by variant exons. 
Tissues 
Human melanocytic lesions were selected from the files of the Department of 
Pathology, University Hospital, Nijmegen, The Netherlands, and the Department of 
Dermatology, University Hospital, Würzburg, Germany, and tested for expression of 
CD44s and CD44v, employing the mAbs described above. Based on histopathologic 
examination of paraffin sections, lesions were divided into five classes: common 
nevocellular nevus (n=19), atypical (dysplastic) nevocellular nevus (n=9), early primary 
cutaneous melanoma (i.e. tumor thickness < 1.5mm) (n = 10), advanced primary 
cutaneous melanoma (i.e. tumor thickness > 1.5mm) (n=9), and melanoma metastasis 
(n=19). 
Immunohistochemistry 
Immunoperoxidase staining was performed as described previously [6]. Briefly, 4 μπι 
cryostat sections were fixed in acetone for 10 min, washed in PBS and incubated with the 
primary antibody for 1 h. Bound mAbs were visualized using the peroxidase based 
Vectastain elite ABC Kit (Vector Laboratories, Burlingame, CA) and amino-ethyl-
carbazole. Lesions were designated "positive" when they were estimated to show staining 
in more than 10% of the melanocytic cells. 
Cell lines and culture conditions 
The human melanoma cell lines 530 and IF6 (non-metastatic) [38,41], M14 and 
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Mel57 (sporadically metastatic) [5,20] and MV3 and BLM (frequently metastatic) [38,39] 
were studied for expression of CD44 variants. The cell lines were grown in DMEM (Life 
technologies, Gaithersburg, MD) supplemented with 1 mM glutamine, 10% (v/v) heat 
inactivated FCS (Hyclone Laboratories Ine, Logan, UK), and antibiotics. Primary 
melanocytes were isolated from human foreskin [34] and cultured for a maximum of five 
passages as described previously [7]. 
Flow cytometry 
Cells were sequentially incubated in PBS containing 1% BSA and 0.02% sodium 
azide with appropriate dilutions of the various antibodies, followed by incubation with 
biotin-conjugated rabbit anti-mouse Ig, and phycoerythrin-labelled streptavidin (Dakopatts, 
Glostrup, Denmark). Fluorescence was measured by a FACScan flow cytometer (Becton 
Dickinson, Mountain View, CA). 
Revene Transcriptase Polymerase Chain Reaction 
5 - 10.107 cells were harvested, washed and lysed by the addition of 0.2 ml of 
RNAzol™ (Campro Scientific, Veenendaal, The Netherlands) per 10* cells. Total RNA 
was extracted by adding 0.2 ml chloroform per 2 ml of cell lysate. After centrifugation at 
12,000x g for 15 min (4°C) the aqueous phase was transferred to a fresh tube and RNA 
was precipitated using isopropanol at -20°C for 45 minutes. Isolated RNA was stored at 
-80° С in 70% ethanol until use. 2μg aliquots of total RNA were used to synthesize 
cDNA using an oligo-dT primer with DNA reverse transcriptase, according to the 
protocol provided with the Perkin Elmer GeneAmp RNA-PCR kit (Perkin Elmer Cetus, 
CT). Amplification of cDNA was performed using CD44-5' and -3' constant primers 
corresponding to positions 513-540 and 900-922 of the standard CD44 sequence described 
by Screaton et al. [30]. Amplification was performed in 35 cycles (30 sec, 94°C; 1 min 
55°C; 2 min 72CC) in a microwave-based Ampliwave DNA incubator (Kreatech 
Biotechnology, Amsterdam, The Netherlands). PCR products were analyzed on a 2% 
agarose gel (Brunschwig, Amsterdam, The Netherlands) containing ethidiumbromide, 
subsequently transferred to nylon filters (Gene Screene Plus; NEN Research Products, 
Boston, MA) and hybridized with a 5'constant CD44-specific oligonucleotide probe or 
exon v5, v6, v7, and vlO specific oligonucleotide probes labelled with gamma[ATP]î2P 
(Amersham, Den Bosch, The Netherlands) by using polynucleotide kinase (Boehringer, 
Mannheim, Germany). 
RESULTS 
Expression of CD44 variants in melanocytic lesions 
Immunohistochemical studies demonstrated differential expression of the various 
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CD44 epitopes in melanocyte lesions (Figs 2,3). In all types of lesions, there was a 
strong homogenous expression of CD44 proteins as determined by the pan-CD44 mAb 
NKI-P1 directed against an epitope on the NH2-terminal constant part of CD44. By 
contrast, expression of epitopes encoded by v6 was not observed with any of the three 
mAbs used, although normal epidermal keratinocytes, when present, strongly stained (not 
shown). 
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Figure 2. Expression of CD44v5 (VFF8), CD44v6 (VFF7), and CD44vlO (VFF14) in human 
melanocytic tumor progression. Bars indicate the percentage of positive tumors. 
Interestingly, there was a marked difference in the expression of v5 and vIO in the 
different types of melanocytic lesions. In the lesions that were positive for v5 or vIO, a 
random heterogeneous staining pattern was observed with 25-100% positive melanocytic 
cells. 
VS was detected in only a low percentage of the common and atypical nevi, and early 
primary melanomas, i.e. in 3/19 (16%), 0/9 (0%), and 2/10 (20%), respectively (Figs 
2,3). However, the majority of the advanced primary melanomas (6/9, 67%), and 
melanoma metastases (11/19, 58%) expressed CD44v5 (Fig. 2,3). Hence, overexpression 
of v5 containing CD44 isoforms is strongly related to tumor progression (p=0.0005). 
VIO encoded epitopes were also differentially expressed in the various types of 
melanocytic lesions. The pattern of expression of vIO, however, was strikingly different 
from that of v5. VIO was detected in 100% of common nevi (19/19), in 67% of atypical 
nevi (6/9), in 10% of early primary melanomas (1/10), in 11% of advanced primary 
melanomas (1/9) and in 32% of the melanoma metastases (6/19) (Figs 2,3). Hence, 
malignant transformation of melanocytes is often associated with a loss of exon vIO 
expression (p=0.026). 
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Figure 3. Expression of CD44v on human melanocyte lesions. n=nevus cells, m=melanoma 
cells, s=stroma. A: Common melanocytic nevus strongly positive for CD44s. B&C: Comparable 
region of the same lesion as in A negative for CD44v5 (VFF8) (B) and positive for CD44vlO 
(VFF14) (C). D: Atypical nevus strongly positive for CD44s. E&F: Comparable region of the 
same lesion as in D negative for CD44v5 (VFF8) (E) and positive for CD44vlO (VFF14) (F). 
G&H: Early primary melanoma strongly positive for CD44s (G) and negative for CD44v5 (VFF8) 
(H). I: Advanced primary melanoma strongly positive for CD44s. J&K: Comparable region from 
the same lesion as in I positive for CD44v5 (VFF8) (J) and negative for CD44vlO (VFF14) (K). 
L: Melanoma metastasis strongly positive for CD44s. M&N: Comparable region from the same 
lesion as in L positive for CD44v5 (VFF8) (M), and negative for CD44vlO (VFF14) (N). 
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Expression of CD44 isoforms on cultured melanocytes and melanoma cell lines 
We next assessed the expression of CD44 isoforms on cultured normal melanocytes 
isolated from human foreskin as well as on a panel of human melanoma cell lines that are 
non- (IF6, 530), sporadically- (M14, Mel57), and highly (BLM, MV3) metastatic after 
s.c. inoculation into nude mice. Cultured normal melanocytes were found to express high 
levels of standard CD44 with a mean relative fluorescence intensity of approximately 
5.103 (not shown). Epitopes encoded by v5, v6, and vlO were hardly or not detectable on 
melanocytes (Fig 4). 
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Figure 4. Expression of CD44v5 (VFF8), CD44v6 (VFF7), and CD44vlO (VFF14) on cultured 
melanocytes and melanoma cell lines which are non- (1F6, 530), sporadically- (MI4, Mel57), or 
frequently (BLM, MV3) metastatic. Binding of different mAbs was measured by FACS. Results 
show mean fluorescence intensity. Negative controls have been subtracted. 
The human melanoma cell lines also showed a strong expression of standard CD44 
epitopes (not shown). This expression of CD44s was independent of the metastatic 
phenotype of the cell lines. Interestingly, however, expression of v5 and v6 containing 
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CD44 splice variants was variable and expression of v6 and particularly v5 related to the 
metastatic potential of the cell lines (Fig 4). Thus, expression of CD44v6 in the highly 
metastatic cell lines was much higher than in the non-metastatic cell lines. High 
expression of CD44v6 was also observed in one of the sporadically metastatic lines (i.e. 
MeL57). Furthermore, CD44v5 was weakly expressed on the non- and sporadically 
metastatic cell lines, but expression on the highly metastatic cell lines was 5-10 fold 
higher. All melanoma cell lines very weakly expressed CD44vlO. 
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Figure 5. Southern blot analysis of RT-PCR amplification products from specimens of cultured 
melanocytes and поп-metastatic, sporadically metastatic, and frequently metastatic human 
melanoma cell lines. A: PCR products obtained with CD44 specific primers 5 ' and 3 ' of the 
variant part, were resolved on 2% agarose containing ethidium bromide, and visualized under 
UV-light. The bright 450 band present in all melanoma cell lines and in the cultured melanocytes 
corresponds to the expected standard CD44 amplification product. Expression of several larger 
splice variants is seen in the cultured melanocytes and all cell lines. B-F: After transfer of the 
PCR products to a Hybond N+ membrane the same filter was hybridized consecutively to B: 
standard CD44; C: exon v5; D: exon v6; E: exon v7; and F: exon vlO CD44 specific probes. 
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RT-PCR analysis demonstrates multiple CD44 splice variants 
To gain insight into the diversity and structure of the CD44 splice variants expressed 
in human melanocytes and melanoma cell lines, RNA prepared from these cells was 
subjected to RT-PCR amplification using primers corresponding to sequences of the 5' 
and the 3' standard constant region of CD44. With these primers a major PCR product of 
approximately 450 basepairs was obtained from the normal melanocytes as well as from 
the melanoma cell lines (Fig 5a). The size of this product corresponds to that expected for 
the standard CD44 message. In addition, up to 6 minor bands of approximately 530, 580, 
615, 660, 850, and 1100 base pairs were obtained from the melanoma cell lines. Human 
cultured melanocytes gave rise to 5 minor bands of 530, 580, 660, 850, and 1100 base 
pairs (Fig 5a). 
Hybridization of the PCR products of melanocytes and melanoma cell lines with 
specific oligonucleotide probes (Fig 5b-f), showed that all contain one to several splice 
variants with v6, v7, and vlO. Except for M14, all melanoma cell lines contained splice 
variants with v5 whereas melanocytes did not hybridize with v5 specific probes. In 
general, the patterns obtained with the different cell lines were very similar. 
DISCUSSION 
Adhesion molecules mediating cell-cell or cell-matrix interactions are involved in 
several steps of the metastatic cascade. In malignant melanoma, increased expression of 
integrins «2/31 [4,21], a3/31 [26], α501 [6], and а ^З [1], and of ICAM1 [19], and 
decrease of integrin a6/31 [27] have been reported to correlate with tumor progression. 
Furthermore, functional studies implicate integrin a5/31 and αν/33 in melanoma cell 
proliferation [10,25] and invasion [31,32]. 
Several studies show a correlation between expression of members of the CD44 
family of adhesion molecules and tumor progression in human non-Hodgkin lymphoma 
[16,17,29] and carcinoma [15,18,23,36,42]. For human melanoma, a correlation has been 
reported in sublines from a single cell line between high CD44 expression and metastatic 
property [3] but in a large panel of different human melanoma cell lines such a 
correlation was not confirmed [8]. In addition, CD44 is strongly expressed in all stages of 
human melanocyte tumor progression in vivo [24]. Our finding of comparable levels of 
CD44s on the surface of normal human melanocytes and melanoma cell lines with 
different metastatic capacities, confirms earlier findings that CD44 expression does not 
correlate with metastatic capacity of melanoma cells [8]. Moreover, in line with previous 
reports [24] we also find that CD44s is strongly expressed in all stages of melanocyte 
tumor progression in vivo. Hence, expression of CD44s seems to be independent of the 
presence of a malignant or metastatic phenotype. However, functional studies have 
provided evidence for a role for CD44 in human melanoma cell motility [9,37] and 
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invasion [9] and we have recently found that a combination of high production of 
hyaluronate and expression of "active" CD44, mediating adhesion to hyaluronate, 
correlates with metastatic capacity of human melanoma cell lines [40]. 
Currently, no evidence exists for the presence of CD44 splice variants in human 
melanoma. Therefore, in the present study we have investigated expression of CD44 
variants, 1) in lesions representing various stages of human melanocytic tumor 
progression in situ, and 2) in a panel of human melanoma cell lines with different 
metastatic potential after s.c. inoculation into nude mice. 
In contrast to CD44s, CD44 isoforms are differentially expressed. Expression of 
CD44 isoforms containing v5, is not found on normal human melanocytes but vS is 
expressed on human melanoma cell lines and its expression is strongly enhanced in the 
highly metastatic cell lines. In addition, vS is expressed in a very low percentage of 
benign melanocytic lesions and early primary melanomas, whereas it is expressed in the 
majority of advanced primary melanomas and melanoma metastases. Thus, enhanced 
expression of CD44v5 is related to high metastatic potential of human melanoma cell lines 
and correlates with human melanocytic tumor progression in vivo. Interestingly, CD44v5 
is also induced in human colorectal tumor progression [42]. Similar to this type of cancer 
where vS is already expressed in early stages of adenoma, v5 can also be detected in a 
few benign melanocytic nevi. However, in contrast to colorectal tumor progression, the 
transition from early primary melanoma to the highly aggressive stage of advanced 
primary melanoma, is attended by a dramatic increase of the percentage of v5 positive 
lesions. It is noteworthy that gastric diffuse type adenocarcinomas and their metastases 
also express CD44v5 and that they are devoid of v6 as well [14]. 
CD44v6 containing isoforms have been related to tumor progression in human 
colorectal carcinomas and malignant lymphomas [22,42]. Moreover, v6 containing 
isoforms have been shown to play a causal role in metastasis of rat pancreatic carcinoma 
cells [11,33]. However, by immunohistochemical staining of malignant melanomas and 
melanoma metastases, we do not detect any expression of CD44v6. This lack of CD44v6 
expression contrasts with the results obtained in the six human melanoma cell lines, which 
all express v6. At present, we have no explanation for the discrepancy in CD44v6 
expression between cultured cell lines and fresh human malignant melanomas. Expression 
of v6 on the melanoma cell lines may be induced by the in vitro culture conditions. 
Alternatively, the v6 epitope might be masked by ligand binding or alterations in the 
conformation of the CD44 molecule in situ. 
In complete contrast to expression of v5, we find that expression of CD44vlO is 
inversely correlated to melanocytic tumor progression in vivo. Most metastases lack 
expression of this variant and in line with this finding, a very low surface expression of 
CD44vlO is found on all melanoma cell lines tested, which all were originally generated 
from metastases. 
At the RNA level, the patterns of CD44 splice variant expression are closely similar 
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in the various cell lines. This finding is remarkable since the cell lines studied are 
mutually unrelated. Hence, the splicing patterns observed do not represent idiosyncratic 
changes of an individual clone but may represent a tissue- or tumor-type specific quality. 
At present, the functional consequence of insertion of various exons into the CD44 
molecule remains unknown. It may be speculated that the ligand binding specificity is 
altered. The 90 kDa CD44s isoform (CD44H) that is expressed on most cells, binds 
hyaluronate [2]. For hyaluronate binding of CD44E, an isoform that contains a 132 
amino-acid inserted domain, the data are conflicting [13,35]. Our cell lines, including 
melanocytes, all express the 90 kDa CD44s molecule [40] and adhesion to hyaluronate 
observed for melanocytes, IF6, Mel57, BLM and MV3 [40] is probably via this isoform. 
Therefore, in this system we cannot look into the role of the splice variants in attachment 
to hyaluronate. Further studies should provide more insight in this matter. 
Taken together, we observed that an increase of CD44v5 and a decrease of CD44vl0 
expression is related to melanocytic tumor progression in vivo and that enhanced 
expression of CD44v5 is related to the metastatic capacity of melanoma cell lines. These 
findings may suggest a role for CD44v5 and CD44vlO in human melanocytic tumor 
progression and melanoma metastasis. 
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In cutaneous melanoma, the standard CD44 molecule is abundantly expressed 
whereas expression of certain splice variants is related to tumor progression and to 
the metastatic potential of cell lines. In the present study we explored the expression 
of CD44 and the pattern of CD44 alternative splicing in uveal melanoma, in relation 
to cell type, diameter, and invasiveness of the tumor. All uveal melanomas strongly 
stained with antibodies to the standard portion of CD44. No expression was found of 
CD44v7 whereas v5, v6, and vlO were expressed (2/12, 5/12, and 8/12 respectively). 
No correlation was observed between expression of certain splice variants and cell 
type, tumor diameter, or invasion of the sclera or Bruch's membrane. All three uveal 
melanoma cell lines tested were strongly CD44 positive and expressed low levels of v6 
containing isoforms at the cell surface, whereas CD44v5, v7, and vlO were absent. 
Our results show that CD44 is strongly expressed in uveal melanoma and that the 
pattern of CD44 alternative splicing is similar to that observed in cutaneous 
melanoma. However, in contrast to cutaneous melanoma it does not seem to be 
related to prognostic parameters in uveal melanoma. 
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INTRODUCTION 
Changes in the adhesive behavior of cells are considered to be important events in the 
process of tumor progression. Cells can bind to the extracellular matrix and to other cells 
via members of the integrin-, selectin-, Cadherin-, immunoglobulin- or CD44 families of 
adhesion receptors [11]. 
CD44 is a family of transmembrane glycoproteins derived from one single gene whose 
members differ structurally as a result of different glycosilation and alternative exon 
splicing [15]. The standard 80-90 kDa CD44 molecule is expressed on most cell types and 
mediates adhesion and migration on hyaluronate [1,24]. For the larger isoforms, generated 
by alternative splicing of 10 exons that are expressed mainly on epithelial cells, data for 
hyaluronate binding are conflicting [see 15]. The expression pattern of CD44 isoforms 
changes during development and differentiation [19], and is altered with tumor progression 
in non-Hodgkin's lymphoma [13], colon carcinoma [10,26], gastric carcinoma [9], and 
cervical carcinoma [3]. A causal role in metastasis of rat prostate carcinoma cells has been 
demonstrated for isoforms containing the variant exon v6 product by transfection [7] and 
antibody blocking studies [21]. 
CD44-mediated hyaluronate binding may play a role in tumorigenesis and metastasis 
of human cutaneous melanoma. Transfection of a CD44 negative melanoma cell line with 
cDNA for the 80-90 kDa CD44 molecule, promotes tumorigenicity [2]. In addition, 
growth and metastasis of melanoma cells can be inhibited by antibodies to CD44 [8]. 
However, expression of CD44 is not related to the metastatic potential of melanoma cells 
[6,25], and CD44 is strongly expressed in all stages of melanocytic tumor progression in 
situ [16,17]. We recently reported that expression of CD44v5 is related to melanocytic 
tumor progression in situ and to the metastatic potential of cell lines in nude mice [16]. 
Melanomas not only originate from melanocytes in the skin, but also from 
melanocytes in the eye, i.e. uveal melanoma. For both types of melanoma, prognosis is 
influenced by the tumor diameter, but in uveal melanoma the cell type (epithelial versus 
spindle) is an additional important parameter. Furthermore, in contrast to cutaneous 
melanoma, uveal melanoma metastasizes primarily to the liver, and as the eye lacks 
lymphatics they do not lymphatically spread. As uveal melanoma thus differs biologically 
and clinically from cutaneous melanoma, uveal melanoma may differ in expression of 
CD44 and in the pattern of CD44 alternative splicing. 
MATERIAL AND METHODS 
Antibodies 
The mAb directed to the constant part of the CD44 molecule was NKI-P2 [18], 
provided by Dr. CG. Figdor (Nijmegen, The Netherlands). MAbs directed to the variant 
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portions of CD44 were VFF8 anti-CD44v5 (IgGl), VFF7 anti-CD44v6 (IgGl), VFF9 
anti-CD44v7 (IgGl), and VFF14 anti-CD44vlO (IgGl), purchased from Bender 
MedSystems (Vienna, Austria), and VFF4 anti-CD44v6 (IgG2b), provided by Dr. ST. 
Pals (Amsterdam, The Netherlands) [13,26]. WT31 anti-CD3 [22] (IgGl), provided by 
Dr. W. Tax (Nijmegen, The Netherlands), was used as a control antibody in 
flowcytometrical analyses. 
Immunohistochemistry 
Specimens of 12 primary uveal melanomas were obtained from patients at the 
University Hospitals in Nijmegen and Leiden, The Netherlands. Diagnosis of primary 
uveal melanomas was microscopically assessed on paraffin sections, discerning spindle 
(n=3), mixed (n=7) and epithelioid (n=2) cell types. Invasion of the sclera was graded 
as not (n=2), superficially (ca. 25% of scleral thickness) (n=3), half (ca. 50% of scleral 
thickness) (n=3), deep (ca. 75% of scleral thickness) (n=l), and episcleral growth 
(n=3). Bruch's membrane was regarded as intact (n=2) or ruptured (n=8). 
Representative parts of all specimens were embedded in Tissue Тек OCT compound 
(Ames Company, Division of Miles Laboratories, Elkhart, IN) and snap frozen in liquid 
nitrogen. In a cryostat 4μιη sections were cut at -25CC, mounted on uncoated slides and 
stored at -80eC until use. Sections were air dried, fixed in acetone for 10 min, and 
incubated with the mAbs at room temperature for 1 h. MAbs were diluted in phosphate 
buffered saline (PBS) containing 1% bovine serum albumin (BSA); optimal working 
dilutions had been previously determined on positive controls (epidermis of normal skin). 
After PBS rinsing, detection of the primary antibodies was achieved using the peroxidase-
based Vectastain Elite ABC system (Vector Laboratories, Burlingame, CA). This 
consisted of a biotinylated horse anti-mouse IgG, followed by an avidin-biotin-peroxidase 
complex (ABC). As a substrate, 3-amino-9-ethyl-carbazole (AEC) in acetate buffer pH 
4.85 containing hydrogen peroxide was used. Finally, sections were counterstained with 
hematoxylin and mounted with Kaiser's glycerol/gelatin (Merck, Darmstadt, Germany). 
Negative controls consisted of incubations replacing the primary antibodies by PBS/BSA. 
The percentage of stained melanocytic cells was estimated as: 0, 1-25, 26-50, 51-75, 
76-100%. Slides were read independently by two observers. Discrepancies exceeding one 
percentage class were found in less than 10% of the cases. These cases were reevaluated 
jointly until consensus was reached. 
Cell lines and culture conditions 
The human uveal melanoma cell lines Mel202 [14], provided by Dr. BR. Ksander 
(Boston, MA); 92-1 [5], provided by Dr. I. de Waard-Siebinga (Leiden, The Netherlands); 
and OCM-1 [12], provided by Dr. GPM. Luyten (Rotterdam, The Netherlands); were 
studied for expression of CD44 splice variants. The cell lines were grown in DMEM 
(Flow, Irvine, UK) supplemented with 10% (v/v) heat-inactivated fetal bovine serum 
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(Hyclone, Logan, UT) and antibiotics. 
Flowcytometry 
Flowcytometry was done as described before [4]. In short, cells were sequentially 
incubated in PBS containing 1% BS A and 0.02% sodium azide with appropriate dilutions 
of the various mAbs, followed by fluorescein-isothiocyanate (FITC) conjugated F(ab')2 
fragments of rabbit anti-mouse Ig (Dako, Glostrup, Denmark). Analyses were performed 
on an Epics Elite flowcytometer (Coulter, Mijdrecht, The Netherlands). 
Table 1. Expression of CD44 splice variants in uveal melanoma lesions. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
cell type 
mixed 
spindle 
mixed 
epith. * 
spindle 
mixed 
mixed 
spindle 
mixed 
mixed 
mixed 
epith. 
diam. 
(mm) 
19 
13.5 
и 
2 
12 
12 
16 
8 
12 
и 
11 
16 
sclera 
(% invasion) 
100 
75 
50 
25 
25 
50 
50 
0 
25 
0 
100 
100 
Bruchs 
rupt. 
rupt. 
intact 
n.i. 
rupt. 
rupt. 
n.i. 
rupt. 
intact 
rupt. 
rupt. 
rupt. 
CD44S 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
CD44v5 CD44v6 CD44v7 CD44vlO 
(% positive cells) 
0 
0 
0 
1-5 
0 
0 
0 
0 
0 
0 
1-5 
0 
0 
0 
0 
1-5 
1-5 
5-25 
0 
0 
5-25 
0 
1-5 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
75-100 
75-100 
50-75 
5-25 
25-50 
0 
100 
0 
75-100 
50-75 
*epith.=epithelioid; diam.=diameter; rupt. = ruptured; n.i.=not identifiable. 
RESULTS 
Expression of CD44 splice variants in uveal melanoma lesions 
By immunohistochemistry we found differential expression of the various CD44 
epitopes in uveal melanoma (Table 1, Fig 1). A strong and homogeneous expression was 
observed in all uveal melanomas with NKI-P2 (Fig la) directed against an epitope on the 
NH2- terminal constant portion of CD44. The quality of the mAbs to CD44v regions was 
tested on normal skin where all mAbs stained keratinocytes (not shown). In addition, as an 
internal control, retinal cells present in some of the lesions stained with all mAbs used 
(not shown). Expression of CD44vlO (Fig Id) could be detected in 8/12 lesions and in 
most positive lesions more than 50% of the tumor cells were positive. CD44v6 was 
detected in 5/12 lesions with VFF4 (Fig lc) and 2 of those lesions also showed a positive 
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reaction with VFF7 anti-CD44v6. Only 2/12 uveal melanomas were found to be positive 
for CD44v5 (Fig lb). Lesions that were positive for CD44v5 or CD44v6 showed 
expression on less then 25% of the tumor cells. Expression of CD44v7 was not detected 
in any of the lesions. Expression of CD44 splice variants showed no relation to tumor 
diameter, cell type, scleral infiltration, or Bruch's membrane invasion. 
Figure 1. Immunohistochemical staining for CD44 splice variants on uveal melanoma lesions. 
Frozen sections of uveal melanomas were stained with NKI-P2 directed against the constant CD44 
portion (A), VFF8 anti-CD44v5 (B), VFF4 anti-CD44v6 (C), or VFF14 anti-CD44vlO (D). 
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Expression of CD44 splice variants on uveal melanoma cell lines 
All 3 uveal melanoma cell lines expressed high levels of CD44 at their surface as 
detected by NKI-P2 (Fig 2). No expression of CD44v5, CD44v7 or CD44vlO was 
observed on any of the cell lines, while CD44v6 was detectable on all 3 cell lines by 2 
CD44v6 mAbs. Expression of CD44v6 was low in comparison to the level of staining 
with NKI-P2, showing that only a minor portion of the abundantly expressed CD44 
molecules, contains the v6 exon product. 
m 9 
fluorescence 
Figure 2. Surface expression of CD44v6 on uveal melanoma cell lines. Three uveal melanoma cell 
lines were stained with VFF4 (thin graph) or VFF7 (thick graph) anti-CD44v6 mAbs. Staining with 
the control anti-CD3 mAb is indicated by the dotted graph. Incubation with mAbs to CD44v5 or 
CD44vlO gave a similar result as anti-CD3 (not shown). Strong staining was observed with NKI-
P2 against a standard epitope and recognizing all CD44 isoforms (filled graph). 
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DISCUSSION 
Our finding that staining with the NKI-P2 mAb directed to the standard portion of 
CD44, is very strong on all uveal melanomas, is in line with findings for cutaneous 
melanomas [16,17]. This mAb detects all CD44 isoforms. The major species detected with 
this mAb on both types of melanoma is probably the standard 80-90 kDa CD44 molecule. 
Also, on the uveal melanoma cell lines, it is most likely that the very high expression 
observed with this mAb, represents predominantly the standard CD44, as it does on cell 
lines derived from cutaneous melanoma [25]. 
Our data show that the CD44 splice variants that can be detected in cutaneous 
melanoma, are also found in uveal melanoma. We find CD44vlO expression in uveal 
melanoma lesions but not on uveal melanoma cell lines, which agrees with the observation 
that CD44vlO is absent or present at a very low level on the surface of cell lines derived 
from cutaneous melanoma whereas cutaneous melanoma lesions can have strong 
expression of vlO in situ [16]. CD44v6 can be detected on cutaneous melanoma cell lines 
[16] and we find v6 expression on each of the uveal melanoma cell lines investigated. 
However, in contrast to the fact that CD44v6 cannot be detected in fresh lesions in any 
stage of cutaneous melanocytic tumor progression in situ [16,20], in the present study we 
find that 5/12 uveal melanomas express this variant. The fact that CD44v6 expression is 
induced on cutaneous melanoma cells by culturing them, and the marked difference 
between fresh cutaneous and uveal melanomas with respect to v6 expression, may suggest 
that the microenvironment of the melanoma cells influences expression of this variant. 
For CD44v5 the opposite pattern is observed. While the majority of the primary 
cutaneous melanomas express CD44v5 [16], only 2 of the 12 uveal melanomas show v5 
expression. Furthermore, in these two lesions only a small percentage of cells was 
positive. In cutaneous melanoma expression of v5 is found preferentially in advanced 
(thick) lesions which are associated with a poor prognosis. For uveal melanoma, even 
lesions with signs of an unfavorable prognosis as based on a large tumor diameter, mixed 
or epithelioid cell types, a broken Bruch's membrane, and complete scleral invasion, are 
negative. Thus, even though previous findings suggested a role for CD44v5 in cutaneous 
melanocytic tumor progression, CD44v5 seems not to be involved in uveal melanoma 
invasion or metastasis. We have previously reported a similar phenomenon for the αν/33 
integrin [23]. Expression of this integrin is acquired in advanced stages of cutaneous 
melanocytic tumor progression whereas it is absent from all primary uveal melanomas. 
Together these findings suggest that the role of adhesion molecules in outgrowth of the 
primary tumor and release of tumor cells leading to distant metastases may differ for 
cutaneous and uveal melanoma. 
In conclusion, our results demonstrate that CD44 is strongly expressed in uveal 
melanoma and that the pattern of CD44 alternative splicing in cutaneous and uveal 
melanoma is similar. In contrast to cutaneous melanoma, expression of CD44v in uveal 
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melanoma is not related to tumor thickness or other prognostic parameters. 
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Summary / Samenvatting 
Summary 
Metastatic spread is the major cause of mortality in cancer patients. In order to go 
through the steps of tumor progression and metastasize, cancer cells must have the 
appropriate adhesive phenotype to be able to cross basement membranes and invade 
tissues. Several cell adhesion receptor families are known that are involved in intercellular 
adhesion and attachment of cells to the extracellular matrix, i.e. Cadherins, selectins, 
members of the immunoglobulin superfamily, integrins, and CD44 molecules. The fact 
that several of these can act as signaling receptors controlling cellular proliferation and 
differentiation, in addition to their role in adhesion and migration events, further 
implicates them in tumor metastasis. General aspects of the cell adhesion receptors and 
evidence for their role in tumor progression and metastasis are reviewed in chapter 1. 
In this thesis, cell adhesion receptors are studied in human melanoma, a highly 
aggressive tumor originating from cutaneous or uveal melanocytes. To investigate changes 
in the expression of cell adhesion receptors with melanocytic tumor progression, patients 
lesions from the different stages in situ are studied, including benign nevi, primary 
melanomas, and metastases (findings for normal melanocytes in situ are difficult to 
interpret because of the close contact with keratinocytes). In addition, expression and 
function of cell adhesion receptors is investigated in cultured human melanocytes and 
human melanoma cell lines with different metastatic potentials in nude mice. 
In chapter 2, the adhesive phenotype of cultured normal melanocytes is investigated. 
It is found that the level of expression of certain integrins in proliferating melanocytes 
differs from that in differentiated melanocytes. As a result, proliferating melanocytes lose 
the ability to adhere to basement membrane components. In contrast, expression of E-
cadherin and binding to keratinocytes via this receptor is found for melanocytes in both 
conditions. 
As E-cadherin on keratinocytes has been shown to be lost in invasive carcinoma, in 
chapter 3 the hypothesis is investigated that a similar phenomenon may occur in 
melanoma. The E-cadherin expression observed for cultured melanocytes and nevus cells 
is indeed lost in metastatic melanoma cell lines, but no expression can be detected in 
nevocellular nevi studied in situ. Furthermore, expression is sometimes detected in 
primary melanomas and metastases. Thus, E-cadherin-mediated adhesion of cultured 
melanocytes to keratinocytes may reflect an artefact, and loss of E-cadherin does not 
seem to be involved in early stages of melanocytic tumor progression. 
In chapter 4, integrin expression is studied in lesions of cutaneous melanocytic tumor 
progression in situ. Acquired expression of a5/31 and αν/33 in advanced stages are the 
major findings. As uveal melanoma differs both clinically and biologically from cutaneous 
melanoma, it may express other adhesion receptors. Indeed, in chapter 5, all primary 
uveal melanomas studied are shown to express a5/31 while none of them express αν/33. 
Adhesion to the endothelial basement membrane may be a critical event in melanoma 
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metastasis. This idea is supported by the finding in chapter 6, that in highly metastatic 
melanoma cell lines, expression and activity of integrins a2/Sl and a6/31 is increased 
compared with melanocytes and non-metastatic melanoma cells, resulting in enhanced 
adhesion to the basement membrane components laminin and collagen via these receptors. 
Experiments described in chapter 7, show that despite the marked emergence of αν/33 
in late stages of melanocyte tumor progression, BLM and MV3 melanoma cells can 
metastasize in the absence of this integrin. The αν/33-negative MV3 cell line expresses 
a501, another integrin emerging in melanocytic tumor progression (chapter 4). In chapter 
8, the mechanism of binding of these two integrins to their common ligand, fibronectin is 
investigated. While αν/33 binds only to the RGD-sequence in fibronectin, α501-binding 
depends on the PHSRN-synergy site as well. By using various reagents that activate the 
integrins, it is shown that aS/31 in its high affinity state can bind to RGD in the 
fibronectin molecule, independent of the synergy site. This implies that a5/31 can be a 
target integrin for the reported inhibition of melanoma metastasis by RGD-peptides. 
Therefore, in chapter 9, a5/31-binding antibodies, peptides, and disintegrins (RGD-
containing peptides from snake venom) are used to test the hypothesis that a5ßl may be 
critically involved in metastasis of the αν/33-negative MV3 cells. The finding that none of 
these reagents inhibits metastasis, while each of them blocks a5/31-mediated adhesion to 
Fn, does not support the hypothesis. In contrast, eristostatin, a disintegrin that does not 
bind a5/31, is found to block MV3 metastasis. Eristostatin binding to MV3 is RGD-
dependent and may involve a4#l . In in vitro adhesion assays, eristostatin does not inhibit 
adhesion to extracellular matrix components or endothelial cells, suggesting that 
eristostatin does not act by interference with the initial adhesion of MV3 cells to the 
vessel wall or to components in the lung tissue. In chapter 9, it is further demonstrated 
that expression of αν/33 in MV3, greatly reduces its metastatic potential. 
Chapters 10-12 deal with CD44 molecules in melanoma. CD44 can be detected in all 
stages of tumor progression in situ and in most cell lines irrespective of their metastatic 
capacity, while experimental evidence exists for a role for CD44 in melanoma growth and 
metastasis. The availability of the CD44 ligand hyaluronate may be critical. The findings 
in chapter 10, that all melanoma cell lines express CD44, that most of them adhere to 
hyaluronate, but that only the highly metastatic cell lines have a high level of hyaluronate 
production, may support that idea. As the pattern of CD44 alternative splicing has been 
related to tumor progression in several malignancies, chapter 11 deals with the expression 
of CD44 splice variants in human cutaneous melanoma. Gain of CD44v5 and loss of 
CD44vlO are found to correlate with melanocytic tumor progression in situ, and gain of 
CD44v5 is also found to be related to the metastatic potential of melanoma cell lines. 
Finally, in chapter 12, CD44 is shown to be abundantly expressed in uveal melanoma, 
and the pattern of CD44 alternative splicing in uveal melanoma is shown to be similar to 
that observed for cutaneous melanoma. 
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Samenvatting 
Uitzaaiing van tumorcellen is de belangrijkste doodsoorzaak bij kankerpatiënten. Om 
de verschillende stappen van tumorprogressie te doorlopen en uit te zaaien, moeten 
kankercellen in staat zijn om basaalmembranen te passeren en weefsels te invaderen. 
Hiervoor is het hechtingsgedrag van de cellen van groot belang. Hechting van cellen aan 
andere cellen en aan de extracellulaire matrix verloopt via cel-adhesie receptoren. Deze 
zijn onder te verdelen in verscheidene families, te weten de cadherines, selectines, leden 
van de Immunoglobuline superfamilie, integrines en CD44 moleculen. Het feit dat 
sommige cel-adhesie receptoren signalen genereren die de celproliferatie en differentiatie 
reguleren, wijst nog verder op hun betrokkenheid bij tumorprogressie en uitzaaiing. 
Algemene aspecten van de cel-adhesie receptoren en aanwijzingen voor een rol voor deze 
moleculen in tumorprogressie en uitzaaiing worden behandeld in hoofdstuk 1. 
In dit proefschrift worden cel-adhesie receptoren onderzocht in het humane 
melanoom, een zeer agressieve tumor welke ontstaat uit de pigment-producerende cellen, 
melanocyten, die zich (doorgaans) in de huid of in het oog bevinden. Om veranderingen 
in expressie van deze moleculen in relatie tot melanocytaire tumorprogressie te 
onderzoeken, is gebruik gemaakt van patiënten lesies, te weten benigne nevi, primaire 
melanomen en uitzaaiingen (de expressie op normale melanocyten in de huid is moeilijk te 
interpreteren vanwege het nauwe contact met andere huidcellen (keratinocyten)). Verder is 
de expressie en functie van cel-adhesie receptoren onderzocht in gekweekte normale 
melanocyten en humane melanoomcellijnen met verschillende capaciteit om uit te zaaien 
in naakte (thymusloze) muizen. 
In hoofdstuk 2 wordt het hechtingsprofiel van gekweekte normale melanocyten 
bestudeerd. Gevonden wordt dat het expressie-niveau van bepaalde integrines in 
prolifererende melanocyten hoger is dan in gedifferentieerde melanocyten terwijl andere 
juist verminderd voorkomen. Dit resulteert voor prolifererende melanocyten in een verlies 
van het vermogen om aan componenten van de basaalmembraan te hechten. De expressie 
van E-cadherine op melanocyten en binding aan keratinocyten via deze receptor, wordt 
gevonden onder beide omstandigheden. 
Aangezien E-cadherine sterk tot expressie komt op keratinocyten maar afwezig is op 
invasieve carcinoomcellen, wordt in hoofdstuk 3 de hypothese onderzocht dat verlies van 
E-cadherine zich eveneens voordoet tijdens melanocytaire tumorprogressie. De E-
cadherine expressie die op gekweekte melanocyten en nevus cellen wordt gedetecteerd, is 
inderdaad afwezig op frequent uitzaaiiende melanoomcellijnen maar in nevocellulaire nevi 
in situ wordt ook geen E-cadherine gevonden. Verder wordt expressie gevonden in enkele 
vergevorderde primaire melanomen en uitzaaiingen. Dus, E-cadherine-gemediëerde 
adhesie van melanocyten aan keratinocyten is mogelijk een kweek-artefact en verlies van 
E-cadherine lijkt geen rol te spelen bij melanocytaire tumorprogressie. 
In hoofdstuk 4 wordt integrine expressie bestudeerd in lesies van verschillende stadia 
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van tumorprogressie van het huidmelanoom. Inductie van α5/31 and αν/33 expressie in 
gevorderde stadia zijn de belangrijkste bevindingen. Aangezien het oogmelanoom zowel 
klinisch als biologisch verschilt van het huidmelanoom zou de expressie van cel-adhesie 
receptoren voor beide vormen kunnen verschillen. Inderdaad wordt in hoofdstuk S 
beschreven dat alle bestudeerde primaire oogmelanomen aSjSl tot expressie brengen 
terwijl ze geen av/33 hebben. 
Hechting aan de endotheliale basaalmembraan van bloedvaten is een kritische stap in 
uitzaaiing van kankercellen. Dit idee wordt ondersteund door de bevinding in hoofdstuk 
6, dat in frequent uitzaaiende melanoomcellijnen de expressie en activiteit van integrines 
a2j81 en a6/31 is verhoogd in vergelijking met niet- of sporadisch metastaserende 
melanoomcellijnen. Dit resulteert in een verhoogd niveau van hechting aan de 
basaaalmembraancomponenten laminine en collageen via deze receptoren. 
De bevindingen beschreven in hoofdstuk 7 laten zien dat, ondanks de opmerkelijke 
opkomst van αν/33 in late stadia van melanocytaire tumorprogressie, BLM en MV3 
melanoomcellen in naakte muizen kunnen uitzaaien in afwezigheid van dit integrine. De 
αν/33-negatieve cellijn MV3, brengt een ander integrine dat opkomt in late stadia van 
tumorprogressie tot expressie, namelijk a5/31. In hoofdstuk 8 wordt het mechanisme van 
hechting van beide receptoren aan hun gemeenschappelijke ligand, fibronectine 
onderzocht. Terwijl αν/33 alleen de RGD-sequentie in het fibronectine molecule bindt, is 
binding van a5/31, zowel van RGD als van de synergistische regio met de PHSRN-
sequentie afhankelijk. Met verscheidene reagentia die de affiniteit van integrines voor hun 
ligand verhogen, wordt echter gedemonstreerd dat a5/31 in de actieve (hoog-affine) 
toestand, RGD in fibronectine kan binden onafhankelijk van de PHSRN-sequentie. Dit 
impliceert dat a5/31 een doelwit-integrine kan zijn voor de eerder beschreven remming 
van melanoom uitzaaiing met RGD-peptiden. Daarom worden in hoofdstuk 9 a5/31-
bindende antilichamen, peptiden en disintegrines (RGD-bevattende peptiden geïsoleerd uit 
slangegif) gebruikt, om de hypothese te testen dat a5/31 van essentieel belang is voor 
uitzaaiing van de αν/33-negatieve cellijn MV3. De bevinding dat geen van deze reagentia 
uitzaaiing van MV3 cellen remt terwijl ze allemaal de hechting aan fibronectine via a5/31 
blokkeren, bevestigt deze hypothese niet. Een disintegrine met een andere bindings-
specificiteit, eristostatine, blokkeert de uitzaaiing van MV3 zeer efficiënt. Eristostatine 
bindt aan MV3 cellen en deze binding is RGD-afhankelijk en verloopt mogelijk via a4/?l, 
maar met in vitro adhesie testen wordt geen remming gevonden van hechting aan 
extracellulaire matrix componenten of aan endotheelcellen. Dit suggereert dat het effect 
van eristostatine niet te wijten is aan verhindering van de initiële hechting aan de 
vaatwand of componenten uit het longweefsel. In hoofdstuk 9 wordt verder aangetoond, 
dat expressie van αν/ЗЗ in MV3 de capaciteit tot uitzaaien drastisch reduceert. 
De hoofdstukken 10-12 behandelen de expressie van CD44 in het humane melanoom. 
CD44 kan worden gedetecteerd in alle stadia van melanocytaire tumorprogressie in situ en 
in de meeste melanoomcellijnen onafhankelijk van hun vermogen tot uitzaaien. Anderzijds 
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hebben experimentele studies aangetoond dat CD44 een rol kan spelen in groei en 
uitzaaiing van melanoomcellen. De beschikbaarheid van het ligand voor CD44, 
hyaluronzuur, zou van kritisch belang kunnen zijn. De bevinding in hoofdstuk 10 dat alle 
melanoomcellijnen CD44 tot expressie brengen en dat de meeste van hen aan 
hyaluronzuur hechten maar dat alleen de frequent uitzaaiende melanoomcellijnen een hoge 
productie van hyaluronzuur hebben, lijkt dit idee te bevestigen. Aangezien het patroon 
van alternatieve splicing van CD44 gerelateerd is aan tumorprogressie in een aantal 
verschillende vormen van kanker, behandelt hoofdstuk 11 de expressie van CD44 splice 
varianten in het humane huidmelanoom. Expressie van CD44 moleculen die het v5-
exonproduct bevatten, blijkt te correleren met melanocytaire tumorprogressie in situ en 
met de capaciteit tot uitzaaien van melanoomcellijnen. Andersom, blijkt verlies van CD44 
moleculen met het vlO-exonproduct gerelateerd te zijn aan melanocytaire tumorprogressie 
in situ. Ten slotte laat hoofdstuk 12 zien dat CD44 ook in oogmelanomen sterk tot 
expressie komt en dat het patroon van alternatieve splicing van CD44 in oogmelanomen 
overeenkomt met dat in huidmelanomen. 
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